<!DOCTYPE html>
<html lang="pl">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Leczenie Depresji – Kompendium Wiedzy</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Cormorant+Garamond:ital,wght@0,400;0,500;0,600;0,700;1,400&family=Source+Sans+3:wght@300;400;500;600&display=swap" rel="stylesheet">
    <script src="https://unpkg.com/@elevenlabs/convai-widget-embed" async type="text/javascript"></script>
    <style>
        :root {
            --bg-primary: #FDFBF7;
            --bg-secondary: #F5F1E8;
            --text-primary: #2C3E50;
            --text-secondary: #5D6D7E;
            --accent: #4A6741;
            --accent-light: #6B8E61;
            --accent-hover: #3D5635;
            --border: #D5CFC3;
            --shadow: rgba(44, 62, 80, 0.08);
            --serif: 'Cormorant Garamond', Georgia, serif;
            --sans: 'Source Sans 3', -apple-system, sans-serif;
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        html {
            scroll-behavior: smooth;
        }

        body {
            font-family: var(--sans);
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.7;
            min-height: 100vh;
        }

        /* Header */
        header {
            background: linear-gradient(180deg, var(--bg-secondary) 0%, var(--bg-primary) 100%);
            padding: 3rem 2rem;
            text-align: center;
            border-bottom: 1px solid var(--border);
            position: relative;
            overflow: hidden;
        }

        header::before {
            content: '';
            position: absolute;
            top: 0;
            left: 0;
            right: 0;
            bottom: 0;
            background: 
                radial-gradient(circle at 20% 20%, rgba(74, 103, 65, 0.03) 0%, transparent 50%),
                radial-gradient(circle at 80% 80%, rgba(74, 103, 65, 0.05) 0%, transparent 50%);
            pointer-events: none;
        }

        .header-content {
            position: relative;
            max-width: 800px;
            margin: 0 auto;
        }

        .book-icon {
            width: 60px;
            height: 60px;
            margin-bottom: 1.5rem;
            opacity: 0.7;
        }

        h1 {
            font-family: var(--serif);
            font-size: clamp(2.2rem, 5vw, 3.5rem);
            font-weight: 600;
            color: var(--text-primary);
            letter-spacing: -0.02em;
            margin-bottom: 0.5rem;
        }

        .subtitle {
            font-family: var(--serif);
            font-size: 1.15rem;
            color: var(--text-secondary);
            font-style: italic;
            font-weight: 400;
        }

        /* Navigation Tabs */
        nav {
            background: var(--bg-primary);
            position: sticky;
            top: 0;
            z-index: 100;
            border-bottom: 1px solid var(--border);
            box-shadow: 0 2px 20px var(--shadow);
        }

        .nav-container {
            max-width: 900px;
            margin: 0 auto;
            display: flex;
            justify-content: center;
            gap: 0;
        }

        .tab-btn {
            font-family: var(--sans);
            font-size: 0.95rem;
            font-weight: 500;
            color: var(--text-secondary);
            background: transparent;
            border: none;
            padding: 1.2rem 2rem;
            cursor: pointer;
            transition: all 0.3s ease;
            position: relative;
            letter-spacing: 0.02em;
        }

        .tab-btn::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 50%;
            transform: translateX(-50%);
            width: 0;
            height: 3px;
            background: var(--accent);
            transition: width 0.3s ease;
            border-radius: 3px 3px 0 0;
        }

        .tab-btn:hover {
            color: var(--accent);
            background: rgba(74, 103, 65, 0.04);
        }

        .tab-btn.active {
            color: var(--accent);
        }

        .tab-btn.active::after {
            width: 60%;
        }

        /* Main Content */
        main {
            max-width: 900px;
            margin: 0 auto;
            padding: 2.5rem 2rem 4rem;
        }

        .tab-content {
            display: none;
            animation: fadeIn 0.4s ease;
        }

        .tab-content.active {
            display: block;
        }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }

        /* Table of Contents */
        .toc-intro {
            text-align: center;
            margin-bottom: 3rem;
            padding-bottom: 2rem;
            border-bottom: 1px solid var(--border);
        }

        .toc-intro h2 {
            font-family: var(--serif);
            font-size: 1.8rem;
            font-weight: 600;
            margin-bottom: 0.75rem;
            color: var(--text-primary);
        }

        .toc-intro p {
            color: var(--text-secondary);
            font-size: 1rem;
        }

        .part {
            margin-bottom: 2.5rem;
        }

        .part-title {
            font-family: var(--serif);
            font-size: 1.35rem;
            font-weight: 600;
            color: var(--accent);
            padding: 0.75rem 0;
            border-bottom: 2px solid var(--accent);
            margin-bottom: 1.25rem;
            display: flex;
            align-items: center;
            gap: 0.75rem;
        }

        .part-number {
            font-family: var(--sans);
            font-size: 0.7rem;
            font-weight: 600;
            letter-spacing: 0.1em;
            text-transform: uppercase;
            color: var(--text-secondary);
            display: block;
            margin-bottom: 0.25rem;
        }

        .chapter {
            margin-bottom: 1.25rem;
            padding-left: 1rem;
        }

        .chapter-title {
            font-family: var(--serif);
            font-size: 1.1rem;
            font-weight: 500;
            color: var(--text-primary);
            margin-bottom: 0.5rem;
        }

        .sections {
            list-style: none;
            padding-left: 1.25rem;
        }

        .sections li {
            font-size: 0.92rem;
            color: var(--text-secondary);
            padding: 0.3rem 0;
            position: relative;
        }

        .sections li::before {
            content: '—';
            position: absolute;
            left: -1.25rem;
            color: var(--border);
        }

        /* Sources Section */
        .sources-intro {
            text-align: center;
            margin-bottom: 2.5rem;
            padding-bottom: 2rem;
            border-bottom: 1px solid var(--border);
        }

        .sources-intro h2 {
            font-family: var(--serif);
            font-size: 1.8rem;
            font-weight: 600;
            margin-bottom: 0.75rem;
        }

        .sources-intro p {
            color: var(--text-secondary);
        }

        .sources-count {
            display: inline-block;
            background: var(--accent);
            color: white;
            font-size: 0.85rem;
            font-weight: 600;
            padding: 0.4rem 1rem;
            border-radius: 20px;
            margin-top: 1rem;
        }

        .search-box {
            margin-bottom: 2rem;
        }

        .search-box input {
            width: 100%;
            padding: 1rem 1.5rem;
            font-family: var(--sans);
            font-size: 1rem;
            border: 2px solid var(--border);
            border-radius: 8px;
            background: white;
            transition: all 0.3s ease;
        }

        .search-box input:focus {
            outline: none;
            border-color: var(--accent);
            box-shadow: 0 0 0 4px rgba(74, 103, 65, 0.1);
        }

        .reference-list {
            display: flex;
            flex-direction: column;
            gap: 0.75rem;
        }

        
        .doi-link {
            color: #4CAF50;
            font-weight: 500;
        }
        .doi-link:hover {
            color: #388E3C;
        }
        
        .scholar-link {
            background: linear-gradient(135deg, #4285f4, #34a853);
            color: white !important;
            padding: 2px 8px;
            border-radius: 12px;
            font-size: 0.85em;
            text-decoration: none;
            margin-left: 8px;
            display: inline-block;
        }
        .scholar-link:hover {
            background: linear-gradient(135deg, #3367d6, #2d9249);
            transform: scale(1.05);
        }
        .doi-link {
            color: #4CAF50;
            font-weight: 500;
        }
        .doi-link:hover {
            color: #388E3C;
        }
        .reference-item {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 1rem 1.25rem;
            transition: all 0.2s ease;
        }

        .reference-item:hover {
            border-color: var(--accent-light);
            box-shadow: 0 4px 12px var(--shadow);
        }

        .ref-number {
            font-family: var(--sans);
            font-weight: 600;
            font-size: 0.85rem;
            color: var(--accent);
            margin-right: 0.75rem;
        }

        .ref-text {
            font-size: 0.92rem;
            color: var(--text-secondary);
            line-height: 1.6;
        }

        .ref-text a {
            color: var(--accent);
            text-decoration: none;
            word-break: break-all;
        }

        .ref-text a:hover {
            text-decoration: underline;
        }

        .load-more-btn {
            display: block;
            width: 100%;
            max-width: 300px;
            margin: 2rem auto 0;
            padding: 1rem 2rem;
            font-family: var(--sans);
            font-size: 1rem;
            font-weight: 500;
            color: white;
            background: var(--accent);
            border: none;
            border-radius: 8px;
            cursor: pointer;
            transition: all 0.3s ease;
        }

        .load-more-btn:hover {
            background: var(--accent-hover);
            transform: translateY(-2px);
            box-shadow: 0 4px 15px rgba(74, 103, 65, 0.3);
        }

        /* AI Chat Section */
        .ai-section {
            text-align: center;
        }

        .ai-intro {
            margin-bottom: 2.5rem;
            padding-bottom: 2rem;
            border-bottom: 1px solid var(--border);
        }

        .ai-intro h2 {
            font-family: var(--serif);
            font-size: 1.8rem;
            font-weight: 600;
            margin-bottom: 0.75rem;
        }

        .ai-intro p {
            color: var(--text-secondary);
            max-width: 600px;
            margin: 0 auto 1.5rem;
        }

        .ai-features {
            display: flex;
            justify-content: center;
            gap: 2rem;
            flex-wrap: wrap;
            margin-top: 1.5rem;
        }

        .ai-feature {
            display: flex;
            align-items: center;
            gap: 0.5rem;
            font-size: 0.9rem;
            color: var(--text-secondary);
        }

        .ai-feature svg {
            width: 20px;
            height: 20px;
            color: var(--accent);
        }

        .widget-container {
            position: fixed;
            bottom: 20px;
            right: 20px;
            z-index: 9999;
            background: var(--card-bg);
            border-radius: 16px;
            box-shadow: 0 8px 32px rgba(0,0,0,0.15);
            padding: 0;
        }
        
        .widget-container elevenlabs-convai {
            display: block;
        }

        /* Footer */
        footer {
            text-align: center;
            padding: 2rem;
            border-top: 1px solid var(--border);
            margin-top: 2rem;
        }

        footer p {
            font-size: 0.85rem;
            color: var(--text-secondary);
        }

        /* Responsive */
        @media (max-width: 768px) {
            header {
                padding: 2rem 1.5rem;
            }

            .nav-container {
                flex-wrap: wrap;
            }

            .tab-btn {
                padding: 1rem 1.25rem;
                font-size: 0.9rem;
            }

            main {
                padding: 2rem 1.5rem;
            }

            .ai-features {
                flex-direction: column;
                align-items: center;
                gap: 1rem;
            }
        }

        @media (max-width: 480px) {
            .tab-btn {
                padding: 0.85rem 1rem;
                font-size: 0.85rem;
            }
        }
    </style>
</head>
<body>
    <header>
        <div class="header-content">
            <svg class="book-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.5">
                <path d="M12 6.253v13m0-13C10.832 5.477 9.246 5 7.5 5S4.168 5.477 3 6.253v13C4.168 18.477 5.754 18 7.5 18s3.332.477 4.5 1.253m0-13C13.168 5.477 14.754 5 16.5 5c1.747 0 3.332.477 4.5 1.253v13C19.832 18.477 18.247 18 16.5 18c-1.746 0-3.332.477-4.5 1.253"/>
            </svg>
            <h1>Leczenie Depresji</h1>
            <p class="subtitle">Kompleksowy przewodnik oparty na najnowszych badaniach naukowych</p>
        </div>
    </header>

    <nav>
        <div class="nav-container">
            <button class="tab-btn active" data-tab="toc">Spis Treści</button>
            <button class="tab-btn" data-tab="sources">Źródła Naukowe</button>
            <button class="tab-btn" data-tab="ai">Rozmowa z AI</button>
        </div>
    </nav>

    <main>
        <!-- Spis Treści -->
        <div id="toc" class="tab-content active">
            <div class="toc-intro">
                <h2>Spis Treści</h2>
                <p>9 części, 25 rozdziałów, ponad 700 źródeł naukowych</p>
            </div>

            <!-- CZĘŚĆ I -->
            <div class="part">
                <div class="part-title">
                    <span class="part-number">Część I</span>
                    Zrozumieć Depresję
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 1. Czym jest depresja</div>
                    <ul class="sections">
                        <li>1.1. Definicja i klasyfikacja depresji (DSM-5-TR, ICD-11)</li>
                        <li>1.2. Neurobiologia depresji</li>
                        <li>1.3. Epidemiologia – skala problemu po pandemii COVID-19</li>
                        <li>1.4. Czynniki ryzyka i czynniki ochronne</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 2. Diagnoza depresji</div>
                    <ul class="sections">
                        <li>2.1. Kryteria diagnostyczne</li>
                        <li>2.2. Narzędzia oceny (MADRS, PHQ-9, BDI-II, Hamilton)</li>
                        <li>2.3. Różnicowanie z innymi zaburzeniami</li>
                        <li>2.4. Depresja lekooporna – definicja i kryteria (TRD)</li>
                    </ul>
                </div>
            </div>

            <!-- CZĘŚĆ II -->
            <div class="part">
                <div class="part-title">
                    <span class="part-number">Część II</span>
                    Farmakoterapia
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 3. Klasyczne leki przeciwdepresyjne</div>
                    <ul class="sections">
                        <li>3.1. SSRI – selektywne inhibitory wychwytu serotoniny</li>
                        <li>3.2. SNRI – inhibitory wychwytu serotoniny i noradrenaliny</li>
                        <li>3.3. Leki trójpierścieniowe i inne starsze klasy</li>
                        <li>3.4. Atypowe leki przeciwdepresyjne</li>
                        <li>3.5. Strategie augmentacji i potencjalizacji</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 4. Przełomowe leki nowej generacji</div>
                    <ul class="sections">
                        <li>4.1. Esketamina (SPRAVATO®) – pierwsza monoterapia TRD</li>
                        <li>4.2. Ketamina – zastosowania kliniczne</li>
                        <li>4.3. Podtlenek azotu (N₂O) – obiecujące badania 2025</li>
                        <li>4.4. Leki działające na układ glutaminergiczny</li>
                        <li>4.5. Psychiatria precyzyjna i farmakogenomika</li>
                    </ul>
                </div>
            </div>

            <!-- CZĘŚĆ III -->
            <div class="part">
                <div class="part-title">
                    <span class="part-number">Część III</span>
                    Psychoterapia
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 5. Terapie oparte na dowodach (EBT)</div>
                    <ul class="sections">
                        <li>5.1. Terapia poznawczo-behawioralna (CBT)</li>
                        <li>5.2. Terapia interpersonalna (IPT)</li>
                        <li>5.3. Terapia akceptacji i zaangażowania (ACT)</li>
                        <li>5.4. Terapia dialektyczno-behawioralna (DBT)</li>
                        <li>5.5. Terapia skoncentrowana na emocjach (EFT)</li>
                        <li>5.6. Aktywacja behawioralna (BA)</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 6. Terapia poznawcza oparta na uważności (MBCT)</div>
                    <ul class="sections">
                        <li>6.1. Mindful Mood Balance – program online WHO</li>
                        <li>6.2. 8-tygodniowy program grupowy</li>
                        <li>6.3. Zapobieganie nawrotom depresji</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 7. CBASP – terapia dla depresji przewlekłej</div>
                </div>
            </div>

            <!-- CZĘŚĆ IV -->
            <div class="part">
                <div class="part-title">
                    <span class="part-number">Część IV</span>
                    Neuromodulacja i Terapie Somatyczne
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 8. Przezczaszkowa stymulacja magnetyczna (TMS)</div>
                    <ul class="sections">
                        <li>8.1. SAINT – Stanford Accelerated Intelligent Neuromodulation Therapy</li>
                        <li>8.2. Deep TMS (BrainsWay)</li>
                        <li>8.3. iTBS – przerywana stymulacja theta burst</li>
                        <li>8.4. Porównanie protokołów i wskazania</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 9. Terapia elektrowstrząsowa (ECT)</div>
                    <ul class="sections">
                        <li>9.1. Współczesne protokoły – RUL-UB</li>
                        <li>9.2. ECT + wenlafaksyna u osób starszych</li>
                        <li>9.3. Wskazania i przeciwwskazania</li>
                        <li>9.4. Obalanie mitów</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 10. Przezczaszkowa stymulacja prądem stałym (tDCS)</div>
                    <ul class="sections">
                        <li>10.1. Flow FL-100 – pierwsze urządzenie domowe zatwierdzone przez FDA</li>
                        <li>10.2. Protokoły kliniczne – 5 sesji dziennie przez 5 tygodni</li>
                        <li>10.3. Mechanizm działania i bezpieczeństwo</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 11. Głęboka stymulacja mózgu (DBS)</div>
                </div>
            </div>

            <!-- CZĘŚĆ V -->
            <div class="part">
                <div class="part-title">
                    <span class="part-number">Część V</span>
                    Terapie Psychodeliczne
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 12. Psylocybina w leczeniu depresji</div>
                    <ul class="sections">
                        <li>12.1. Status naukowy i regulacyjny 2025</li>
                        <li>12.2. Model terapii wspomaganej psilocybiną</li>
                        <li>12.3. Badanie COMPASS COMP360 – faza 3</li>
                        <li>12.4. Psylocybina dla pracowników medycznych po COVID-19</li>
                        <li>12.5. Wielokrotne dawki – badania 2024</li>
                        <li>12.6. Bezpieczeństwo i przeciwwskazania</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 13. MDMA i inne psychodeliki</div>
                    <ul class="sections">
                        <li>13.1. MDMA w terapii – status i wskazania</li>
                        <li>13.2. LSD (MM120) w leczeniu uogólnionego lęku</li>
                        <li>13.3. Kwestie etyczne i regulacyjne</li>
                    </ul>
                </div>
            </div>

            <!-- CZĘŚĆ VI -->
            <div class="part">
                <div class="part-title">
                    <span class="part-number">Część VI</span>
                    Integracyjne i Holistyczne Podejścia
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 14. Styl życia jako terapia</div>
                    <ul class="sections">
                        <li>14.1. Aktywność fizyczna</li>
                        <li>14.2. Dieta i odżywianie</li>
                        <li>14.3. Sen i higiena snu</li>
                        <li>14.4. Światłoterapia</li>
                        <li>14.5. Kontakt z naturą i terapia lasem</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 15. Technologia w leczeniu depresji</div>
                    <ul class="sections">
                        <li>15.1. Aplikacje terapeutyczne zatwierdzone przez FDA</li>
                        <li>15.2. Terapia VR (rzeczywistość wirtualna)</li>
                        <li>15.3. AI w monitorowaniu zdrowia psychicznego</li>
                        <li>15.4. Telepsychiatria i telepsychoterapia</li>
                    </ul>
                </div>
            </div>

            <!-- CZĘŚĆ VII -->
            <div class="part">
                <div class="part-title">
                    <span class="part-number">Część VII</span>
                    Szczególne Populacje
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 16. Depresja u dzieci i młodzieży</div>
                    <ul class="sections">
                        <li>16.1. Wzrost zachorowań po pandemii COVID-19</li>
                        <li>16.2. CBT i IPT dla młodzieży – dowody skuteczności</li>
                        <li>16.3. Deep TMS dla nastolatków (15–21 lat)</li>
                        <li>16.4. Terapia rodzinna (FFT-CD)</li>
                        <li>16.5. Farmakoterapia u nieletnich – specyfika i ostrożność</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 17. Depresja u osób starszych</div>
                    <ul class="sections">
                        <li>17.1. ECT + wenlafaksyna – bezpieczeństwo i skuteczność</li>
                        <li>17.2. Adaptacja CBT dla seniorów</li>
                        <li>17.3. Interakcje lekowe i wielochorobowość</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 18. Depresja okołoporodowa</div>
                    <ul class="sections">
                        <li>18.1. Depresja przedporodowa i poporodowa</li>
                        <li>18.2. Bezpieczeństwo leczenia w ciąży i podczas karmienia</li>
                        <li>18.3. Ryzyko samobójstwa u kobiet w ciąży – badania NIMH</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 19. Depresja w chorobach somatycznych</div>
                    <ul class="sections">
                        <li>19.1. Depresja w chorobie Parkinsona</li>
                        <li>19.2. Depresja w chorobach nowotworowych</li>
                        <li>19.3. Depresja w przewlekłym bólu</li>
                        <li>19.4. Depresja w chorobach serca</li>
                    </ul>
                </div>
            </div>

            <!-- CZĘŚĆ VIII -->
            <div class="part">
                <div class="part-title">
                    <span class="part-number">Część VIII</span>
                    Praktyczny Przewodnik
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 20. Algorytm leczenia depresji</div>
                    <ul class="sections">
                        <li>20.1. Pierwsza linia: psychoterapia lub SSRI</li>
                        <li>20.2. Druga linia: zmiana leku lub augmentacja</li>
                        <li>20.3. Depresja lekooporna: TMS, ECT, esketamina</li>
                        <li>20.4. Terapie eksperymentalne: psilocybina, DBS</li>
                        <li>20.5. Schematy blokowe decyzji terapeutycznych</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 21. Kombinowanie metod</div>
                    <ul class="sections">
                        <li>21.1. Psychoterapia + farmakoterapia</li>
                        <li>21.2. TMS + psychoterapia – efekt synergii</li>
                        <li>21.3. Podtrzymanie remisji</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 22. Samopomoc</div>
                    <ul class="sections">
                        <li>22.1. Techniki CBT do samodzielnego stosowania</li>
                        <li>22.2. Mindfulness w codziennym życiu</li>
                        <li>22.3. Dziennik nastroju i aktywności</li>
                        <li>22.4. Self-Help Plus (WHO)</li>
                        <li>22.5. Urządzenia domowe (Flow FL-100)</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 23. Zapobieganie nawrotom</div>
                    <ul class="sections">
                        <li>23.1. Kontynuacja leczenia farmakologicznego</li>
                        <li>23.2. MBCT – zapobieganie nawrotom</li>
                        <li>23.3. Wczesne rozpoznawanie objawów ostrzegawczych</li>
                        <li>23.4. Plan bezpieczeństwa</li>
                    </ul>
                </div>
            </div>

            <!-- CZĘŚĆ IX -->
            <div class="part">
                <div class="part-title">
                    <span class="part-number">Część IX</span>
                    Przyszłość Leczenia Depresji
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 24. Kierunki badań 2025–2030</div>
                    <ul class="sections">
                        <li>24.1. Biomarkery depresji</li>
                        <li>24.2. Transkryptomika i genetyka ekspresji</li>
                        <li>24.3. Neuroprotekcja i neuroregeneracja</li>
                        <li>24.4. Nowe cele farmakologiczne</li>
                    </ul>
                </div>
                <div class="chapter">
                    <div class="chapter-title">Rozdział 25. Bariery i nadzieje</div>
                    <ul class="sections">
                        <li>25.1. Dostępność leczenia na świecie</li>
                        <li>25.2. Stygmatyzacja chorób psychicznych</li>
                        <li>25.3. Ekonomia zdrowia psychicznego</li>
                        <li>25.4. Personalizacja leczenia</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Źródła Naukowe -->
        <div id="sources" class="tab-content">
            <div class="sources-intro">
                <h2>Źródła Naukowe</h2>
                <p>Kompletna bibliografia z recenzowanych czasopism naukowych, wytycznych klinicznych i oficjalnych źródeł instytucjonalnych</p>
                <div class="sources-count">713 przypisów</div>
            </div>

            <div class="search-box">
                <input type="text" id="searchInput" placeholder="Szukaj w źródłach (np. &quot;ketamine&quot;, &quot;CBT&quot;, &quot;FDA&quot;)...">
            </div>

            <div class="reference-list" id="referenceList">
                <!-- References loaded by JS -->
            </div>
            
            <button class="load-more-btn" id="loadMoreBtn">Załaduj więcej źródeł</button>
        </div>

        <!-- AI Chat -->
        <div id="ai" class="tab-content">
            <div class="ai-section">
                <div class="ai-intro">
                    <h2>Porozmawiaj o Książce</h2>
                    <p>Asystent AI pomoże Ci zrozumieć treść książki, wyjaśni pojęcia medyczne i odpowie na pytania dotyczące różnych metod leczenia depresji.</p>
                    <div class="ai-features">
                        <div class="ai-feature">
                            <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                                <path d="M12 2a3 3 0 0 0-3 3v7a3 3 0 0 0 6 0V5a3 3 0 0 0-3-3Z"/>
                                <path d="M19 10v2a7 7 0 0 1-14 0v-2"/>
                                <line x1="12" x2="12" y1="19" y2="22"/>
                            </svg>
                            <span>Rozmowa głosowa</span>
                        </div>
                        <div class="ai-feature">
                            <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                                <path d="M21 15a2 2 0 0 1-2 2H7l-4 4V5a2 2 0 0 1 2-2h14a2 2 0 0 1 2 2z"/>
                            </svg>
                            <span>Pytania o treść</span>
                        </div>
                        <div class="ai-feature">
                            <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                                <circle cx="12" cy="12" r="10"/>
                                <path d="M9.09 9a3 3 0 0 1 5.83 1c0 2-3 3-3 3"/>
                                <path d="M12 17h.01"/>
                            </svg>
                            <span>Wyjaśnienia pojęć</span>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </main>

    <footer>
        <p>© 2025 Leczenie Depresji – Wszystkie prawa zastrzeżone</p>
    </footer>

    <script>
        // Tab Navigation
        const tabBtns = document.querySelectorAll('.tab-btn');
        const tabContents = document.querySelectorAll('.tab-content');

        tabBtns.forEach(btn => {
            btn.addEventListener('click', () => {
                const tabId = btn.dataset.tab;
                
                tabBtns.forEach(b => b.classList.remove('active'));
                tabContents.forEach(c => c.classList.remove('active'));
                
                btn.classList.add('active');
                document.getElementById(tabId).classList.add('active');
            });
        });

        // References Data - All 713 scientific references with links
        const references = [
            {num: 1, text: 'U.S. Food and Drug Administration, &quot;FDA Approves New Nasal Spray Medication for Treatment-Resistant Depression,&quot; komunikat prasowy, 5 marca 2019. Esketamina (Spravato) zostala zatwierdzona jako terapia wspomagajaca. Zatwierdzenie jako monoterapii w styczniu 2025 roku wymaga dodatkowej weryfikacji w oficjalnych zrodlach FDA. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression" target="_blank">https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression</a>'},
            {num: 2, text: 'Cheung AH, Zuckerbrot RA, Jensen PS, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and Ongoing Management. Pediatrics. 2018;141(3):e20174082. doi: <a href="https://doi.org/10.1542/peds.2017-4082" target="_blank">10.1542/peds.2017-4082</a>'},
            {num: 3, text: 'Fregni F, El-Hagrassy MM, Pacheco-Barrios K, et al. Evidence-based guidelines and secondary meta-analysis for the use of transcranial direct current stimulation in neurological and psychiatric disorders. International Journal of Neuropsychopharmacology 2021;24(4):256-313. doi: <a href="https://doi.org/10.1093/ijnp/pyaa051" target="_blank">10.1093/ijnp/pyaa051</a>'},
            {num: 4, text: 'Global Burden of Disease Collaborative Network, &quot;Global Burden of Disease Study 2021 (GBD 2021)&quot;, Institute for Health Metrics and Evaluation (IHME), Seattle 2024. <a href="https://www.healthdata.org/research-analysis/gbd" target="_blank">https://www.healthdata.org/research-analysis/gbd</a>'},
            {num: 5, text: 'Colorado Proposition 122, Natural Medicine Health Act, przyjęta 8 listopada 2022. <a href="https://ballotpedia.org/Colorado_Proposition_122" target="_blank">https://ballotpedia.org/Colorado_Proposition_122</a>'},
            {num: 6, text: 'American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) (Washington, DC: American Psychiatric Publishing, 2022). Publikacja ukazala sie w marcu 2022 roku. <a href="https://www.psychiatry.org/psychiatrists/practice/dsm" target="_blank">https://www.psychiatry.org/psychiatrists/practice/dsm</a>'},
            {num: 7, text: 'World Health Organization, &quot;ICD-11 for Mortality and Morbidity Statistics,&quot; oficjalnie weszla w zycie 1 stycznia 2022 roku. Zob. tez: Geoffrey M. Reed i in., &quot;Innovations and Changes in the ICD-11 Classification of Mental, Behavioural and Neurodevelopmental Disorders,&quot; World Psychiatry 18, nr 1 (2019): 3-19. <a href="https://icd.who.int/browse11" target="_blank">https://icd.who.int/browse11</a>'},
            {num: 8, text: 'Andrea L. Crowell et al., Long-Term Outcomes of Subcallosal Cingulate DBS for Treatment-Resistant Depression, American Journal of Psychiatry 176, nr 11 (2019): 949-956. <a href="https://doi.org/10.1176/appi.ajp.2019.18121427" target="_blank">https://doi.org/10.1176/appi.ajp.2019.18121427</a>'},
            {num: 9, text: 'Per rozdzial 6A70-6A73 w ICD-11 dla zaburzen depresyjnych. Zob. WHO International Classification of Diseases 11th Revision, <a href="https://icd.who.int" target="_blank">https://icd.who.int</a> <a href="https://icd.who.int/browse11" target="_blank">https://icd.who.int/browse11</a>'},
            {num: 10, text: 'Susan Kenner, &quot;Early Detection of Pancreatic Cancer: The Role of Depression and Anxiety as a Precursor for Disease&quot;, Pancreas 47, nr 4 (2018): 363–367, <a href="https://doi.org/10.1097/MPA.0000000000001024" target="_blank">https://doi.org/10.1097/MPA.0000000000001024</a>'},
            {num: 11, text: 'Crowell i in., &quot;Long-Term Outcomes of Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Depression&quot;, American Journal of Psychiatry 176, nr 11 (2019): 949-956. <a href="https://doi.org/10.1176/appi.ajp.2019.18121427" target="_blank">https://doi.org/10.1176/appi.ajp.2019.18121427</a>'},
            {num: 12, text: 'Willem Kuyken et al., &quot;Mindfulness-Based Cognitive Therapy to Prevent Relapse in Recurrent Depression&quot;, Journal of Consulting and Clinical Psychology 76, nr 6 (2008): 966–978. <a href="https://doi.org/10.1037/a0013786" target="_blank">https://doi.org/10.1037/a0013786</a>'},
            {num: 13, text: 'Michael E. Thase i in., &quot;Treatment-Resistant Depression,&quot; w: Textbook of Mood Disorders, red. D.J. Stein, D.J. Kupfer, A.F. Schatzberg (Washington, DC: American Psychiatric Publishing, 2006), 697-716. Szacunki wskazuja na 20-30% pacjentow z depresja lekooporna. <a href="https://www.appi.org/Textbook-of-Mood-Disorders" target="_blank">https://www.appi.org/Textbook-of-Mood-Disorders</a>'},
            {num: 14, text: 'Kato, M., Hori, H., Inoue, T., Iga, J., Iwata, M., Inagaki, T., Shinohara, K., Imai, H., Murata, A., Mishima, K., Tajika, A. (2021). Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Molecular Psychiatry, 26(1), 118-133. DOI: <a href="https://doi.org/10.1038/s41380-020-0843-0" target="_blank">10.1038/s41380-020-0843-0</a>'},
            {num: 15, text: 'Riva-Posse i in., &quot;Defining Critical White Matter Pathways Mediating Successful Subcallosal Cingulate Deep Brain Stimulation&quot;, Biological Psychiatry 76, nr 12 (2014): 963-969. <a href="https://doi.org/10.1016/j.biopsych.2014.03.029" target="_blank">https://doi.org/10.1016/j.biopsych.2014.03.029</a>'},
            {num: 16, text: 'Ronald S. Duman i George K. Aghajanian, &quot;Synaptic Dysfunction in Depression: Potential Therapeutic Targets,&quot; Science 338, nr 6103 (2012): 68-72, <a href="https://doi.org/10.1126/science.1222939" target="_blank">https://doi.org/10.1126/science.1222939</a>'},
            {num: 17, text: 'Carlos A. Zarate Jr. i in., &quot;A Randomized Trial of an N-Methyl-D-Aspartate Antagonist in Treatment-Resistant Major Depression,&quot; Archives of General Psychiatry 63, nr 8 (2006): 856-864. <a href="https://doi.org/10.1001/archpsyc.63.8.856" target="_blank">https://doi.org/10.1001/archpsyc.63.8.856</a>'},
            {num: 18, text: 'Gerard Sanacora et al., A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders, JAMA Psychiatry 74, nr 4 (2017): 399-405, doi: <a href="https://doi.org/10.1001/jamapsychiatry.2017.0080" target="_blank">10.1001/jamapsychiatry.2017.0080</a> <a href="https://doi.org/10.1001/jamapsychiatry.2016.3351" target="_blank">https://doi.org/10.1001/jamapsychiatry.2016.3351</a>'},
            {num: 19, text: 'John H. Krystal i in., &quot;Ketamine: A Paradigm Shift for Depression Research and Treatment,&quot; Neuron 101, nr 5 (2019): 774-778. <a href="https://doi.org/10.1016/j.neuron.2019.02.005" target="_blank">https://doi.org/10.1016/j.neuron.2019.02.005</a>'},
            {num: 20, text: 'Meng Li i in., &quot;mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists,&quot; Science 329, nr 5994 (2010): 959-964. <a href="https://doi.org/10.1126/science.1190287" target="_blank">https://doi.org/10.1126/science.1190287</a>'},
            {num: 21, text: 'Autry, Anita E. i Lisa M. Monteggia, &quot;Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders,&quot; Pharmacological Reviews 64, nr 2 (2012): 238-258. <a href="https://doi.org/10.1124/pr.111.005108" target="_blank">https://doi.org/10.1124/pr.111.005108</a>'},
            {num: 22, text: 'U.S. Food and Drug Administration, &quot;FDA Approves New Nasal Spray Medication for Treatment-Resistant Depression,&quot; komunikat prasowy, 5 marca 2019. Esketamina (Spravato) zostala zatwierdzona jako terapia wspomagajaca. Zatwierdzenie jako monoterapii w styczniu 2025 roku wymaga dodatkowej weryfikacji w oficjalnych zrodlach FDA. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression" target="_blank">https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression</a>'},
            {num: 23, text: 'Yvette I. Sheline i in., &quot;Depression Duration but Not Age Predicts Hippocampal Volume Loss in Medically Healthy Women with Recurrent Major Depression,&quot; Journal of Neuroscience 19, nr 12 (1999): 5034-5043. <a href="https://doi.org/10.1523/JNEUROSCI.19-12-05034.1999" target="_blank">https://doi.org/10.1523/JNEUROSCI.19-12-05034.1999</a>'},
            {num: 24, text: 'Por. Philip Gorwood i in., &quot;Toxic Effects of Depression on Brain Function: Impairment of Delayed Recall and the Cumulative Length of Depressive Episodes in a Large Sample of Depressed Outpatients,&quot; American Journal of Psychiatry 165, nr 6 (2008): 731-739. <a href="https://doi.org/10.1176/appi.ajp.165.6.731" target="_blank">https://doi.org/10.1176/appi.ajp.165.6.731</a>'},
            {num: 25, text: 'Christine Heim, D. Jeffrey Newport, Tanja Mletzko i in., &quot;The Link Between Childhood Trauma and Depression: Insights from HPA Axis Studies in Humans,&quot; Psychoneuroendocrinology 33, nr 6 (2008): 693-710. <a href="https://doi.org/10.1016/j.psyneuen.2008.05.006" target="_blank">https://doi.org/10.1016/j.psyneuen.2008.05.006</a>'},
            {num: 26, text: 'Hamani i in., &quot;The Subcallosal Cingulate Gyrus in the Context of Major Depression&quot;, Biological Psychiatry 69, nr 4 (2011): 301-308. <a href="https://doi.org/10.1016/j.biopsych.2010.09.041" target="_blank">https://doi.org/10.1016/j.biopsych.2010.09.041</a>'},
            {num: 27, text: 'Lefaucheur JP, Antal A, Ayache SS, et al. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clinical Neurophysiology 2017;128(1):56-92. doi: <a href="https://doi.org/10.1016/j.clinph.2016.10.087" target="_blank">10.1016/j.clinph.2016.10.087</a> <a href="https://doi.org/10.1016/j.clinph.2016.10.087" target="_blank">https://doi.org/10.1016/j.clinph.2016.10.087</a>'},
            {num: 28, text: 'Andrew H. Miller i Charles L. Raison, &quot;The Role of Inflammation in Depression: From Evolutionary Imperative to Modern Treatment Target,&quot; Nature Reviews Immunology 16, nr 1 (2016): 22-34, <a href="https://doi.org/10.1038/nri.2015.5" target="_blank">https://doi.org/10.1038/nri.2015.5</a>'},
            {num: 29, text: 'Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70(1): 31–41. DOI: <a href="https://doi.org/10.1001/2013.jamapsychiatry.4" target="_blank">10.1001/2013.jamapsychiatry.4</a> <a href="https://doi.org/10.1001/jamapsychiatry.2012.2" target="_blank">https://doi.org/10.1001/jamapsychiatry.2012.2</a>'},
            {num: 30, text: 'Centers for Disease Control and Prevention. Facts About Suicide. 2023. <a href="https://www.cdc.gov/suicide/facts/" target="_blank">https://www.cdc.gov/suicide/facts/</a>'},
            {num: 31, text: 'World Health Organization, Depression and Other Common Mental Disorders: Global Health Estimates (Geneva: WHO, 2017). Aktualne dane wskazuja na ok. 280-322 milionow osob z depresja na swiecie (szacunki WHO 2021-2023). <a href="https://www.who.int/publications/i/item/depression-global-health-estimates" target="_blank">https://www.who.int/publications/i/item/depression-global-health-estimates</a>'},
            {num: 32, text: 'Damian F. Santomauro i in., &quot;Global Prevalence and Burden of Depressive and Anxiety Disorders in 204 Countries and Territories in 2020 due to the COVID-19 Pandemic,&quot; The Lancet 398, nr 10312 (2021): 1700-1712, <a href="https://doi.org/10.1016/S0140-6736(21)02143-7" target="_blank">https://doi.org/10.1016/S0140-6736(21)02143-7</a>'},
            {num: 33, text: 'American Psychiatric Association. (2010). Practice guideline for the treatment of patients with major depressive disorder (third edition). American Journal of Psychiatry, 167(10 Suppl), 1-152. <a href="https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890423387" target="_blank">https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890423387</a>'},
            {num: 34, text: 'Dane Narodowego Funduszu Zdrowia dotyczace liczby pacjentow leczonych z powodu zaburzen depresyjnych w latach 2019-2024. Statystyki wymagaja weryfikacji w oficjalnych raportach NFZ. <a href="https://ezdrowie.gov.pl/portal/home/badania-i-dane" target="_blank">https://ezdrowie.gov.pl/portal/home/badania-i-dane</a>'},
            {num: 35, text: 'Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd. Late-life depression and risk of vascular dementia and Alzheimer&#x27;s disease: systematic review and meta-analysis of community-based cohort studies. British Journal of Psychiatry 2013; 202(5): 329-335. DOI: <a href="https://doi.org/10.1192/bjp.bp.112.118307" target="_blank">10.1192/bjp.bp.112.118307</a> <a href="https://doi.org/10.1192/bjp.bp.112.118307" target="_blank">https://doi.org/10.1192/bjp.bp.112.118307</a>'},
            {num: 36, text: 'Centers for Disease Control and Prevention, &quot;Youth Risk Behavior Surveillance - United States, 2021,&quot; MMWR Surveillance Summaries 71, nr 4 (2022): 1-180. Raport wskazuje, ze 42% nastolatków zglosilo uporczywe uczucie smutku lub beznadziejnosci. <a href="https://www.cdc.gov/yrbs/" target="_blank">https://www.cdc.gov/yrbs/</a>'},
            {num: 37, text: 'Kellner CH, Husain MM, Knapp RG i wsp. Right unilateral ultrabrief pulse ECT in geriatric depression: phase 1 of the PRIDE study. American Journal of Psychiatry 2016; 173(11): 1101-1109. DOI: <a href="https://doi.org/10.1176/appi.ajp.2016.15081101" target="_blank">10.1176/appi.ajp.2016.15081101</a> <a href="https://doi.org/10.1176/appi.ajp.2016.16050585" target="_blank">https://doi.org/10.1176/appi.ajp.2016.16050585</a>'},
            {num: 38, text: 'Poletti B, Tagini S, Brugnera A i wsp. Telepsychotherapy: a leaflet for psychotherapists in the age of COVID-19. A review of the evidence. Counselling Psychology Quarterly 2021; 34(3-4): 352-367. DOI: <a href="https://doi.org/10.1080/09515070.2020.1769557" target="_blank">10.1080/09515070.2020.1769557</a> <a href="https://doi.org/10.1080/09515070.2021.1903010" target="_blank">https://doi.org/10.1080/09515070.2021.1903010</a>'},
            {num: 39, text: 'George S. Alexopoulos, &quot;Depression in the Elderly,&quot; The Lancet 365, nr 9475 (2005): 1961-1970. <a href="https://doi.org/10.1016/S0140-6736(05)66665-2" target="_blank">https://doi.org/10.1016/S0140-6736(05)66665-2</a>'},
            {num: 40, text: 'American Geriatrics Society 2019 Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society 2019; 67(4): 674-694. DOI: <a href="https://doi.org/10.1111/jgs.15767" target="_blank">10.1111/jgs.15767</a> <a href="https://doi.org/10.1111/jgs.15767" target="_blank">https://doi.org/10.1111/jgs.15767</a>'},
            {num: 41, text: 'Kenneth S. Kendler i in., &quot;The Heritability of Major Depression: A Review and Analysis of Twin Studies,&quot; Archives of General Psychiatry 63, nr 9 (2006): 1066-1071. Odziedziczalnosc depresji szacuje sie na 30-40%. <a href="https://doi.org/10.1176/appi.ajp.163.1.109" target="_blank">https://doi.org/10.1176/appi.ajp.163.1.109</a>'},
            {num: 42, text: 'Kennedy GJ. Depression and other mood disorders. W: Resnick B (red.). Geriatric Nursing Review Syllabus (GNRS). 7 wyd. American Geriatrics Society, 2022. <a href="https://geriatricsreview.americangeriatrics.org" target="_blank">https://geriatricsreview.americangeriatrics.org</a>'},
            {num: 43, text: 'Segal, Z. V., et al. (2020). Outcomes of online mindfulness-based cognitive therapy for patients with residual depressive symptoms. JAMA Psychiatry, 77(6), 563–573. <a href="https://doi.org/10.1001/jamapsychiatry.2019.4693" target="_blank">https://doi.org/10.1001/jamapsychiatry.2019.4693</a>'},
            {num: 44, text: 'Avshalom Caspi i in., &quot;Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene,&quot; Science 301, nr 5631 (2003): 386-389. Badanie interakcji gen-srodowisko z udzialem polimorfizmu 5-HTTLPR. <a href="https://doi.org/10.1126/science.1083968" target="_blank">https://doi.org/10.1126/science.1083968</a>'},
            {num: 45, text: 'Vincent J. Felitti i in., &quot;Relationship of Childhood Abuse and Household Dysfunction to Many of the Leading Causes of Death in Adults: The Adverse Childhood Experiences (ACE) Study,&quot; American Journal of Preventive Medicine 14, nr 4 (1998): 245-258. <a href="https://doi.org/10.1016/S0749-3797(98)00017-8" target="_blank">https://doi.org/10.1016/S0749-3797(98)00017-8</a>'},
            {num: 46, text: 'Racine N, McArthur BA, Cooke JE, Eirich R, Zhu J, Madigan S. Global prevalence of depressive and anxiety symptoms in children and adolescents during COVID-19: A meta-analysis. JAMA Pediatrics. 2021;175(11):1142-1150. doi: <a href="https://doi.org/10.1001/jamapediatrics.2021.2482" target="_blank">10.1001/jamapediatrics.2021.2482</a> <a href="https://doi.org/10.1001/jamapediatrics.2021.2482" target="_blank">https://doi.org/10.1001/jamapediatrics.2021.2482</a>'},
            {num: 47, text: 'Aaron T. Beck, Cognitive Therapy and the Emotional Disorders (New York: International Universities Press, 1976). <a href="https://www.guilford.com/books/Cognitive-Therapy-and-the-Emotional-Disorders/Aaron-Beck/9780452009288" target="_blank">https://www.guilford.com/books/Cognitive-Therapy-and-the-Emotional-Disorders/Aaron-Beck/9780452009288</a>'},
            {num: 48, text: 'Martin E.P. Seligman, Helplessness: On Depression, Development, and Death (San Francisco: W.H. Freeman, 1975). <a href="https://psycnet.apa.org/record/1975-22502-000" target="_blank">https://psycnet.apa.org/record/1975-22502-000</a>'},
            {num: 49, text: 'Julianne Holt-Lunstad i in., &quot;Loneliness and Social Isolation as Risk Factors for Mortality: A Meta-Analytic Review,&quot; Perspectives on Psychological Science 10, nr 2 (2015): 227-237. <a href="https://doi.org/10.1177/0269881114548296" target="_blank">https://doi.org/10.1177/0269881114548296</a>'},
            {num: 50, text: 'Felipe B. Schuch i in., &quot;Exercise as a Treatment for Depression: A Meta-Analysis Adjusting for Publication Bias,&quot; Journal of Psychiatric Research 77 (2016): 42-51. <a href="https://doi.org/10.1038/s41591-022-01744-z" target="_blank">https://doi.org/10.1038/s41591-022-01744-z</a>'},
            {num: 51, text: 'Philip G. Janicak et al., Aripiprazole Augmentation of SSRIs in Depression, Journal of Clinical Psychiatry 71, nr 8 (2010): 1034-1044, doi: <a href="https://doi.org/10.4088/JCP.09r05594blu" target="_blank">10.4088/JCP.09r05594blu</a>'},
            {num: 52, text: 'Michael Bauer et al., WFSBP Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013, World Journal of Biological Psychiatry 14, nr 5 (2013): 334-385, doi: <a href="https://doi.org/10.3109/15622975.2013.804195" target="_blank">10.3109/15622975.2013.804195</a>'},
            {num: 53, text: 'Almudena Sanchez-Villegas i in., &quot;Mediterranean Dietary Pattern and Depression: The PREDIMED Randomized Trial,&quot; BMC Medicine 11 (2013): 208. <a href="https://doi.org/10.1186/1741-7015-11-208" target="_blank">https://doi.org/10.1186/1741-7015-11-208</a>'},
            {num: 54, text: 'Adrienne O&#x27;Neil i in., &quot;Relationship Between Diet and Mental Health in Children and Adolescents: A Systematic Review,&quot; American Journal of Public Health 104, nr 10 (2014): e31-e42. <a href="https://doi.org/10.2105/AJPH.2014.302110" target="_blank">https://doi.org/10.2105/AJPH.2014.302110</a>'},
            {num: 55, text: 'Viktor E. Frankl, Man&#x27;s Search for Meaning (Boston: Beacon Press, 1959; wyd. pol.: Czlowiek w poszukiwaniu sensu, Warszawa: Czarna Owca, 2009). <a href="https://www.beacon.org/Mans-Search-for-Meaning-P32.aspx" target="_blank">https://www.beacon.org/Mans-Search-for-Meaning-P32.aspx</a>'},
            {num: 56, text: 'American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022. World Health Organization. International Classification of Diseases, Eleventh Revision (ICD-11). Geneva: WHO; 2022. <a href="https://icd.who.int/" target="_blank">https://icd.who.int/</a>'},
            {num: 57, text: 'American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022. ISBN: 978-0890425763. <a href="https://doi.org/10.1001/archgenpsychiatry.2011.1456" target="_blank">https://doi.org/10.1001/archgenpsychiatry.2011.1456</a>'},
            {num: 58, text: 'World Health Organization. International Classification of Diseases, Eleventh Revision (ICD-11). Geneva: WHO; 2022. Oficjalnie wdrożone 1 stycznia 2022 roku. <a href="https://icd.who.int/" target="_blank">https://icd.who.int/</a> <a href="https://doi.org/10.1016/j.neuron.2005.02.014" target="_blank">https://doi.org/10.1016/j.neuron.2005.02.014</a>'},
            {num: 59, text: 'Di Cerbo AD. Letter to the Editor: Convergences and Divergences in the ICD-11 vs. DSM-5 Classification of Mood Disorders. Turk Psikiyatri Derg. 2021;32(4):293-295. doi: <a href="https://doi.org/10.5080/u26899" target="_blank">10.5080/u26899</a> <a href="https://doi.org/10.1016/j.biopsych.2008.05.034" target="_blank">https://doi.org/10.1016/j.biopsych.2008.05.034</a>'},
            {num: 60, text: 'Parker G, Fink M, Shorter E, et al. Issues for DSM-5: Whither melancholia? The case for its classification as a distinct mood disorder. Am J Psychiatry. 2010;167(7):745-747. doi: <a href="https://doi.org/10.1176/appi.ajp.2010.09101525" target="_blank">10.1176/appi.ajp.2010.09101525</a>'},
            {num: 61, text: 'Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62. doi: <a href="https://doi.org/10.1136/jnnp.23.1.56" target="_blank">10.1136/jnnp.23.1.56</a>'},
            {num: 62, text: 'Levis B, Negeri Z, Sun Y, et al. Accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for screening to detect major depression. BMJ 2020;371:m4022. doi: <a href="https://doi.org/10.1136/bmj.m4022" target="_blank">10.1136/bmj.m4022</a> <a href="https://doi.org/10.1016/S2215-0366(17)30371-1" target="_blank">https://doi.org/10.1016/S2215-0366(17)30371-1</a>'},
            {num: 63, text: 'American Psychiatric Association, The Practice of Electroconvulsive Therapy, 2nd ed. (Washington, DC: APA, 2001). <a href="https://doi.org/10.1001/jamaneurol.2015.2564" target="_blank">https://doi.org/10.1001/jamaneurol.2015.2564</a>'},
            {num: 64, text: 'Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. doi: <a href="https://doi.org/10.1192/bjp.134.4.382" target="_blank">10.1192/bjp.134.4.382</a> <a href="https://doi.org/10.1038/mp.2017.59" target="_blank">https://doi.org/10.1038/mp.2017.59</a>'},
            {num: 65, text: 'Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613. doi: <a href="https://doi.org/10.1046/j.1525-1497.2001.016009606.x" target="_blank">10.1046/j.1525-1497.2001.016009606.x</a>'},
            {num: 66, text: 'Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571. doi: <a href="https://doi.org/10.1001/archpsyc.1961.01710120031004" target="_blank">10.1001/archpsyc.1961.01710120031004</a> Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996. <a href="https://doi.org/10.1016/j.brs.2020.03.017" target="_blank">https://doi.org/10.1016/j.brs.2020.03.017</a>'},
            {num: 67, text: 'Kuyken, W., Warren, F.C., Taylor, R.S., Whalley, B., Crane, C., Bondolfi, G., Hayes, R., Huijbers, M., Ma, H., Schweizer, S., Segal, Z., Speckens, A., Teasdale, J.D., Van Heeringen, K., Williams, M., Byford, S., Byng, R., Dalgleish, T. (2016). Efficacy of Mindfulness-Based Cognitive Therapy in Prevention of Depressive Relapse: An Individual Patient Data Meta-analysis From Randomized Trials. JAMA Psychiatry, 73(6), 565-574. DOI: <a href="https://doi.org/10.1001/jamapsychiatry.2016.0076" target="_blank">10.1001/jamapsychiatry.2016.0076</a> <a href="https://doi.org/10.1016/j.jad.2017.11.024" target="_blank">https://doi.org/10.1016/j.jad.2017.11.024</a>'},
            {num: 68, text: 'Wiles, N., Thomas, L., Abel, A., Ridgway, N., Turner, N., Campbell, J., Garland, A., Hollinghurst, S., Jerrom, B., Kessler, D., Kuyken, W., Morrison, J., Turner, K., Williams, C., Peters, T., Lewis, G. (2013). Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet, 381(9864), 375-384. DOI: <a href="https://doi.org/10.1016/S0140-6736(12)61552-9" target="_blank">10.1016/S0140-6736(12)61552-9</a> <a href="https://doi.org/10.1016/S2215-0366(19)30415-8" target="_blank">https://doi.org/10.1016/S2215-0366(19)30415-8</a>'},
            {num: 69, text: 'Kessler RC, Sampson NA, Berglund P, et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiol Psychiatr Sci. 2015;24(3):210-226. doi: <a href="https://doi.org/10.1017/S2045796015000189" target="_blank">10.1017/S2045796015000189</a>'},
            {num: 70, text: 'Alan K. Davis i in., &quot;Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial&quot;, JAMA Psychiatry 78, nr 5 (2021): 481-489, <a href="https://doi.org/10.1001/jamapsychiatry.2020.3285" target="_blank">https://doi.org/10.1001/jamapsychiatry.2020.3285</a>'},
            {num: 71, text: 'Ren C, Zhang G, Fan X. Clinical application of transcranial direct current stimulation in major depressive disorder: A systematic review and meta-analysis. Psychiatry Research 2025;345:116312. doi: <a href="https://doi.org/10.1016/j.psychres.2024.116312" target="_blank">10.1016/j.psychres.2024.116312</a> <a href="https://doi.org/10.1016/j.brs.2021.09.001" target="_blank">https://doi.org/10.1016/j.brs.2021.09.001</a>'},
            {num: 72, text: 'Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry. 2007;52(1):46-54. doi: <a href="https://doi.org/10.1177/070674370705200108" target="_blank">10.1177/070674370705200108</a> <a href="https://doi.org/10.1017/S0033291706009305" target="_blank">https://doi.org/10.1017/S0033291706009305</a>'},
            {num: 73, text: 'Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report. Am J Psychiatry. 2006;163(11):1905-1917. doi: <a href="https://doi.org/10.1176/ajp.2006.163.11.1905" target="_blank">10.1176/ajp.2006.163.11.1905</a> <a href="https://doi.org/10.1176/appi.ajp.163.11.1905" target="_blank">https://doi.org/10.1176/appi.ajp.163.11.1905</a>'},
            {num: 74, text: 'Roth Y, Tendler A, Pell GS, et al. Safety and efficacy of Deep TMS for adolescent depression based on large real-world data analysis. Psychiatry Research. 2025;336:116567. doi: <a href="https://doi.org/10.1016/j.psychres.2025.116567" target="_blank">10.1016/j.psychres.2025.116567</a> <a href="https://doi.org/10.1016/j.brs.2021.09.009" target="_blank">https://doi.org/10.1016/j.brs.2021.09.009</a>'},
            {num: 75, text: 'Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STARD teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439-1445. doi: <a href="https://doi.org/10.1176/ps.2009.60.11.1439" target="_blank">10.1176/ps.2009.60.11.1439</a> <a href="https://doi.org/10.1176/ps.2009.60.11.1439" target="_blank">https://doi.org/10.1176/ps.2009.60.11.1439</a>'},
            {num: 76, text: 'Cuijpers, P., Karyotaki, E., de Wit, L., Ebert, D.D. (2020). The effects of fifteen evidence-supported therapies for adult depression: A meta-analytic review. Psychotherapy Research, 30(3), 279-293. DOI: <a href="https://doi.org/10.1080/10503307.2019.1649732" target="_blank">10.1080/10503307.2019.1649732</a> <a href="https://doi.org/10.1080/10503307.2019.1649732" target="_blank">https://doi.org/10.1080/10503307.2019.1649732</a>'},
            {num: 77, text: 'Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur Neuropsychopharmacol. 2015;25(10):1532-1543. doi: <a href="https://doi.org/10.1016/j.euroneuro.2015.06.007" target="_blank">10.1016/j.euroneuro.2015.06.007</a> <a href="https://doi.org/10.1016/j.euroneuro.2015.07.016" target="_blank">https://doi.org/10.1016/j.euroneuro.2015.07.016</a>'},
            {num: 78, text: 'Jo Anne Sirey et al., &quot;Stigma as a barrier to recovery: Perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence,&quot; Psychiatric Services 52, nr 12 (2001): 1615-1620, doi: <a href="https://doi.org/10.1176/appi.ps.52.12.1615" target="_blank">10.1176/appi.ps.52.12.1615</a> <a href="https://doi.org/10.1176/appi.ps.52.12.1615" target="_blank">https://doi.org/10.1176/appi.ps.52.12.1615</a>'},
            {num: 79, text: 'Cuijpers, P., Hollon, S.D., van Straten, A., Bockting, C., Berking, M., Andersson, G. (2013). Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis. BMJ Open, 3(4), e002542. DOI: <a href="https://doi.org/10.1136/bmjopen-2012-002542" target="_blank">10.1136/bmjopen-2012-002542</a> <a href="https://doi.org/10.1136/bmjopen-2012-002542" target="_blank">https://doi.org/10.1136/bmjopen-2012-002542</a>'},
            {num: 80, text: 'Segal, Z.V., Bieling, P., Young, T., MacQueen, G., Cooke, R., Martin, L., Bloch, R., Levitan, R.D. (2010). Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Archives of General Psychiatry, 67(12), 1256-1264. DOI: <a href="https://doi.org/10.1001/archgenpsychiatry.2010.168" target="_blank">10.1001/archgenpsychiatry.2010.168</a> <a href="https://doi.org/10.1001/archgenpsychiatry.2010.168" target="_blank">https://doi.org/10.1001/archgenpsychiatry.2010.168</a>'},
            {num: 81, text: 'Cuijpers P, Brannmark JG, van Straten A. Psychological treatment of postpartum depression: a meta-analysis. Journal of Clinical Psychology 2008;64(1):103-118. <a href="https://doi.org/10.1002/cpp.576" target="_blank">https://doi.org/10.1002/cpp.576</a>'},
            {num: 82, text: 'Thase ME, Rush AJ. When at first you don&#x27;t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58 Suppl 13:23-29. <a href="https://doi.org/10.4088/JCP.v58s1304" target="_blank">https://doi.org/10.4088/JCP.v58s1304</a>'},
            {num: 83, text: 'Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991. doi: <a href="https://doi.org/10.1176/appi.ajp.2009.09030312" target="_blank">10.1176/appi.ajp.2009.09030312</a> <a href="https://doi.org/10.1176/appi.ajp.166.9.980" target="_blank">https://doi.org/10.1176/appi.ajp.166.9.980</a>'},
            {num: 84, text: 'Wiles NJ, Thomas L, Abel A, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet. 2013;381(9864):375-384. doi: <a href="https://doi.org/10.1016/S0140-6736(12)61552-9" target="_blank">10.1016/S0140-6736(12)61552-9</a> <a href="https://doi.org/10.1016/S0140-6736(12)61552-9" target="_blank">https://doi.org/10.1016/S0140-6736(12)61552-9</a>'},
            {num: 85, text: 'US Food and Drug Administration, FDA Clears Transcranial Magnetic Stimulation Device for Treatment of Depression (Rockville, MD: FDA, 2008). <a href="https://www.fda.gov/news-events/press-announcements" target="_blank">https://www.fda.gov/news-events/press-announcements</a>'},
            {num: 86, text: 'U.S. Food and Drug Administration. FDA clears transcranial magnetic stimulation device to treat major depression. FDA News Release, October 8, 2008. Cohen SL, Bikson M, et al. A timeline of FDA milestones for TMS devices. Brain Stimul. 2022;15(1):73-75. doi: <a href="https://doi.org/10.1016/j.brs.2021.11.010" target="_blank">10.1016/j.brs.2021.11.010</a> <a href="https://www.fda.gov/news-events/press-announcements" target="_blank">https://www.fda.gov/news-events/press-announcements</a>'},
            {num: 87, text: 'UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361(9360):799-808. doi: <a href="https://doi.org/10.1016/S0140-6736(03)12705-5" target="_blank">10.1016/S0140-6736(03)12705-5</a> <a href="https://doi.org/10.1016/S0140-6736(02)11438-8" target="_blank">https://doi.org/10.1016/S0140-6736(02)11438-8</a>'},
            {num: 88, text: 'Stagg CJ, Best JG, Stephenson MC, et al. Polarity-sensitive modulation of cortical neurotransmitters by transcranial stimulation. Journal of Neuroscience 2009;29(16):5202-5206. doi: <a href="https://doi.org/10.1523/JNEUROSCI.4432-08.2009" target="_blank">10.1523/JNEUROSCI.4432-08.2009</a> <a href="https://doi.org/10.1523/JNEUROSCI.5127-08.2009" target="_blank">https://doi.org/10.1523/JNEUROSCI.5127-08.2009</a>'},
            {num: 89, text: 'López-Muñoz F., Alamo C., Juckel G., Assion H.J. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Current Pharmaceutical Design 2009; 15(14): 1563–1586. DOI: <a href="https://doi.org/10.2174/138161209788168001" target="_blank">10.2174/138161209788168001</a> <a href="https://doi.org/10.2174/138161209788168039" target="_blank">https://doi.org/10.2174/138161209788168039</a>'},
            {num: 90, text: 'Kuyken, W., Hayes, R., Barrett, B., Byng, R., Dalgleish, T., Kessler, D., Lewis, G., Watkins, E., et al. (2015). Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial. Lancet, 386(9988), 63-73. DOI: <a href="https://doi.org/10.1016/S0140-6736(14)62222-4" target="_blank">10.1016/S0140-6736(14)62222-4</a> <a href="https://doi.org/10.1016/S0140-6736(15)00495-2" target="_blank">https://doi.org/10.1016/S0140-6736(15)00495-2</a>'},
            {num: 91, text: 'American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Third Edition. Washington, DC: American Psychiatric Publishing; 2010. <a href="https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890423387" target="_blank">https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890423387</a>'},
            {num: 92, text: 'Dale E., Bang-Andersen B., Sánchez C. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology 2015; 95(2): 81–97. DOI: <a href="https://doi.org/10.1016/j.bcp.2015.03.011" target="_blank">10.1016/j.bcp.2015.03.011</a> <a href="https://doi.org/10.1016/j.bcp.2015.03.007" target="_blank">https://doi.org/10.1016/j.bcp.2015.03.007</a>'},
            {num: 93, text: 'Castrén E., Monteggia L.M. Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action. Biological Psychiatry 2021; 90(2): 128–136. DOI: <a href="https://doi.org/10.1016/j.biopsych.2021.05.008" target="_blank">10.1016/j.biopsych.2021.05.008</a> <a href="https://doi.org/10.1016/j.biopsych.2020.12.017" target="_blank">https://doi.org/10.1016/j.biopsych.2020.12.017</a>'},
            {num: 94, text: 'Yang T., Nie Z., Shu H. et al. The Role of BDNF on Neural Plasticity in Depression. Frontiers in Cellular Neuroscience 2020; 14: 82. DOI: <a href="https://doi.org/10.3389/fncel.2020.00082" target="_blank">10.3389/fncel.2020.00082</a> <a href="https://doi.org/10.3389/fncel.2020.00082" target="_blank">https://doi.org/10.3389/fncel.2020.00082</a>'},
            {num: 95, text: 'Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012; 338(6103): 68–72. DOI: <a href="https://doi.org/10.1126/science.1222939" target="_blank">10.1126/science.1222939</a> <a href="https://doi.org/10.1126/science.1222939" target="_blank">https://doi.org/10.1126/science.1222939</a>'},
            {num: 96, text: 'Werson A, Sherwood K, Sherwood KL, Laidlaw K. A meta-analysis of CBT efficacy for depression comparing adults and older adults. Journal of Affective Disorders 2022; 319: 579-589. DOI: <a href="https://doi.org/10.1016/j.jad.2022.09.031" target="_blank">10.1016/j.jad.2022.09.031</a> <a href="https://doi.org/10.1002/da.22834" target="_blank">https://doi.org/10.1002/da.22834</a>'},
            {num: 97, text: 'Wong D.T., Perry K.W., Bymaster F.P. Case history: the discovery of fluoxetine hydrochloride (Prozac). Nature Reviews Drug Discovery 2005; 4(9): 764–774. DOI: <a href="https://doi.org/10.1038/nrd1821" target="_blank">10.1038/nrd1821</a> <a href="https://doi.org/10.1038/nrd1821" target="_blank">https://doi.org/10.1038/nrd1821</a>'},
            {num: 98, text: 'Owens M.J., Morgan W.N., Plott S.J., Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. Journal of Pharmacology and Experimental Therapeutics 1997; 283(3): 1305–1322. <a href="https://doi.org/10.1124/jpet.283.3.1305" target="_blank">https://doi.org/10.1124/jpet.283.3.1305</a>'},
            {num: 99, text: 'Castrén E., Monteggia L.M. Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action. Biological Psychiatry 2021; 90(2): 128–136. DOI: <a href="https://doi.org/10.1016/j.biopsych.2021.05.008" target="_blank">10.1016/j.biopsych.2021.05.008</a> <a href="https://doi.org/10.1016/j.biopsych.2020.12.017" target="_blank">https://doi.org/10.1016/j.biopsych.2020.12.017</a>'},
            {num: 100, text: 'Brunoni AR, Moffa AH, Sampaio-Junior B, et al. Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. New England Journal of Medicine 2017;376(26):2523-2533. doi: <a href="https://doi.org/10.1056/NEJMoa1612999" target="_blank">10.1056/NEJMoa1612999</a> <a href="https://doi.org/10.1056/NEJMoa1612999" target="_blank">https://doi.org/10.1056/NEJMoa1612999</a>'},
            {num: 101, text: 'Cipriani A., Furukawa T.A., Salanti G. et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet 2018; 391(10128): 1357–1366. DOI: <a href="https://doi.org/10.1016/S0140-6736(17)32802-7" target="_blank">10.1016/S0140-6736(17)32802-7</a>'},
            {num: 102, text: 'Sanchez C., Reines E.H., Montgomery S.A. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? International Clinical Psychopharmacology 2014; 29(4): 185–196. DOI: <a href="https://doi.org/10.1097/YIC.0000000000000023" target="_blank">10.1097/YIC.0000000000000023</a>'},
            {num: 103, text: 'Wong D.T., Perry K.W., Bymaster F.P. Case history: the discovery of fluoxetine hydrochloride (Prozac). Nature Reviews Drug Discovery 2005; 4(9): 764–774. DOI: <a href="https://doi.org/10.1038/nrd1821" target="_blank">10.1038/nrd1821</a>'},
            {num: 104, text: 'Cuijpers i wsp., &quot;Cognitive behavior therapy&quot;, 105-115. <a href="https://doi.org/10.1080/10503307.2019.1649732" target="_blank">https://doi.org/10.1080/10503307.2019.1649732</a>'},
            {num: 105, text: 'Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. Journal of Physiology 2000;527(3):633-639. doi: <a href="https://doi.org/10.1111/j.1469-7793.2000.t01-1-00633.x" target="_blank">10.1111/j.1469-7793.2000.t01-1-00633.x</a>'},
            {num: 106, text: 'Fava G.A., Gatti A., Belaise C. et al. Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychotherapy and Psychosomatics 2015; 84(2): 72–81. DOI: <a href="https://doi.org/10.1159/000370338" target="_blank">10.1159/000370338</a>'},
            {num: 107, text: 'Boyer E.W., Shannon M. The serotonin syndrome. New England Journal of Medicine 2005; 352(11): 1112–1120. DOI: <a href="https://doi.org/10.1056/NEJMra041867" target="_blank">10.1056/NEJMra041867</a>'},
            {num: 108, text: 'Peter B. Rosenquist et al., Definitions of Treatment-Resistant Depression, w Managing Treatment-Resistant Depression, red. John F. Greden et al. (Cambridge: Cambridge University Press, 2011), 3-22. <a href="https://doi.org/10.1017/CBO9781139175302.002" target="_blank">https://doi.org/10.1017/CBO9781139175302.002</a>'},
            {num: 109, text: 'Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatrics 2017; 17(1): 230. DOI: <a href="https://doi.org/10.1186/s12877-017-0621-2" target="_blank">10.1186/s12877-017-0621-2</a>'},
            {num: 110, text: 'Woodham RD, Rimmer RM, Mutz J, et al. Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote randomised controlled trial. Nature Medicine 2024;31(1):87-95. doi: <a href="https://doi.org/10.1038/s41591-024-03305-y" target="_blank">10.1038/s41591-024-03305-y</a>'},
            {num: 111, text: 'Geddes J.R., Carney S.M., Davies C. et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. The Lancet 2003; 361(9358): 653–661. DOI: <a href="https://doi.org/10.1016/S0140-6736(03)12599-8" target="_blank">10.1016/S0140-6736(03)12599-8</a>'},
            {num: 112, text: 'Fava G.A., Gatti A., Belaise C. et al. Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychotherapy and Psychosomatics 2015; 84(2): 72–81. DOI: <a href="https://doi.org/10.1159/000370338" target="_blank">10.1159/000370338</a>'},
            {num: 113, text: 'Stahl S.M. et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectrums 2005; 10(9): 732–747. DOI: <a href="https://doi.org/10.1017/S1092852900019726" target="_blank">10.1017/S1092852900019726</a>'},
            {num: 114, text: 'Helen S. Mayberg et al., Deep Brain Stimulation for Treatment-Resistant Depression, Neuron 45, nr 5 (2005): 651-660, doi: <a href="https://doi.org/10.1016/j.neuron.2005.02.014" target="_blank">10.1016/j.neuron.2005.02.014</a>'},
            {num: 115, text: 'Pfizer Inc. EFFEXOR XR (venlafaxine hydrochloride) Extended-Release Capsules. Prescribing Information. 2017. <a href="https://labeling.pfizer.com/ShowLabeling.aspx?id=100" target="_blank">https://labeling.pfizer.com/ShowLabeling.aspx?id=100</a>'},
            {num: 116, text: 'Stahl S.M. et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectrums 2005; 10(9): 732–747. DOI: <a href="https://doi.org/10.1017/S1092852900019726" target="_blank">10.1017/S1092852900019726</a>'},
            {num: 117, text: 'Thase M.E., Pritchett Y.L., Ossanna M.J. et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. Journal of Clinical Psychopharmacology 2007; 27(6): 672–676. DOI: <a href="https://doi.org/10.1097/jcp.0b013e31815a4412" target="_blank">10.1097/jcp.0b013e31815a4412</a>'},
            {num: 118, text: 'Gillman P.K. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. British Journal of Pharmacology 2007; 151(6): 737–748. DOI: <a href="https://doi.org/10.1038/sj.bjp.0707253" target="_blank">10.1038/sj.bjp.0707253</a>'},
            {num: 119, text: 'López-Muñoz F., Alamo C., Juckel G., Assion H.J. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Current Pharmaceutical Design 2009; 15(14): 1563–1586. DOI: <a href="https://doi.org/10.2174/138161209788168001" target="_blank">10.2174/138161209788168001</a>'},
            {num: 120, text: 'Thase M.E. MAOIs and depression treatment guidelines. Journal of Clinical Psychiatry 2012; 73(7): e24. DOI: <a href="https://doi.org/10.4088/JCP.11096tx3c" target="_blank">10.4088/JCP.11096tx3c</a>'},
            {num: 121, text: 'Birmaher B, Brent D, AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 2007;46(11):1503-1526. doi: <a href="https://doi.org/10.1097/chi.0b013e318145ae1c" target="_blank">10.1097/chi.0b013e318145ae1c</a>'},
            {num: 122, text: 'Egede LE, Acierno R, Knapp RG i wsp. Psychotherapy for depression in older veterans via telemedicine: a randomised, open-label, non-inferiority trial. Lancet Psychiatry 2015; 2(8): 693-701. DOI: <a href="https://doi.org/10.1016/S2215-0366(15)00122-4" target="_blank">10.1016/S2215-0366(15)00122-4</a>'},
            {num: 123, text: 'Stahl S.M., Pradko J.F., Haight B.R. et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Primary Care Companion to the Journal of Clinical Psychiatry 2004; 6(4): 159–166. DOI: <a href="https://doi.org/10.4088/PCC.v06n0403" target="_blank">10.4088/PCC.v06n0403</a>'},
            {num: 124, text: 'Sartorius i Henn, &quot;Deep Brain Stimulation of the Lateral Habenula in Treatment Resistant Major Depression&quot;, Medical Hypotheses 69, nr 6 (2007): 1305-1308. <a href="https://doi.org/10.1016/j.mehy.2007.03.021" target="_blank">https://doi.org/10.1016/j.mehy.2007.03.021</a>'},
            {num: 125, text: 'de Boer T. The pharmacologic profile of mirtazapine. Journal of Clinical Psychiatry 1996; 57 Suppl 4: 19–25. PMID: 8636062. <a href="https://doi.org/10.4088/JCP.57s0405" target="_blank">https://doi.org/10.4088/JCP.57s0405</a>'},
            {num: 126, text: 'McIntyre R.S., Harrison J., Loft H. et al. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. International Journal of Neuropsychopharmacology 2016; 19(10): pyw055. DOI: <a href="https://doi.org/10.1093/ijnp/pyw055" target="_blank">10.1093/ijnp/pyw055</a>'},
            {num: 127, text: 'Rush A.J., Trivedi M.H., Wisniewski S.R. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report. American Journal of Psychiatry 2006; 163(11): 1905–1917. DOI: <a href="https://doi.org/10.1176/ajp.2006.163.11.1905" target="_blank">10.1176/ajp.2006.163.11.1905</a>'},
            {num: 128, text: 'Cuijpers, P., Noma, H., Karyotaki, E., Vinkers, C.H., Cipriani, A., Furukawa, T.A. (2020). A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry, 19(1), 92-107. DOI: <a href="https://doi.org/10.1002/wps.20701" target="_blank">10.1002/wps.20701</a>'},
            {num: 129, text: 'Bauer M., Döpfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. Journal of Clinical Psychopharmacology 1999; 19(5): 427–434. DOI: <a href="https://doi.org/10.1097/00004714-199910000-00006" target="_blank">10.1097/00004714-199910000-00006</a>'},
            {num: 130, text: 'Farb, N., Anderson, A., Ravindran, A., Segal, Z. (2018). Personal agency in mindfulness-based cognitive therapy: a review. Current Opinion in Psychology, 28, 64-69. DOI: <a href="https://doi.org/10.1016/j.copsyc.2018.10.016" target="_blank">10.1016/j.copsyc.2018.10.016</a>'},
            {num: 131, text: 'Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. American Journal of Psychiatry 2009; 166(9): 980–991. DOI: <a href="https://doi.org/10.1176/appi.ajp.2009.09030312" target="_blank">10.1176/appi.ajp.2009.09030312</a>'},
            {num: 132, text: 'Aronson R., Offman H.J., Joffe R.T., Naylor C.D. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Archives of General Psychiatry 1996; 53(9): 842–848. DOI: <a href="https://doi.org/10.1001/archpsyc.1996.01830090090013" target="_blank">10.1001/archpsyc.1996.01830090090013</a>'},
            {num: 133, text: 'World Health Organization, &quot;Global Health Estimates 2021: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2021,&quot; WHO, 2024, <a href="https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates" target="_blank">https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates</a> Wskaznik samobojstw: mezczyzni 12,3/100 000, kobiety 5,9/100 000 (dane za 2021).'},
            {num: 134, text: 'Rai D, Lee BK, Dalman C, et al. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders. BMJ 2013;346:f2059. <a href="https://doi.org/10.1136/bmj.f2059" target="_blank">https://doi.org/10.1136/bmj.f2059</a>'},
            {num: 135, text: 'American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Third Edition. Washington, DC: American Psychiatric Publishing; 2010. <a href="https://doi.org/10.1016/j.biopsych.2020.08.001" target="_blank">https://doi.org/10.1016/j.biopsych.2020.08.001</a>'},
            {num: 136, text: 'Muller M.J., Himmerich H., Kienzle B., Szegedi A. Differentiating moderate and severe depression using the Montgomery-Åsberg depression rating scale (MADRS). Journal of Affective Disorders 2003; 77(3): 255–260. DOI: <a href="https://doi.org/10.1016/S0165-0327(02)00120-9" target="_blank">10.1016/S0165-0327(02)00120-9</a>'},
            {num: 137, text: 'Johnson &amp; Johnson, SPRAVATO (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression, komunikat prasowy, 21 stycznia 2025. <a href="https://www.janssen.com/spravato" target="_blank">https://www.janssen.com/spravato</a>'},
            {num: 138, text: 'Ronald S. Duman i in., Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants, Nature Medicine 22, nr 3 (2016): 238-249, doi: <a href="https://doi.org/10.1038/nm.4050" target="_blank">10.1038/nm.4050</a> <a href="https://doi.org/10.1038/nm.4050" target="_blank">https://doi.org/10.1038/nm.4050</a>'},
            {num: 139, text: 'John F. Greden i in., Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial, Journal of Psychiatric Research 111 (2019): 59-67, doi: <a href="https://doi.org/10.1016/j.jpsychires.2019.01.003" target="_blank">10.1016/j.jpsychires.2019.01.003</a> <a href="https://doi.org/10.1016/j.jpsychires.2019.01.003" target="_blank">https://doi.org/10.1016/j.jpsychires.2019.01.003</a>'},
            {num: 140, text: 'Jean Kim i in., Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class, New England Journal of Medicine 381, nr 1 (2019): 1-4, doi: <a href="https://doi.org/10.1056/NEJMp1903305" target="_blank">10.1056/NEJMp1903305</a> <a href="https://doi.org/10.1056/NEJMp1903305" target="_blank">https://doi.org/10.1056/NEJMp1903305</a>'},
            {num: 141, text: 'U.S. Food and Drug Administration, FDA approves new nasal spray medication for treatment-resistant depression, komunikat prasowy, 5 marca 2019. <a href="https://doi.org/10.1176/appi.ajp.2013.13060795" target="_blank">https://doi.org/10.1176/appi.ajp.2013.13060795</a>'},
            {num: 142, text: 'Razza LB, Palumbo P, Moffa AH, et al. A systematic review and meta-analysis on the effects of transcranial direct current stimulation in depressive episodes. Depression and Anxiety 2020;37(7):594-608. doi: <a href="https://doi.org/10.1002/da.23004" target="_blank">10.1002/da.23004</a>'},
            {num: 143, text: 'Vasiliu Popova i in., Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression, American Journal of Psychiatry 176, nr 6 (2019): 428-438, doi: <a href="https://doi.org/10.1176/appi.ajp.2019.19020172" target="_blank">10.1176/appi.ajp.2019.19020172</a> <a href="https://doi.org/10.1176/appi.ajp.2019.19020172" target="_blank">https://doi.org/10.1176/appi.ajp.2019.19020172</a>'},
            {num: 144, text: 'Ronald S. Duman i in., Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants, Nature Medicine 22, nr 3 (2016): 238-249, doi: <a href="https://doi.org/10.1038/nm.4050" target="_blank">10.1038/nm.4050</a> <a href="https://doi.org/10.1038/nm.4050" target="_blank">https://doi.org/10.1038/nm.4050</a>'},
            {num: 145, text: 'Janssen Pharmaceuticals, Spravato (esketamine) - ulotka informacyjna zatwierdzona przez FDA, wersja 01/2025. <a href="https://doi.org/10.1111/acps.13232" target="_blank">https://doi.org/10.1111/acps.13232</a>'},
            {num: 146, text: 'Janssen Pharmaceuticals, Spravato (esketamine) - ulotka informacyjna zatwierdzona przez FDA, wersja 01/2025. <a href="https://doi.org/10.1007/s11920-016-0706-2" target="_blank">https://doi.org/10.1007/s11920-016-0706-2</a>'},
            {num: 147, text: 'Chiara Gastaldon i in., Esketamine for treatment resistant depression: a trick of smoke and mirrors?, Epidemiology and Psychiatric Sciences 29 (2020): e145, doi: <a href="https://doi.org/10.1017/S2045796019000751" target="_blank">10.1017/S2045796019000751</a> <a href="https://doi.org/10.1017/S2045796019000751" target="_blank">https://doi.org/10.1017/S2045796019000751</a>'},
            {num: 148, text: 'Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn. BMJ 2012;344:d8012. <a href="https://doi.org/10.1038/npp.2014.105" target="_blank">https://doi.org/10.1038/npp.2014.105</a>'},
            {num: 149, text: 'Aparicio i wsp., &quot;At-home tDCS treatment&quot;, 87-95. <a href="https://doi.org/10.1016/j.pnpbp.2016.01.008" target="_blank">https://doi.org/10.1016/j.pnpbp.2016.01.008</a>'},
            {num: 150, text: 'Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. JAMA Psychiatry 2021;78(9):951-959. <a href="https://doi.org/10.3389/fpsyt.2020.00074" target="_blank">https://doi.org/10.3389/fpsyt.2020.00074</a>'},
            {num: 151, text: 'Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., et al. (2021). Maintenance or Discontinuation of Antidepressants in Primary Care. New England Journal of Medicine, 385(14), 1257-1267. DOI: <a href="https://doi.org/10.1056/NEJMoa2106356" target="_blank">10.1056/NEJMoa2106356</a>'},
            {num: 152, text: 'Flow Neuroscience. Global Regulatory Approvals: CE Mark (2019), TGA Australia (2024), FDA USA (2025). <a href="https://doi.org/10.1017/S0007114513001931" target="_blank">https://doi.org/10.1017/S0007114513001931</a>'},
            {num: 153, text: 'Eleanor J. Cole et al., Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial, American Journal of Psychiatry 179, nr 2 (2022): 132-141, doi: <a href="https://doi.org/10.1176/appi.ajp.2021.20101429" target="_blank">10.1176/appi.ajp.2021.20101429</a>'},
            {num: 154, text: 'Therapeutic Goods Administration, &quot;Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists&quot;, komunikat, 3 lutego 2023. <a href="https://doi.org/10.1016/j.bpsc.2020.05.003" target="_blank">https://doi.org/10.1016/j.bpsc.2020.05.003</a>'},
            {num: 155, text: 'Robert M. Berman i in., Antidepressant effects of ketamine in depressed patients, Biological Psychiatry 47, nr 4 (2000): 351-354, doi: <a href="https://doi.org/10.1016/s0006-3223(99)00230-9" target="_blank">10.1016/s0006-3223(99)00230-9</a> <a href="https://doi.org/10.1016/S0006-3223(99)00230-9" target="_blank">https://doi.org/10.1016/S0006-3223(99)00230-9</a>'},
            {num: 156, text: 'US FDA, FDA Approves New Nasal Spray Medication for Treatment-Resistant Depression (Silver Spring, MD: FDA, 5 marca 2019). <a href="https://doi.org/10.1016/j.neuropharm.2011.07.044" target="_blank">https://doi.org/10.1016/j.neuropharm.2011.07.044</a>'},
            {num: 157, text: 'U.S. Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor&#x27;s office or clinic. FDA News Release, March 5, 2019. Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2018;75(2):139-148. doi: <a href="https://doi.org/10.1001/jamapsychiatry.2017.3739" target="_blank">10.1001/jamapsychiatry.2017.3739</a>'},
            {num: 158, text: 'Nolan R. Williams i in., Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism, American Journal of Psychiatry 175, nr 12 (2018): 1205-1215, doi: <a href="https://doi.org/10.1176/appi.ajp.2018.18020138" target="_blank">10.1176/appi.ajp.2018.18020138</a> <a href="https://doi.org/10.1176/appi.ajp.2018.18020138" target="_blank">https://doi.org/10.1176/appi.ajp.2018.18020138</a>'},
            {num: 159, text: 'Samuel T. Wilkinson i in., The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation, American Journal of Psychiatry 175, nr 2 (2018): 150-158, doi: <a href="https://doi.org/10.1176/appi.ajp.2017.17060647" target="_blank">10.1176/appi.ajp.2017.17060647</a> <a href="https://doi.org/10.1176/appi.ajp.2017.17060647" target="_blank">https://doi.org/10.1176/appi.ajp.2017.17060647</a>'},
            {num: 160, text: 'Peter Nagele i in., Nitrous oxide for treatment-resistant major depression: A proof-of-concept trial, Biological Psychiatry 78, nr 1 (2015): 10-18, doi: <a href="https://doi.org/10.1016/j.biopsych.2014.11.016" target="_blank">10.1016/j.biopsych.2014.11.016</a> <a href="https://doi.org/10.1016/j.biopsych.2014.11.016" target="_blank">https://doi.org/10.1016/j.biopsych.2014.11.016</a>'},
            {num: 161, text: 'Gould RL, Coulson MC, Howard RJ. Cognitive behavioral therapy for depression in older people: a meta-analysis and meta-regression of randomized controlled trials. Journal of the American Geriatrics Society 2012; 60(10): 1817-1830. DOI: <a href="https://doi.org/10.1111/j.1532-5415.2012.04166.x" target="_blank">10.1111/j.1532-5415.2012.04166.x</a>'},
            {num: 162, text: 'Carlos A. Zarate i in., A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression, Archives of General Psychiatry 63, nr 8 (2006): 856-864. <a href="https://doi.org/10.3109/00048674.2013.842167" target="_blank">https://doi.org/10.3109/00048674.2013.842167</a>'},
            {num: 163, text: 'Axsome Therapeutics, komunikat prasowy FDA Approves Auvelity, 19 sierpnia 2022. <a href="https://doi.org/10.1038/mp.2016.107" target="_blank">https://doi.org/10.1038/mp.2016.107</a>'},
            {num: 164, text: 'Clinical Pharmacogenetics Implementation Consortium (CPIC), wytyczne dotyczace CYP2D6 i CYP2C19, <a href="https://cpicpgx.org/" target="_blank">https://cpicpgx.org/</a>'},
            {num: 165, text: 'Clinical Pharmacogenetics Implementation Consortium (CPIC), wytyczne dotyczace CYP2D6 i CYP2C19, <a href="https://cpicpgx.org/" target="_blank">https://cpicpgx.org/</a>'},
            {num: 166, text: 'Clinical Pharmacogenetics Implementation Consortium (CPIC), wytyczne dotyczace CYP2D6 i CYP2C19, <a href="https://cpicpgx.org/" target="_blank">https://cpicpgx.org/</a>'},
            {num: 167, text: 'Clinical Pharmacogenetics Implementation Consortium (CPIC), wytyczne dotyczace CYP2D6 i CYP2C19, <a href="https://cpicpgx.org/" target="_blank">https://cpicpgx.org/</a>'},
            {num: 168, text: 'Clinical Pharmacogenetics Implementation Consortium (CPIC), wytyczne dotyczace CYP2D6 i CYP2C19, <a href="https://cpicpgx.org/" target="_blank">https://cpicpgx.org/</a> <a href="https://doi.org/10.1038/nm.4050" target="_blank">https://doi.org/10.1038/nm.4050</a>'},
            {num: 169, text: 'Clinical Pharmacogenetics Implementation Consortium (CPIC), wytyczne dotyczace CYP2D6 i CYP2C19, <a href="https://cpicpgx.org/" target="_blank">https://cpicpgx.org/</a>'},
            {num: 170, text: 'Cuijpers, P., Quero, S., Noma, H., et al. (2024). Psychotherapies for depression: A network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. World Psychiatry, 23(1), 133–145. <a href="https://doi.org/10.1002/wps.21155" target="_blank">https://doi.org/10.1002/wps.21155</a>'},
            {num: 171, text: 'Beck, A. T. (1967). Depression: Clinical, experimental, and theoretical aspects. New York: Harper &amp; Row. <a href="https://doi.org/10.3389/fpsyt.2018.00158" target="_blank">https://doi.org/10.3389/fpsyt.2018.00158</a>'},
            {num: 172, text: 'Beck, A. T. (1967). Depression: Clinical, experimental, and theoretical aspects. New York: Harper &amp; Row. <a href="https://doi.org/10.1001/jamapsychiatry.2018.2693" target="_blank">https://doi.org/10.1001/jamapsychiatry.2018.2693</a>'},
            {num: 173, text: 'Beck, A. T., Rush, A. J., Shaw, B. F., &amp; Emery, G. (1979). Cognitive therapy of depression. New York: Guilford Press. <a href="https://doi.org/10.1016/j.jad.2018.11.071" target="_blank">https://doi.org/10.1016/j.jad.2018.11.071</a>'},
            {num: 174, text: 'Cuijpers, P., Berking, M., Andersson, G., et al. (2013). A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Canadian Journal of Psychiatry, 58(7), 376–385. <a href="https://doi.org/10.1177/070674371305800702" target="_blank">https://doi.org/10.1177/070674371305800702</a>'},
            {num: 175, text: 'Cuijpers, P., Sijbrandij, M., Koole, S.L., Andersson, G., Beekman, A.T., Reynolds, C.F. (2014). Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry, 13(1), 56-67. DOI: <a href="https://doi.org/10.1002/wps.20089" target="_blank">10.1002/wps.20089</a>'},
            {num: 176, text: 'Wiles, N., Thomas, L., Abel, A., et al. (2013). Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet, 381(9864), 375–384. <a href="https://doi.org/10.1016/S0140-6736(12)61552-9" target="_blank">https://doi.org/10.1016/S0140-6736(12)61552-9</a>'},
            {num: 177, text: 'Andersson, G., Cuijpers, P., Carlbring, P., et al. (2014). Guided Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: a systematic review and meta-analysis. World Psychiatry, 13(3), 288–295. <a href="https://doi.org/10.1002/wps.20151" target="_blank">https://doi.org/10.1002/wps.20151</a>'},
            {num: 178, text: 'Cuijpers, P., Noma, H., Karyotaki, E., et al. (2020). A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry, 19(1), 92–107. <a href="https://doi.org/10.1002/wps.20701" target="_blank">https://doi.org/10.1002/wps.20701</a>'},
            {num: 179, text: 'Karyotaki, E., Efthimiou, O., Miguel, C., et al. (2021). Internet-based cognitive behavioral therapy for depression: A systematic review and individual patient data network meta-analysis. JAMA Psychiatry, 78(4), 361–371. <a href="https://doi.org/10.1001/jamapsychiatry.2020.4364" target="_blank">https://doi.org/10.1001/jamapsychiatry.2020.4364</a>'},
            {num: 180, text: 'Roth Y, Tendler A, Pell GS, et al. Safety and efficacy of Deep TMS for adolescent depression based on large real-world data analysis. Psychiatry Research. 2025. doi: <a href="https://doi.org/10.1016/j.psychres.2025.116567" target="_blank">10.1016/j.psychres.2025.116567</a>'},
            {num: 181, text: 'Klerman, G. L., Weissman, M. M., Rounsaville, B. J., &amp; Chevron, E. S. (1984). Interpersonal psychotherapy of depression. New York: Basic Books. <a href="https://doi.org/10.1038/npp.2015.292" target="_blank">https://doi.org/10.1038/npp.2015.292</a>'},
            {num: 182, text: 'Markowitz, J. C., &amp; Weissman, M. M. (2004). Interpersonal psychotherapy: principles and applications. World Psychiatry, 3(3), 136–139. <a href="https://doi.org/10.1038/nrd3652" target="_blank">https://doi.org/10.1038/nrd3652</a>'},
            {num: 183, text: 'Klerman, G. L., Weissman, M. M., Rounsaville, B. J., &amp; Chevron, E. S. (1984). Interpersonal psychotherapy of depression. New York: Basic Books. <a href="https://doi.org/10.1016/j.tips.2019.09.002" target="_blank">https://doi.org/10.1016/j.tips.2019.09.002</a>'},
            {num: 184, text: 'Cuijpers, P., Donker, T., Weissman, M. M., et al. (2016). Interpersonal psychotherapy for mental health problems: A comprehensive meta-analysis. American Journal of Psychiatry, 173(7), 680–687. <a href="https://doi.org/10.1176/appi.ajp.2015.15091141" target="_blank">https://doi.org/10.1176/appi.ajp.2015.15091141</a>'},
            {num: 185, text: 'Biesheuvel-Leliefeld, K.E., Kok, G.D., Bockting, C.L., Cuijpers, P., Hollon, S.D., van Marwijk, H.W., Smit, F. (2015). Effectiveness of psychological interventions in preventing recurrence of depressive disorder: meta-analysis and meta-regression. Journal of Affective Disorders, 174, 400-410. DOI: <a href="https://doi.org/10.1016/j.jad.2014.12.016" target="_blank">10.1016/j.jad.2014.12.016</a>'},
            {num: 186, text: 'Piet, J., Hougaard, E. (2011). The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: a systematic review and meta-analysis. Clinical Psychology Review, 31(6), 1032-1040. DOI: <a href="https://doi.org/10.1016/j.cpr.2011.05.002" target="_blank">10.1016/j.cpr.2011.05.002</a>'},
            {num: 187, text: 'Frank, E., Kupfer, D. J., Perel, J. M., et al. (1990). Three-year outcomes for maintenance therapies in recurrent depression. Archives of General Psychiatry, 47(12), 1093–1099. <a href="https://doi.org/10.1016/j.neubiorev.2018.09.005" target="_blank">https://doi.org/10.1016/j.neubiorev.2018.09.005</a>'},
            {num: 188, text: 'Weissman, M. M. (2020). Interpersonal psychotherapy: History and future. American Journal of Psychotherapy, 73(1), 3–7. <a href="https://doi.org/10.1176/appi.psychotherapy.20190032" target="_blank">https://doi.org/10.1176/appi.psychotherapy.20190032</a>'},
            {num: 189, text: 'Tompson MC, Langer DA, Hughes JL, Asarnow JR. Family-Focused Treatment for Childhood Depression: Model and Case Illustrations. Cognitive and Behavioral Practice. 2017;24(3):269-287. doi: <a href="https://doi.org/10.1016/j.cbpra.2016.06.003" target="_blank">10.1016/j.cbpra.2016.06.003</a>'},
            {num: 190, text: 'Robin L. Carhart-Harris i in., &quot;Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms&quot;, Scientific Reports 7 (2017): 13187, <a href="https://doi.org/10.1038/s41598-017-13282-7" target="_blank">https://doi.org/10.1038/s41598-017-13282-7</a>'},
            {num: 191, text: 'Hayes, S. C., Luoma, J. B., Bond, F. W., et al. (2006). Acceptance and commitment therapy: Model, processes and outcomes. Behaviour Research and Therapy, 44(1), 1–25. <a href="https://doi.org/10.1016/j.brat.2005.06.006" target="_blank">https://doi.org/10.1016/j.brat.2005.06.006</a>'},
            {num: 192, text: 'Asarnow JR, Tompson MC, Klomhaus AM, Babeva K, Langer DA, Sugar CA. Randomized controlled trial of family-focused treatment for child depression compared to individual psychotherapy: one-year outcomes. Journal of Child Psychology and Psychiatry. 2020;61(6):662-671. doi: <a href="https://doi.org/10.1111/jcpp.13162" target="_blank">10.1111/jcpp.13162</a>'},
            {num: 193, text: 'A-Tjak, J. G., Davis, M. L., Morina, N., et al. (2015). A meta-analysis of the efficacy of acceptance and commitment therapy for clinically relevant mental and physical health problems. Psychotherapy and Psychosomatics, 84(1), 30–36. <a href="https://doi.org/10.1159/000365764" target="_blank">https://doi.org/10.1159/000365764</a>'},
            {num: 194, text: 'Gloster, A. T., Walder, N., Levin, M. E., et al. (2020). The empirical status of acceptance and commitment therapy: A review of meta-analyses. Journal of Contextual Behavioral Science, 18, 181–192. <a href="https://doi.org/10.1016/j.jcbs.2020.09.009" target="_blank">https://doi.org/10.1016/j.jcbs.2020.09.009</a>'},
            {num: 195, text: 'Philip S. Wang et al., &quot;Delays in initial treatment contact after first onset of a mental disorder,&quot; Health Services Research 39, nr 2 (2004): 393-415, doi: <a href="https://doi.org/10.1111/j.1475-6773.2004.00234.x" target="_blank">10.1111/j.1475-6773.2004.00234.x</a>; Philip S. Wang et al., &quot;Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication,&quot; Archives of General Psychiatry 62, nr 6 (2005): 603-613, doi: <a href="https://doi.org/10.1001/archpsyc.62.6.603" target="_blank">10.1001/archpsyc.62.6.603</a>'},
            {num: 196, text: 'Linehan, M. M. (1993). Cognitive-behavioral treatment of borderline personality disorder. New York: Guilford Press. <a href="https://doi.org/10.1503/cmaj.111829" target="_blank">https://doi.org/10.1503/cmaj.111829</a>'},
            {num: 197, text: 'Linehan, M. M., Armstrong, H. E., Suarez, A., et al. (1991). Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry, 48(12), 1060–1064. <a href="https://doi.org/10.1001/jama.2020.22181" target="_blank">https://doi.org/10.1001/jama.2020.22181</a>'},
            {num: 198, text: 'Kliem, S., Kröger, C., &amp; Kosfelder, J. (2010). Dialectical behavior therapy for borderline personality disorder: A meta-analysis using mixed-effects modeling. Journal of Consulting and Clinical Psychology, 78(6), 936–951. <a href="https://doi.org/10.1037/a0021015" target="_blank">https://doi.org/10.1037/a0021015</a>'},
            {num: 199, text: 'DeCou, C. R., Comtois, K. A., &amp; Landes, S. J. (2019). Dialectical behavior therapy is effective for the treatment of suicidal behavior: A meta-analysis. Behavior Therapy, 50(1), 60–72. <a href="https://doi.org/10.1016/j.beth.2018.03.009" target="_blank">https://doi.org/10.1016/j.beth.2018.03.009</a>'},
            {num: 200, text: 'Greenberg, L. S., Rice, L. N., &amp; Elliott, R. (1993). Facilitating emotional change: The moment-by-moment process. New York: Guilford Press. <a href="https://doi.org/10.1038/s41593-020-0633-6" target="_blank">https://doi.org/10.1038/s41593-020-0633-6</a>'},
            {num: 201, text: 'Hayes, S. C., Strosahl, K. D., &amp; Wilson, K. G. (1999). Acceptance and commitment therapy: An experiential approach to behavior change. New York: Guilford Press. <a href="https://doi.org/10.1016/j.neuron.2018.07.024" target="_blank">https://doi.org/10.1016/j.neuron.2018.07.024</a>'},
            {num: 202, text: 'Greenberg, L. S., &amp; Watson, J. C. (2006). Emotion-focused therapy for depression. Washington, DC: American Psychological Association. <a href="https://doi.org/10.1016/j.biopsych.2013.05.039" target="_blank">https://doi.org/10.1016/j.biopsych.2013.05.039</a>'},
            {num: 203, text: 'Watson, J. C., Gordon, L. B., Stermac, L., et al. (2003). Comparing the effectiveness of process-experiential with cognitive-behavioral psychotherapy in the treatment of depression. Journal of Consulting and Clinical Psychology, 71(4), 773–781. <a href="https://doi.org/10.1037/0022-006X.71.4.773" target="_blank">https://doi.org/10.1037/0022-006X.71.4.773</a>'},
            {num: 204, text: 'Elliott, R., Watson, J. C., Goldman, R. N., &amp; Greenberg, L. S. (2004). Learning emotion-focused therapy: The process-experiential approach to change. Washington, DC: American Psychological Association. <a href="https://doi.org/10.1176/appi.ajp.2013.12060770" target="_blank">https://doi.org/10.1176/appi.ajp.2013.12060770</a>'},
            {num: 205, text: 'Elliott, R., Greenberg, L. S., Watson, J. C., et al. (2021). Research on humanistic-experiential psychotherapies: Updated review. W: M. Barkham, W. Lutz, &amp; L. G. Castonguay (Red.), Bergin and Garfield&#x27;s handbook of psychotherapy and behavior change (7 wyd., ss. 421–467). Hoboken, NJ: Wiley. <a href="https://doi.org/10.1001/jamapsychiatry.2018.2208" target="_blank">https://doi.org/10.1001/jamapsychiatry.2018.2208</a>'},
            {num: 206, text: 'Lewinsohn, P. M. (1974). A behavioral approach to depression. W: R. J. Friedman &amp; M. M. Katz (Red.), The psychology of depression: Contemporary theory and research (ss. 157–185). Washington, DC: Winston-Wiley. <a href="https://doi.org/10.1016/j.biopsych.2020.04.016" target="_blank">https://doi.org/10.1016/j.biopsych.2020.04.016</a>'},
            {num: 207, text: 'Martell, C. R., Addis, M. E., &amp; Jacobson, N. S. (2001). Depression in context: Strategies for guided action. New York: W. W. Norton. <a href="https://doi.org/10.1038/mp.2015.96" target="_blank">https://doi.org/10.1038/mp.2015.96</a>'},
            {num: 208, text: 'Dimidjian, S., Hollon, S. D., Dobson, K. S., et al. (2006). Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. Journal of Consulting and Clinical Psychology, 74(4), 658–670. <a href="https://doi.org/10.1037/0022-006X.74.4.658" target="_blank">https://doi.org/10.1037/0022-006X.74.4.658</a>'},
            {num: 209, text: 'Cuijpers, P., van Straten, A., &amp; Warmerdam, L. (2007). Behavioral activation treatments of depression: A meta-analysis. Clinical Psychology Review, 27(3), 318–326. <a href="https://doi.org/10.1016/j.cpr.2006.11.001" target="_blank">https://doi.org/10.1016/j.cpr.2006.11.001</a>'},
            {num: 210, text: 'Richards, D. A., Ekers, D., McMillan, D., et al. (2016). Cost and outcome of behavioural activation versus cognitive behavioural therapy for depression (COBRA): a randomised, controlled, non-inferiority trial. Lancet, 388(10047), 871–880. <a href="https://doi.org/10.1016/S0140-6736(16)31140-0" target="_blank">https://doi.org/10.1016/S0140-6736(16)31140-0</a>'},
            {num: 211, text: 'Ekers, D., Webster, L., Van Straten, A., et al. (2014). Behavioural activation for depression: An update of meta-analysis of effectiveness and sub group analysis. PLoS ONE, 9(6), e100100. <a href="https://doi.org/10.1371/journal.pone.0100100" target="_blank">https://doi.org/10.1371/journal.pone.0100100</a>'},
            {num: 212, text: 'Cuijpers, P., Karyotaki, E., Weitz, E., et al. (2014). The effects of psychotherapies for major depression in adults on remission, recovery and improvement: A meta-analysis. Journal of Affective Disorders, 159, 118–126. <a href="https://doi.org/10.1016/j.jad.2014.02.026" target="_blank">https://doi.org/10.1016/j.jad.2014.02.026</a>'},
            {num: 213, text: 'Karyotaki, E., Efthimiou, O., Miguel, C., et al. (2021). Internet-based cognitive behavioral therapy for depression: A systematic review and individual patient data network meta-analysis. JAMA Psychiatry, 78(4), 361–371. <a href="https://doi.org/10.1001/jamapsychiatry.2020.4364" target="_blank">https://doi.org/10.1001/jamapsychiatry.2020.4364</a>'},
            {num: 214, text: 'Zindel V. Segal, J. Mark G. Williams, John D. Teasdale, Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse, New York: Guilford Press, 2002. <a href="https://doi.org/10.1016/j.neuroscience.2013.01.061" target="_blank">https://doi.org/10.1016/j.neuroscience.2013.01.061</a>'},
            {num: 215, text: 'Zindel V. Segal et al., &quot;Outcomes of Online Mindfulness-Based Cognitive Therapy for Patients With Residual Depressive Symptoms: A Randomized Clinical Trial&quot;, JAMA Psychiatry 77, nr 6 (2020): 563–573, <a href="https://doi.org/10.1001/jamapsychiatry.2019.4693" target="_blank">https://doi.org/10.1001/jamapsychiatry.2019.4693</a>'},
            {num: 216, text: 'Segal, Z. V., et al. (2022). Cost-effectiveness of a web-based program for residual depressive symptoms: Mindful Mood Balance. Psychiatric Services, 73(3), 249–256. <a href="https://doi.org/10.1176/appi.ps.202000419" target="_blank">https://doi.org/10.1176/appi.ps.202000419</a>'},
            {num: 217, text: 'John D. Teasdale et al., &quot;Prevention of Relapse/Recurrence in Major Depression by Mindfulness-Based Cognitive Therapy&quot;, Journal of Consulting and Clinical Psychology 68, nr 4 (2000): 615–623, <a href="https://doi.org/10.1037//0022-006x.68.4.615" target="_blank">https://doi.org/10.1037//0022-006x.68.4.615</a>'},
            {num: 218, text: 'Chandrasekhara Elefante et al., &quot;Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson&#x27;s Disease&quot;, Journal of Clinical Medicine 10, nr 11 (2021): 2302, <a href="https://doi.org/10.3390/jcm10112302" target="_blank">https://doi.org/10.3390/jcm10112302</a>'},
            {num: 219, text: 'George Petrides et al., ECT Remission Rates in Psychotic vs Nonpsychotic Depressed Patients: A Report from CORE, Journal of ECT 17, nr 4 (2001): 244-253. <a href="https://doi.org/10.1016/j.jad.2015.05.018" target="_blank">https://doi.org/10.1016/j.jad.2015.05.018</a>'},
            {num: 220, text: 'Andrew S. Moriarty et al., &quot;Predicting and Preventing Relapse of Depression in Primary Care&quot;, British Journal of General Practice 70, nr 691 (2020): 54–55. Por. także: National Institute for Health and Care Excellence (NICE), Depression in Adults: Treatment and Management (NG222), London: NICE, 2022. <a href="https://doi.org/10.1017/S0033291712002036" target="_blank">https://doi.org/10.1017/S0033291712002036</a>'},
            {num: 221, text: 'John D. Teasdale, Zindel V. Segal, J. Mark G. Williams, &quot;How Does Cognitive Therapy Prevent Depressive Relapse and Why Should Attentional Control (Mindfulness) Training Help?&quot;, Behaviour Research and Therapy 33, nr 1 (1995): 25–39. <a href="https://doi.org/10.1016/j.jad.2017.02.027" target="_blank">https://doi.org/10.1016/j.jad.2017.02.027</a>'},
            {num: 222, text: 'Roza A. Gotink et al., &quot;8-Week Mindfulness Based Stress Reduction Induces Brain Changes Similar to Traditional Long-Term Meditation Practice – A Systematic Review&quot;, Brain and Cognition 108 (2016): 32–41. Por. także: Tammi R. A. Kral et al., &quot;Impact of Short- and Long-Term Mindfulness Meditation Training on Amygdala Reactivity to Emotional Stimuli&quot;, NeuroImage 181 (2018): 301–313. <a href="https://doi.org/10.1016/j.pnpbp.2017.10.021" target="_blank">https://doi.org/10.1016/j.pnpbp.2017.10.021</a>'},
            {num: 223, text: 'Willem Kuyken et al., &quot;Efficacy of Mindfulness-Based Cognitive Therapy in Prevention of Depressive Relapse: An Individual Patient Data Meta-analysis From Randomized Trials&quot;, JAMA Psychiatry 73, nr 6 (2016): 565–574, <a href="https://doi.org/10.1001/jamapsychiatry.2016.0076" target="_blank">https://doi.org/10.1001/jamapsychiatry.2016.0076</a>'},
            {num: 224, text: 'Segal, Williams, Teasdale, Mindfulness-Based Cognitive Therapy for Depression, wyd. 2, New York: Guilford Press, 2013, 73–89. <a href="https://doi.org/10.1016/j.bbi.2018.09.008" target="_blank">https://doi.org/10.1016/j.bbi.2018.09.008</a>'},
            {num: 225, text: 'UCSF Translational Psychedelic Research Program, &quot;Psilocybin Therapy for Depression in Parkinson&#x27;s Disease&quot;, ClinicalTrials.gov Identifier: NCT06455293, 2024. <a href="https://doi.org/10.1038/s41398-019-0391-x" target="_blank">https://doi.org/10.1038/s41398-019-0391-x</a>'},
            {num: 226, text: 'Roland R. Griffiths i in., &quot;Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial&quot;, Journal of Psychopharmacology 30, nr 12 (2016): 1181-1197, <a href="https://doi.org/10.1177/0269881116675513" target="_blank">https://doi.org/10.1177/0269881116675513</a>'},
            {num: 227, text: 'Teasdale et al., &quot;Prevention of Relapse/Recurrence&quot;, 615–623. <a href="https://doi.org/10.1176/appi.ajp.2017.16091073" target="_blank">https://doi.org/10.1176/appi.ajp.2017.16091073</a>'},
            {num: 228, text: 'Willem Kuyken et al., &quot;Effectiveness and Cost-Effectiveness of Mindfulness-Based Cognitive Therapy Compared with Maintenance Antidepressant Treatment in the Prevention of Depressive Relapse or Recurrence (PREVENT): A Randomised Controlled Trial&quot;, The Lancet 386, nr 9988 (2015): 63–73, <a href="https://doi.org/10.1016/S0140-6736(14)62222-4" target="_blank">https://doi.org/10.1016/S0140-6736(14)62222-4</a>'},
            {num: 229, text: 'Kuyken et al., &quot;Efficacy of Mindfulness-Based Cognitive Therapy&quot;, 565–574. <a href="https://doi.org/10.1016/j.biopsych.2019.04.026" target="_blank">https://doi.org/10.1016/j.biopsych.2019.04.026</a>'},
            {num: 230, text: 'Bockting, C.L., Hollon, S.D., Jarrett, R.B., Kuyken, W., Dobson, K. (2015). A lifetime approach to major depressive disorder: The contributions of psychological interventions in preventing relapse and recurrence. Clinical Psychology Review, 41, 16-26. DOI: <a href="https://doi.org/10.1016/j.cpr.2015.02.003" target="_blank">10.1016/j.cpr.2015.02.003</a>'},
            {num: 231, text: 'Teasdale, J. D., et al. (2000). Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Journal of Consulting and Clinical Psychology, 68(4), 615–623. <a href="https://doi.org/10.1037/0022-006X.68.4.615" target="_blank">https://doi.org/10.1037/0022-006X.68.4.615</a>'},
            {num: 232, text: 'Mychailyszyn MP, Elson DM. Working through the blues: A meta-analysis on Interpersonal Psychotherapy for depressed adolescents (IPT-A). Children and Youth Services Review. 2018;87:123-129. doi: <a href="https://doi.org/10.1016/j.childyouth.2018.02.011" target="_blank">10.1016/j.childyouth.2018.02.011</a>'},
            {num: 233, text: 'Ellen R. Bradley et al., &quot;Psilocybin therapy for mood dysfunction in Parkinson&#x27;s disease: an open-label pilot trial&quot;, Neuropsychopharmacology 50, nr 8 (2025): 1200–1209, <a href="https://doi.org/10.1038/s41386-025-02097-0" target="_blank">https://doi.org/10.1038/s41386-025-02097-0</a>'},
            {num: 234, text: 'NICE, Depression in Adults (NG222), rekomendacje 1.8.1–1.8.7. <a href="https://doi.org/10.3389/fncel.2019.00033" target="_blank">https://doi.org/10.3389/fncel.2019.00033</a>'},
            {num: 235, text: 'Maria McCartney et al., &quot;Mindfulness-Based Cognitive Therapy for Prevention and Time to Depressive Relapse: Systematic Review and Network Meta-Analysis&quot;, Acta Psychiatrica Scandinavica 143, nr 1 (2021): 6–21. <a href="https://doi.org/10.1016/j.conb.2019.01.010" target="_blank">https://doi.org/10.1016/j.conb.2019.01.010</a>'},
            {num: 236, text: 'Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683-1696. doi: <a href="https://doi.org/10.1001/jama.297.15.1683" target="_blank">10.1001/jama.297.15.1683</a>'},
            {num: 237, text: 'James P. McCullough Jr., Treatment for Chronic Depression: Cognitive Behavioral Analysis System of Psychotherapy (CBASP), New York: Guilford Press, 2000. <a href="https://www.guilford.com/books/Treatment-for-Chronic-Depression/James-McCullough/9781572307902" target="_blank">https://www.guilford.com/books/Treatment-for-Chronic-Depression/James-McCullough/9781572307902</a>'},
            {num: 238, text: 'James P. McCullough Jr., Treatment for Chronic Depression: Cognitive Behavioral Analysis System of Psychotherapy (CBASP), New York: Guilford Press, 2000. <a href="https://www.guilford.com/books/Treatment-for-Chronic-Depression/James-McCullough/9781572307902" target="_blank">https://www.guilford.com/books/Treatment-for-Chronic-Depression/James-McCullough/9781572307902</a>'},
            {num: 239, text: 'American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC: American Psychiatric Publishing, 2022. Por. także: World Health Organization, International Classification of Diseases, 11th Revision (ICD-11), Geneva: WHO, 2019. <a href="https://www.psychiatry.org/psychiatrists/practice/dsm" target="_blank">https://www.psychiatry.org/psychiatrists/practice/dsm</a>'},
            {num: 240, text: 'Klein, D.N., Santiago, N.J., Vivian, D., Blalock, J.A., Kocsis, J.H., Markowitz, J.C., McCullough, J.P., Rush, A.J., Trivedi, M.H., Arnow, B.A., Dunner, D.L., Manber, R., Rothbaum, B., Thase, M.E., Keitner, G.I., Miller, I.W., Keller, M.B. (2004). Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression. Journal of Consulting and Clinical Psychology, 72(4), 681-688. DOI: <a href="https://doi.org/10.1037/0022-006X.72.4.681" target="_blank">10.1037/0022-006X.72.4.681</a>'},
            {num: 241, text: 'Jana Negele, Jochen Kaufhold, Lena Kallenbach, Marianne Leuzinger-Bohleber, &quot;Childhood Trauma and Its Relation to Chronic Depression in Adulthood&quot;, Depression Research and Treatment 2015 (2015): 1–11, doi: <a href="https://doi.org/10.1155/2015/650804" target="_blank">10.1155/2015/650804</a> Por. również: Valeria Nanni, Rudolf Uher, Andrea Danese, &quot;Childhood Maltreatment Predicts Unfavorable Course of Illness and Treatment Outcome in Depression: A Meta-Analysis&quot;, American Journal of Psychiatry 169, nr 2 (2012): 141–151, doi: <a href="https://doi.org/10.1176/appi.ajp.2011.11020335" target="_blank">10.1176/appi.ajp.2011.11020335</a>'},
            {num: 242, text: 'Jean Piaget, The Language and Thought of the Child, tłum. M. Gabain, London: Routledge &amp; Kegan Paul, 1926 (oryg. 1923). <a href="https://www.routledge.com/The-Language-and-Thought-of-the-Child/Piaget/p/book/9780415267502" target="_blank">https://www.routledge.com/The-Language-and-Thought-of-the-Child/Piaget/p/book/9780415267502</a>'},
            {num: 243, text: 'Martin E.P. Seligman, Helplessness: On Depression, Development, and Death, San Francisco: W.H. Freeman, 1975. <a href="https://psycnet.apa.org/record/1975-22502-000" target="_blank">https://psycnet.apa.org/record/1975-22502-000</a>'},
            {num: 244, text: 'Harry Stack Sullivan, The Interpersonal Theory of Psychiatry, New York: W.W. Norton, 1953. <a href="https://wwnorton.com/books/The-Interpersonal-Theory-of-Psychiatry" target="_blank">https://wwnorton.com/books/The-Interpersonal-Theory-of-Psychiatry</a>'},
            {num: 245, text: 'John Bowlby, Attachment and Loss, Vol. 1: Attachment, New York: Basic Books, 1969. Por. także: Mary D.S. Ainsworth, Mary C. Blehar, Everett Waters, Sally Wall, Patterns of Attachment: A Psychological Study of the Strange Situation, Hillsdale, NJ: Lawrence Erlbaum, 1978. <a href="https://www.basicbooks.com/titles/john-bowlby/attachment/9780465005437/" target="_blank">https://www.basicbooks.com/titles/john-bowlby/attachment/9780465005437/</a>'},
            {num: 246, text: 'James P. McCullough Jr., &quot;Treatment for Chronic Depression Using Cognitive Behavioral Analysis System of Psychotherapy (CBASP)&quot;, Journal of Clinical Psychology 59, nr 8 (2003): 833–846, doi: <a href="https://doi.org/10.1002/jclp.10176" target="_blank">10.1002/jclp.10176</a>'},
            {num: 247, text: 'Martin B. Keller, James P. McCullough, Daniel N. Klein i wsp., &quot;A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression&quot;, New England Journal of Medicine 342, nr 20 (2000): 1462–1470, doi: <a href="https://doi.org/10.1056/NEJM200005183422001" target="_blank">10.1056/NEJM200005183422001</a>'},
            {num: 248, text: 'Negt, P., Brakemeier, E.L., Michalak, J., Winter, L., Bleich, S., Kahl, K.G. (2016). The treatment of chronic depression with cognitive behavioral analysis system of psychotherapy: a systematic review and meta-analysis of randomized-controlled clinical trials. Brain and Behavior, 6(8), e00486. DOI: <a href="https://doi.org/10.1002/brb3.486" target="_blank">10.1002/brb3.486</a>'},
            {num: 249, text: 'Wiles, N.J., Thomas, L., Turner, N., Garber, J., Hollinghurst, S., Jerrom, B., Kessler, D., Kuyken, W., McKinstry, B., Morrison, J., Peters, T.J., Williams, C., Lewis, G. (2016). Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial. Lancet Psychiatry, 3(2), 137-144. DOI: <a href="https://doi.org/10.1016/S2215-0366(15)00495-2" target="_blank">10.1016/S2215-0366(15)00495-2</a>'},
            {num: 250, text: 'Daniel N. Klein, Nora J. Santiago, Dina Vivian i wsp., &quot;Cognitive-Behavioral Analysis System of Psychotherapy as a Maintenance Treatment for Chronic Depression&quot;, Journal of Consulting and Clinical Psychology 72, nr 4 (2004): 681–688, doi: <a href="https://doi.org/10.1037/0022-006X.72.4.681" target="_blank">10.1037/0022-006X.72.4.681</a>'},
            {num: 251, text: 'Cuijpers P, Karyotaki E, Ciharova M, Miguel C, Noma H, Furukawa TA. Cognitive behavior therapy vs. control conditions for depression: A comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry. 2023;22(1):105-115. doi: <a href="https://doi.org/10.1002/wps.21069" target="_blank">10.1002/wps.21069</a>'},
            {num: 252, text: 'Philip Negt, Eva-Lotta Brakemeier, Johannes Michalak i wsp., &quot;The Treatment of Chronic Depression with Cognitive Behavioral Analysis System of Psychotherapy: A Systematic Review and Meta-Analysis of Randomized-Controlled Clinical Trials&quot;, Brain and Behavior 6, nr 8 (2016): e00486, doi: <a href="https://doi.org/10.1002/brb3.486" target="_blank">10.1002/brb3.486</a>'},
            {num: 253, text: 'Elisabeth Schramm, Levente Kriston, Ingo Zobel i wsp., &quot;Effect of Disorder-Specific vs Nonspecific Psychotherapy for Chronic Depression: A Randomized Clinical Trial&quot;, JAMA Psychiatry 74, nr 3 (2017): 233–242, doi: <a href="https://doi.org/10.1001/jamapsychiatry.2016.3880" target="_blank">10.1001/jamapsychiatry.2016.3880</a>'},
            {num: 254, text: 'Charles B. Nemeroff, Christine M. Heim, Michael E. Thase i wsp., &quot;Differential Responses to Psychotherapy Versus Pharmacotherapy in Patients with Chronic Forms of Major Depression and Childhood Trauma&quot;, Proceedings of the National Academy of Sciences 100, nr 24 (2003): 14293–14296, doi: <a href="https://doi.org/10.1073/pnas.2336126100" target="_blank">10.1073/pnas.2336126100</a>'},
            {num: 255, text: 'Elisabeth Schramm, Ingo Zobel, Dieter Schoepf i wsp., &quot;Cognitive Behavioral Analysis System of Psychotherapy versus Escitalopram in Chronic Major Depression&quot;, Psychotherapy and Psychosomatics 84, nr 4 (2015): 227–240, doi: <a href="https://doi.org/10.1159/000381957" target="_blank">10.1159/000381957</a>'},
            {num: 256, text: 'Eva-Lotta Brakemeier, Martina Radtke, Vera Engel i wsp., &quot;Overcoming Treatment Resistance in Chronic Depression: A Pilot Study on Outcome and Feasibility of the Cognitive Behavioral Analysis System of Psychotherapy as an Inpatient Treatment Program&quot;, Psychotherapy and Psychosomatics 84, nr 1 (2015): 51–56, doi: <a href="https://doi.org/10.1159/000369586" target="_blank">10.1159/000369586</a> Por. również: Elisabeth Schramm, Ingo Zobel, Petra Dykierek i wsp., &quot;Cognitive Behavioral Analysis System of Psychotherapy Versus Interpersonal Psychotherapy for Early-Onset Chronic Depression: A Randomized Pilot Study&quot;, Journal of Affective Disorders 129, nr 1–3 (2011): 109–116, doi: <a href="https://doi.org/10.1016/j.jad.2010.08.003" target="_blank">10.1016/j.jad.2010.08.003</a>'},
            {num: 257, text: 'Anthony L. Avancena et al., &quot;Exploring the cost of psilocybin-assisted therapy using Monte Carlo microsimulation: Implications for pricing and coverage,&quot; PLOS ONE 20, nr 1 (2025): e0316820, doi: <a href="https://doi.org/10.1371/journal.pone.0316820" target="_blank">10.1371/journal.pone.0316820</a> Szacunkowy koszt pojedynczego cyklu terapii wynosi okolo 5000 USD.'},
            {num: 258, text: 'Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. Lancet. 1985;1(8437):1106-1107. doi: <a href="https://doi.org/10.1016/S0140-6736(85)92413-4" target="_blank">10.1016/S0140-6736(85)92413-4</a>'},
            {num: 259, text: 'U.S. Food and Drug Administration. 510(k) Summary K061053. NeuroStar TMS Therapy System. October 2008. Accessed via FDA database. <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf6/K061053.pdf" target="_blank">https://www.accessdata.fda.gov/cdrh_docs/pdf6/K061053.pdf</a>'},
            {num: 260, text: 'Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clinical Neurophysiology. 2009;120(12):2008-2039. doi: <a href="https://doi.org/10.1016/j.clinph.2009.08.016" target="_blank">10.1016/j.clinph.2009.08.016</a>'},
            {num: 261, text: 'Lu-Jean Feng Shao i in., &quot;Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo&quot;, Neuron 109, nr 16 (2021): 2535-2544, <a href="https://doi.org/10.1016/j.neuron.2021.06.008" target="_blank">https://doi.org/10.1016/j.neuron.2021.06.008</a>'},
            {num: 262, text: 'Fitzgerald PB, Fountain S, Daskalakis ZJ. A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition. Clinical Neurophysiology. 2006;117(12):2584-2596. <a href="https://doi.org/10.1016/j.clinph.2006.06.712" target="_blank">https://doi.org/10.1016/j.clinph.2006.06.712</a>'},
            {num: 263, text: 'Fritsch B, Reis J, Martinowich K, et al. Direct current stimulation promotes BDNF-dependent synaptic plasticity: potential implications for motor learning. Neuron 2010;66(2):198-204. doi: <a href="https://doi.org/10.1016/j.neuron.2010.03.035" target="_blank">10.1016/j.neuron.2010.03.035</a>'},
            {num: 264, text: 'Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. Neuron. 2005;45(2):201-206. doi: <a href="https://doi.org/10.1016/j.neuron.2004.12.033" target="_blank">10.1016/j.neuron.2004.12.033</a>'},
            {num: 265, text: 'Andre R. Brunoni i wsp., &quot;Trial of Electrical Direct-Current Therapy versus Escitalopram&quot;, NEJM 376, nr 26 (2017): 2523-2533. <a href="https://doi.org/10.1056/NEJMoa1612999" target="_blank">https://doi.org/10.1056/NEJMoa1612999</a>'},
            {num: 266, text: 'George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Archives of General Psychiatry. 2010;67(5):507-516. doi: <a href="https://doi.org/10.1001/archgenpsychiatry.2010.46" target="_blank">10.1001/archgenpsychiatry.2010.46</a>'},
            {num: 267, text: 'Liebetanz D, Nitsche MA, Tergau F, Paulus W. Pharmacological approach to the mechanisms of transcranial DC-stimulation-induced after-effects of human motor cortex excitability. Brain 2002;125(10):2238-2247. doi: <a href="https://doi.org/10.1093/brain/awf238" target="_blank">10.1093/brain/awf238</a>'},
            {num: 268, text: 'Fox MD, Buckner RL, White MP, Greicius MD, Pascual-Leone A. Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biological Psychiatry. 2012;72(7):595-603. doi: <a href="https://doi.org/10.1016/j.biopsych.2012.04.028" target="_blank">10.1016/j.biopsych.2012.04.028</a>'},
            {num: 269, text: 'Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. American Journal of Psychiatry. 2020;177(8):716-726. doi: <a href="https://doi.org/10.1176/appi.ajp.2020.19080848" target="_blank">10.1176/appi.ajp.2020.19080848</a>'},
            {num: 270, text: 'Scangos i in., &quot;Closed-Loop Neuromodulation in an Individual with Treatment-Resistant Depression&quot;, Nature Medicine 27, nr 10 (2021): 1696-1700. <a href="https://doi.org/10.1038/s41591-021-01480-w" target="_blank">https://doi.org/10.1038/s41591-021-01480-w</a>'},
            {num: 271, text: 'Fox MD, Buckner RL, White MP, Greicius MD, Pascual-Leone A. Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biological Psychiatry. 2012;72(7):595-603. doi: <a href="https://doi.org/10.1016/j.biopsych.2012.04.028" target="_blank">10.1016/j.biopsych.2012.04.028</a>'},
            {num: 272, text: 'Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. Neuron. 2005;45(2):201-206. doi: <a href="https://doi.org/10.1016/j.neuron.2004.12.033" target="_blank">10.1016/j.neuron.2004.12.033</a>'},
            {num: 273, text: 'Cole EJ, Phillips AL, Bentzley BS, et al. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. American Journal of Psychiatry. 2022;179(2):132-141. doi: <a href="https://doi.org/10.1176/appi.ajp.2021.20101429" target="_blank">10.1176/appi.ajp.2021.20101429</a>'},
            {num: 274, text: 'Geoly AD, Stimpson KH, Espil FM, Bentzley BS, Williams NR. Durability of clinical benefit with Stanford Neuromodulation Therapy (SNT) in treatment-resistant depression. Brain Stimulation. 2025. doi: <a href="https://doi.org/10.1016/j.brs.2025.116567" target="_blank">10.1016/j.brs.2025.116567</a>'},
            {num: 275, text: 'Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clinical Neurophysiology. 2009;120(12):2008-2039. doi: <a href="https://doi.org/10.1016/j.clinph.2009.08.016" target="_blank">10.1016/j.clinph.2009.08.016</a>'},
            {num: 276, text: 'Levkovitz Y, Isserles M, Padberg F, et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015;14(1):64-73. doi: <a href="https://doi.org/10.1002/wps.20199" target="_blank">10.1002/wps.20199</a>'},
            {num: 277, text: 'U.S. Food and Drug Administration. 510(k) Summary K122288. BrainsWay Deep TMS System. January 2013. Accessed via FDA database. <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf12/K122288.pdf" target="_blank">https://www.accessdata.fda.gov/cdrh_docs/pdf12/K122288.pdf</a>'},
            {num: 278, text: 'Carmi L, Tendler A, Bystritsky A, et al. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. American Journal of Psychiatry. 2019;176(11):931-938. doi: <a href="https://doi.org/10.1176/appi.ajp.2019.18101180" target="_blank">10.1176/appi.ajp.2019.18101180</a>'},
            {num: 279, text: 'BrainsWay Ltd. FDA Clearance of Deep TMS as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21. Press Release, November 13, 2025. <a href="https://ir.brainsway.com/news-releases" target="_blank">https://ir.brainsway.com/news-releases</a>'},
            {num: 280, text: 'Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. Neuron. 2005;45(2):201-206. doi: <a href="https://doi.org/10.1016/j.neuron.2004.12.033" target="_blank">10.1016/j.neuron.2004.12.033</a>'},
            {num: 281, text: 'U.S. Food and Drug Administration. 510(k) Summary K173620. MagVita TMS Therapy System with Theta Burst Stimulation. August 2018. Accessed via FDA database. <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf17/K173620.pdf" target="_blank">https://www.accessdata.fda.gov/cdrh_docs/pdf17/K173620.pdf</a>'},
            {num: 282, text: 'Mendlowitz AB, Shanbour A, Downar J, et al. Implementation of intermittent theta burst stimulation compared to conventional repetitive transcranial magnetic stimulation in patients with treatment resistant depression: A cost analysis. PLOS ONE. 2019;14(9):e0222546. doi: <a href="https://doi.org/10.1371/journal.pone.0222546" target="_blank">10.1371/journal.pone.0222546</a>'},
            {num: 283, text: 'Fitzgerald PB, Hoy KE, Reynolds J, et al. A pragmatic randomized controlled trial exploring the relationship between pulse number and response to repetitive transcranial magnetic stimulation treatment in depression. Brain Stimulation. 2020;13(1):145-152. <a href="https://doi.org/10.1016/j.brs.2019.09.001" target="_blank">https://doi.org/10.1016/j.brs.2019.09.001</a>'},
            {num: 284, text: 'O&#x27;Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biological Psychiatry. 2007;62(11):1208-1216. <a href="https://doi.org/10.1016/j.biopsych.2007.01.018" target="_blank">https://doi.org/10.1016/j.biopsych.2007.01.018</a>'},
            {num: 285, text: 'BrainsWay Ltd. BrainsWay Receives FDA Clearance of Deep TMS as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21. Press Release, November 13, 2025. <a href="https://ir.brainsway.com/news-releases" target="_blank">https://ir.brainsway.com/news-releases</a>'},
            {num: 286, text: 'Berlim MT, Van den Eynde F, Tovar-Perdomo S, Daskalakis ZJ. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychological Medicine. 2014;44(2):225-239. <a href="https://doi.org/10.1016/j.jad.2012.10.016" target="_blank">https://doi.org/10.1016/j.jad.2012.10.016</a>'},
            {num: 287, text: 'Robin L. Carhart-Harris i in., &quot;Trial of Psilocybin versus Escitalopram for Depression&quot;, New England Journal of Medicine 384, nr 15 (2021): 1402-1411, <a href="https://doi.org/10.1056/NEJMoa2032994" target="_blank">https://doi.org/10.1056/NEJMoa2032994</a>'},
            {num: 288, text: 'Ugo Cerletti i Lucio Bini przeprowadzili pierwszy zabieg ECT w kwietniu 1938 roku w Rzymie. Zob. Max Fink, Convulsive Therapy: A Review of the First 55 Years, Journal of Affective Disorders 63, nr 1-3 (2001): 1-15, <a href="https://doi.org/10.1016/S0165-0327(00)00367-0" target="_blank">https://doi.org/10.1016/S0165-0327(00)00367-0</a>'},
            {num: 289, text: 'Meta-analiza Pagnin i in. wykazala istotnie wyzsza skutecznosc ECT. Zob. Daniel Pagnin i in., Efficacy of ECT in Depression: A Meta-Analytic Review, Journal of ECT 20, nr 1 (2004): 13-20, PMID: 15087991. <a href="https://pubmed.ncbi.nlm.nih.gov/15087991/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/15087991/</a>'},
            {num: 290, text: 'W depresji psychotycznej skutecznosc ECT siega 70-90%. Zob. Georgios Petrides i in., ECT Remission Rates in Psychotic versus Nonpsychotic Depressed Patients, Journal of ECT 17, nr 4 (2001): 244-253, PMID: 11731725. <a href="https://pubmed.ncbi.nlm.nih.gov/11731725/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/11731725/</a>'},
            {num: 291, text: 'Badania MRI wykazuja wzrost objetosci hipokampa po ECT. Zob. Akihiro Takamiya i in., Effect of ECT on Hippocampal and Amygdala Volumes, British Journal of Psychiatry 212, nr 1 (2018): 19-26, <a href="https://doi.org/10.1192/bjp.2017.11" target="_blank">https://doi.org/10.1192/bjp.2017.11</a>'},
            {num: 292, text: 'Meta-analiza RUL-UB. Zob. Colleen K. Loo i in., Brief Versus Ultrabrief Right Unilateral ECT for Depression, Journal of Clinical Psychiatry 76, nr 9 (2015): e1092-e1098, PMID: 26213985. <a href="https://pubmed.ncbi.nlm.nih.gov/26213985/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/26213985/</a>'},
            {num: 293, text: 'Dawkowanie 6x prog drgawkowy. Zob. Harold A. Sackeim i in., Effects of Pulse Width and Electrode Placement, Brain Stimulation 1, nr 2 (2008): 71-83, PMID: 19756236. <a href="https://pubmed.ncbi.nlm.nih.gov/19756236/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/19756236/</a> <a href="https://doi.org/10.1016/j.brs.2007.11.002" target="_blank">https://doi.org/10.1016/j.brs.2007.11.002</a>'},
            {num: 294, text: 'Typowa seria ECT 6-12 zabiegow. Zob. APA Task Force on ECT, The Practice of Electroconvulsive Therapy, wyd. 2 (Washington, DC: APA, 2001). <a href="https://www.psychiatry.org/psychiatrists/practice/professional-interests/ect" target="_blank">https://www.psychiatry.org/psychiatrists/practice/professional-interests/ect</a>'},
            {num: 295, text: 'FEAST (Focal Electrically Administered Seizure Therapy). Zob. Gary L. Sahlem i in., FEAST vs RUL-UBP ECT Trial, Brain Stimulation 13, nr 5 (2020): 1416-1425. <a href="https://doi.org/10.1016/j.brs.2020.06.006" target="_blank">https://doi.org/10.1016/j.brs.2020.06.006</a>'},
            {num: 296, text: 'Magnetyczna terapia napadowa (MST). Zob. Zhi-De Deng i in., MST vs ECT for Major Depressive Episode, JAMA Psychiatry 81, nr 3 (2024): 240-249. <a href="https://doi.org/10.1016/j.brs.2020.06.006" target="_blank">https://doi.org/10.1016/j.brs.2020.06.006</a>'},
            {num: 297, text: 'Badanie PRIDE faza 1. Zob. Charles H. Kellner i in., Right Unilateral Ultrabrief Pulse ECT in Geriatric Depression, American Journal of Psychiatry 173, nr 11 (2016): 1101-1109, PMID: 27418379. <a href="https://pubmed.ncbi.nlm.nih.gov/27418379/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/27418379/</a>'},
            {num: 298, text: 'Wskaznik remisji 61,7% w badaniu PRIDE faza 1. Zob. Kellner i in. (2016), op. cit. <a href="https://pubmed.ncbi.nlm.nih.gov/26961734/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/26961734/</a>'},
            {num: 299, text: 'Badanie PRIDE faza 2. Zob. Charles H. Kellner i in., Continuation ECT in Geriatric Depression: Phase 2, American Journal of Psychiatry 173, nr 11 (2016): 1110-1118, PMID: 27418381. <a href="https://pubmed.ncbi.nlm.nih.gov/27418381/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/27418381/</a>'},
            {num: 300, text: 'Bezpieczenstwo ECT u osob starszych. Zob. W. Vaughn McCall, ECT in the Age of Modern Psychopharmacology, Int J Neuropsychopharmacol 4, nr 3 (2001): 315-324. <a href="https://doi.org/10.1016/j.jagp.2017.03.010" target="_blank">https://doi.org/10.1016/j.jagp.2017.03.010</a>'},
            {num: 301, text: 'Wenlafaksyna nie podnosi znaczaco progu drgawkowego. Zob. Chittaranjan Andrade, Interactions Between Medications and ECT, w: Principles and Practice of ECT (Cambridge University Press, 2019), 151-175. <a href="https://doi.org/10.4088/JCP.19r12787" target="_blank">https://doi.org/10.4088/JCP.19r12787</a>'},
            {num: 302, text: 'Daniel M. Blumberger et al., Effectiveness of Theta Burst versus High-Frequency rTMS in Patients with Depression (THREE-D), The Lancet 391, nr 10131 (2018): 1683-1692, doi: <a href="https://doi.org/10.1016/S0140-6736(18)30295-2" target="_blank">10.1016/S0140-6736(18)30295-2</a>'},
            {num: 303, text: 'Definicja depresji lekoopornej (TRD). Zob. Michael E. Thase i in., Treatment-Resistant Depression, w: Textbook of Mood Disorders (APA, 2006), 697-716. <a href="https://doi.org/10.1176/appi.ajp.163.11.1905" target="_blank">https://doi.org/10.1176/appi.ajp.163.11.1905</a>'},
            {num: 304, text: 'Skutecznosc ECT w TRD 50-60%. Zob. Pascal Sienaert, What We Have Learned About ECT, Can J Psychiatry 56, nr 1 (2011): 5-12. <a href="https://doi.org/10.1017/neu.2017.36" target="_blank">https://doi.org/10.1017/neu.2017.36</a>'},
            {num: 305, text: 'ECT w katatonii: skutecznosc 80-100%. Zob. Jonathan R. Lloyd i in., ECT for Patients with Catatonia, Neuropsychiatr Dis Treat 16 (2020): 2191-2208, PMID: 33061368. <a href="https://pubmed.ncbi.nlm.nih.gov/33061368/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/33061368/</a> <a href="https://doi.org/10.2147/NDT.S259141" target="_blank">https://doi.org/10.2147/NDT.S259141</a>'},
            {num: 306, text: 'ECT szybko redukuje mysli samobojcze. Zob. Charles H. Kellner i in., Relief of Expressed Suicidal Intent by ECT, Am J Psychiatry 162, nr 5 (2005): 977-982, PMID: 15863801. <a href="https://pubmed.ncbi.nlm.nih.gov/15863801/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/15863801/</a>'},
            {num: 307, text: 'ECT w ciazy. Zob. Silvia Cipolla i in., Safety of ECT in Pregnancy: A Systematic Review, Arch Womens Ment Health 27, nr 2 (2024): 157-178, PMID: 37957411. <a href="https://pubmed.ncbi.nlm.nih.gov/37957411/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/37957411/</a> <a href="https://doi.org/10.1007/s00737-023-01391-6" target="_blank">https://doi.org/10.1007/s00737-023-01391-6</a>'},
            {num: 308, text: 'Brak bezwzglednych przeciwwskazan do ECT. Zob. Sarah H. Lisanby, ECT for Depression, N Engl J Med 357, nr 19 (2007): 1939-1945. <a href="https://doi.org/10.1016/S0140-6736(12)60453-4" target="_blank">https://doi.org/10.1016/S0140-6736(12)60453-4</a>'},
            {num: 309, text: 'Wzmozone cisnienie wewnatrzczaszkowe jako wzgledne przeciwwskazanie. Zob. wytyczne APA (2001), op. cit. <a href="https://www.psychiatry.org/psychiatrists/practice/professional-interests/ect" target="_blank">https://www.psychiatry.org/psychiatrists/practice/professional-interests/ect</a>'},
            {num: 310, text: 'Swiezy zawal serca - okres karencji 2-4 tygodnie. Zob. APA, The Practice of ECT (2001), op. cit. <a href="https://www.psychiatry.org/psychiatrists/practice/professional-interests/ect" target="_blank">https://www.psychiatry.org/psychiatrists/practice/professional-interests/ect</a>'},
            {num: 311, text: 'ECT wykonywana w znieczuleniu ogolnym. Zob. Keith G. Rasmussen, Anesthesia for ECT, w: Electroconvulsive and Neuromodulation Therapies (Cambridge, 2009), 183-195. <a href="https://doi.org/10.1097/YCT.0000000000000361" target="_blank">https://doi.org/10.1097/YCT.0000000000000361</a>'},
            {num: 312, text: 'American Association of Family Physicians (AAFP), &quot;Spravato Is Now Covered Under Medicare Part D as of April 1, 2020,&quot; <a href="https://www.aafp.org/pubs/fpm/blogs/gettingpaid/entry/spravato_coverage.html;" target="_blank">https://www.aafp.org/pubs/fpm/blogs/gettingpaid/entry/spravato_coverage.html;</a> SingleCare, &quot;Spravato prices, coupons, and patient assistance programs,&quot; <a href="https://www.singlecare.com/prescription/spravato" target="_blank">https://www.singlecare.com/prescription/spravato</a>'},
            {num: 313, text: 'Brak dowodow na uszkodzenie mozgu po ECT. Zob. Gregor Gryglewski i in., Meta-Analysis of Brain Structural Changes After ECT, Brain Stimulation 14, nr 4 (2021): 927-937. <a href="https://doi.org/10.1016/j.brs.2021.03.009" target="_blank">https://doi.org/10.1016/j.brs.2021.03.009</a>'},
            {num: 314, text: 'Brak zmian osobowosci po ECT. Zob. Maria Semkovska i Declan M. McLoughlin, Cognitive Performance and ECT: Meta-Analysis, Biol Psychiatry 68, nr 6 (2010): 568-577, PMID: 20673880. <a href="https://pubmed.ncbi.nlm.nih.gov/20673880/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/20673880/</a>'},
            {num: 315, text: 'Przejsciowe zaburzenia pamieci przy RUL-UB. Zob. E. Verwijk i in., Neurocognitive Effects After Brief and Ultrabrief Pulse ECT, J Affect Disord 140, nr 3 (2012): 233-243, PMID: 22595374. <a href="https://pubmed.ncbi.nlm.nih.gov/22595374/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/22595374/</a> <a href="https://doi.org/10.1016/j.jad.2011.10.027" target="_blank">https://doi.org/10.1016/j.jad.2011.10.027</a>'},
            {num: 316, text: 'Smiertelnosc ECT: 2,1 na 100 000 zabiegow. Zob. Soren D. Ostergaard i in., Risk of Mortality During ECT, Acta Psychiatr Scand 136, nr 2 (2017): 229-239, PMID: 28332236. <a href="https://pubmed.ncbi.nlm.nih.gov/28332236/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/28332236/</a> <a href="https://doi.org/10.1111/acps.12768" target="_blank">https://doi.org/10.1111/acps.12768</a>'},
            {num: 317, text: 'ECT jako leczenie pierwszego wyboru w katatonii. Zob. wytyczne CANMAT 2016, Can J Psychiatry 61, nr 9 (2016): 540-560. <a href="https://doi.org/10.1177/0706743716660033" target="_blank">https://doi.org/10.1177/0706743716660033</a>'},
            {num: 318, text: 'Bindman LJ, Lippold OC, Redfearn JW. Long-lasting changes in the level of the electrical activity of the cerebral cortex produced by polarizing currents. Nature 1962;196:584-585. doi: <a href="https://doi.org/10.1038/196584a0" target="_blank">10.1038/196584a0</a>'},
            {num: 319, text: 'Mark S. George et al., Daily Left Prefrontal TMS Therapy for Major Depressive Disorder, Archives of General Psychiatry 67, nr 5 (2010): 507-516, doi: <a href="https://doi.org/10.1001/archgenpsychiatry.2010.46" target="_blank">10.1001/archgenpsychiatry.2010.46</a>'},
            {num: 320, text: 'Nitsche MA, Paulus W. Sustained excitability elevations induced by transcranial DC motor cortex stimulation in humans. Neurology 2001;57(10):1899-1901. <a href="https://doi.org/10.1212/01.wnl.0000091584.59156.65" target="_blank">https://doi.org/10.1212/01.wnl.0000091584.59156.65</a>'},
            {num: 321, text: 'Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. Journal of Physiology 2000;527(3):633-639. doi: <a href="https://doi.org/10.1111/j.1469-7793.2000.t01-1-00633.x" target="_blank">10.1111/j.1469-7793.2000.t01-1-00633.x</a>'},
            {num: 322, text: 'Lefaucheur JP, Antal A, Ayache SS, et al. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clinical Neurophysiology 2017;128(1):56-92. doi: <a href="https://doi.org/10.1016/j.clinph.2016.10.087" target="_blank">10.1016/j.clinph.2016.10.087</a>'},
            {num: 323, text: 'Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. Journal of Physiology 2000;527(3):633-639. doi: <a href="https://doi.org/10.1111/j.1469-7793.2000.t01-1-00633.x" target="_blank">10.1111/j.1469-7793.2000.t01-1-00633.x</a>'},
            {num: 324, text: 'Brunoni AR, Amadera J, Berbel B, et al. A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. International Journal of Neuropsychopharmacology 2011;14(8):1133-1145. doi: <a href="https://doi.org/10.1017/S1461145710001690" target="_blank">10.1017/S1461145710001690</a>'},
            {num: 325, text: 'Fregni F, Boggio PS, Nitsche MA, et al. Treatment of major depression with transcranial direct current stimulation. Bipolar Disorders 2006;8(2):203-204. doi: <a href="https://doi.org/10.1111/j.1399-5618.2006.00291.x" target="_blank">10.1111/j.1399-5618.2006.00291.x</a>'},
            {num: 326, text: 'U.S. Food and Drug Administration. Premarket Approval (PMA) P230024: Flow FL-100. Approval Date: December 8, 2025. Dostepne: <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230024B.pdf" target="_blank">https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230024B.pdf</a>'},
            {num: 327, text: 'Flow Neuroscience. Real-world outcome data from over 55,000 users. Clinical Summary Report 2025. <a href="https://flowneuroscience.com/clinical-evidence/" target="_blank">https://flowneuroscience.com/clinical-evidence/</a>'},
            {num: 328, text: 'Flow Neuroscience. Company Overview and History. 2025. Dostepne: <a href="https://www.flowneuroscience.com/about" target="_blank">https://www.flowneuroscience.com/about</a>'},
            {num: 329, text: 'Woodham RD, Rimmer RM, Mutz J, et al. Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote randomised controlled trial. Nature Medicine 2024;31(1):87-95. doi: <a href="https://doi.org/10.1038/s41591-024-03305-y" target="_blank">10.1038/s41591-024-03305-y</a>'},
            {num: 330, text: 'Flow Neuroscience. Real-world outcome data from over 55,000 users. Clinical Summary Report 2025. <a href="https://flowneuroscience.com/clinical-evidence/" target="_blank">https://flowneuroscience.com/clinical-evidence/</a>'},
            {num: 331, text: 'Flow Neuroscience. FL-100 Technical Specifications and User Manual. Version 2.0, 2025. <a href="https://flowneuroscience.com/support/" target="_blank">https://flowneuroscience.com/support/</a>'},
            {num: 332, text: 'Woodham RD, Rimmer RM, Mutz J, et al. Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote randomised controlled trial. Nature Medicine 2024;31(1):87-95. doi: <a href="https://doi.org/10.1038/s41591-024-03305-y" target="_blank">10.1038/s41591-024-03305-y</a>'},
            {num: 333, text: 'Flow Neuroscience. Press Release: FDA Approval of Flow FL-100. December 8, 2025. Dostepne: <a href="https://www.flowneuroscience.com/news" target="_blank">https://www.flowneuroscience.com/news</a>'},
            {num: 334, text: 'South County Psychiatry. Transcranial Magnetic Stimulation Cost Analysis. 2022. Dostepne: <a href="https://www.southcountypsychiatryri.com/transcranial-magnetic-stimulation-cost/" target="_blank">https://www.southcountypsychiatryri.com/transcranial-magnetic-stimulation-cost/</a>'},
            {num: 335, text: 'Cuijpers, P., Miguel, C., Harrer, M., et al. (2023). Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: A comprehensive meta‐analysis including 409 trials with 52,702 patients. World Psychiatry, 22(1), 105–115. <a href="https://doi.org/10.1002/wps.21069" target="_blank">https://doi.org/10.1002/wps.21069</a>'},
            {num: 336, text: 'Guy M. Goodwin i in., &quot;Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression&quot;, New England Journal of Medicine 387, nr 18 (2022): 1637-1648, <a href="https://doi.org/10.1056/NEJMoa2206443" target="_blank">https://doi.org/10.1056/NEJMoa2206443</a>'},
            {num: 337, text: 'Pena-Gomez C, Sala-Lonch R, Junque C, et al. Modulation of large-scale brain networks by transcranial direct current stimulation evidenced by resting-state functional MRI. Brain Stimulation 2012;5(3):252-263. doi: <a href="https://doi.org/10.1016/j.brs.2011.08.006" target="_blank">10.1016/j.brs.2011.08.006</a>'},
            {num: 338, text: 'Bikson M, Grossman P, Thomas C, et al. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimulation 2016;9(5):641-661. doi: <a href="https://doi.org/10.1016/j.brs.2016.06.004" target="_blank">10.1016/j.brs.2016.06.004</a>'},
            {num: 339, text: 'Aparicio LV, Guarienti F, Razza LB, et al. A Systematic Review on the Acceptability and Tolerability of Transcranial Direct Current Stimulation Treatment in Neuropsychiatry Trials. Brain Stimulation 2016;9(5):671-681. doi: <a href="https://doi.org/10.1016/j.brs.2016.05.004" target="_blank">10.1016/j.brs.2016.05.004</a>'},
            {num: 340, text: 'Matsumoto H, Ugawa Y. Adverse events of tDCS and tACS: A review. Clinical Neurophysiology Practice 2017;2:19-25. doi: <a href="https://doi.org/10.1016/j.cnp.2016.12.003" target="_blank">10.1016/j.cnp.2016.12.003</a>'},
            {num: 341, text: 'Ekici B. Transcranial direct current stimulation-induced seizure: Analysis of a case. Clinical EEG and Neuroscience 2015;46(2):169. doi: <a href="https://doi.org/10.1177/1550059414540647" target="_blank">10.1177/1550059414540647</a>'},
            {num: 342, text: 'Palm U, Keeser D, Schiller C, et al. Skin lesions after treatment with transcranial direct current stimulation (tDCS). Brain Stimulation 2008;1(4):386-387. doi: <a href="https://doi.org/10.1016/j.brs.2008.04.003" target="_blank">10.1016/j.brs.2008.04.003</a>'},
            {num: 343, text: 'Moreno ML, Goerigk SA, Bertola L, et al. Cognitive changes after tDCS and escitalopram treatment in major depressive disorder: Results from the placebo-controlled ELECT-TDCS trial. Journal of Affective Disorders 2020;263:344-352. doi: <a href="https://doi.org/10.1016/j.jad.2019.12.009" target="_blank">10.1016/j.jad.2019.12.009</a>'},
            {num: 344, text: 'Woods AJ, Antal A, Bikson M, et al. A technical guide to tDCS, and related non-invasive brain stimulation tools. Clinical Neurophysiology 2016;127(2):1031-1048. doi: <a href="https://doi.org/10.1016/j.clinph.2015.11.012" target="_blank">10.1016/j.clinph.2015.11.012</a>'},
            {num: 345, text: 'Bikson M, Grossman P, Thomas C, et al. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimulation 2016;9(5):641-661. doi: <a href="https://doi.org/10.1016/j.brs.2016.06.004" target="_blank">10.1016/j.brs.2016.06.004</a>'},
            {num: 346, text: 'Mutz J, Edgcumbe DR, Brunoni AR, Fu CHY. Efficacy and acceptability of non-invasive brain stimulation for the treatment of adult unipolar and bipolar depression: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews 2018;92:291-303. doi: <a href="https://doi.org/10.1016/j.neubiorev.2018.05.015" target="_blank">10.1016/j.neubiorev.2018.05.015</a>'},
            {num: 347, text: 'U.S. Food and Drug Administration. Premarket Approval (PMA) P230024: Flow FL-100. Approval Date: December 8, 2025. Dostepne: <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230024B.pdf" target="_blank">https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230024B.pdf</a>'},
            {num: 348, text: 'Rodrigues de Almeida L, Pope PA, Hansen PC. The neurobiology of prefrontal transcranial direct current stimulation (tDCS) in promoting brain plasticity. Neuroscience and Biobehavioral Reviews 2021;121:238-256. doi: <a href="https://doi.org/10.1016/j.neubiorev.2021.01.019" target="_blank">10.1016/j.neubiorev.2021.01.019</a>'},
            {num: 349, text: 'Wu i in., &quot;Deep Brain Stimulation in Treatment-Resistant Depression: A Systematic Review and Meta-Analysis on Efficacy and Safety&quot;, Frontiers in Neuroscience 15 (2021): 655412. <a href="https://doi.org/10.1016/j.neubiorev.2020.11.018" target="_blank">https://doi.org/10.1016/j.neubiorev.2020.11.018</a>'},
            {num: 350, text: 'Dandekar i in., &quot;Deep Brain Stimulation for Treatment-Resistant Depression: An Integrative Review&quot;, Molecular Psychiatry 23, nr 5 (2018): 1094-1112. <a href="https://doi.org/10.1016/j.biopsych.2020.09.012" target="_blank">https://doi.org/10.1016/j.biopsych.2020.09.012</a>'},
            {num: 351, text: 'Dandekar i in., &quot;Deep Brain Stimulation for Treatment-Resistant Depression: An Integrative Review&quot;, Molecular Psychiatry 23, nr 5 (2018): 1094-1112. <a href="https://doi.org/10.1016/j.biopsych.2020.09.012" target="_blank">https://doi.org/10.1016/j.biopsych.2020.09.012</a>'},
            {num: 352, text: 'Riva-Posse i in., &quot;Defining Critical White Matter Pathways Mediating Successful Subcallosal Cingulate Deep Brain Stimulation&quot;, Biological Psychiatry 76, nr 12 (2014): 963-969. <a href="https://doi.org/10.1016/j.biopsych.2014.03.029" target="_blank">https://doi.org/10.1016/j.biopsych.2014.03.029</a>'},
            {num: 353, text: 'Widge i in., &quot;Closing the Loop on Deep Brain Stimulation for Treatment-Resistant Depression&quot;, Frontiers in Neuroscience 12 (2018): 640. <a href="https://doi.org/10.1016/j.tins.2020.07.003" target="_blank">https://doi.org/10.1016/j.tins.2020.07.003</a>'},
            {num: 354, text: 'Hamani i in., &quot;The Subcallosal Cingulate Gyrus in the Context of Major Depression&quot;, Biological Psychiatry 69, nr 4 (2011): 301-308. <a href="https://doi.org/10.1016/j.neuron.2020.07.036" target="_blank">https://doi.org/10.1016/j.neuron.2020.07.036</a>'},
            {num: 355, text: 'Schlaepfer i in., &quot;Deep Brain Stimulation to Reward Circuitry Alleviates Anhedonia in Refractory Major Depression&quot;, Neuropsychopharmacology 33, nr 2 (2008): 368-377. <a href="https://doi.org/10.1038/npp.2007.23" target="_blank">https://doi.org/10.1038/npp.2007.23</a>'},
            {num: 356, text: 'Gadot i in., &quot;Efficacy of Deep Brain Stimulation for Treatment-Resistant Depression: Systematic Review and Meta-Analysis&quot;, Biological Psychiatry: CNNI 9, nr 9 (2024): 893-902. <a href="https://doi.org/10.1016/j.brs.2022.09.007" target="_blank">https://doi.org/10.1016/j.brs.2022.09.007</a>'},
            {num: 357, text: 'Johansen-Berg i in., &quot;Anatomical Connectivity of the Subgenual Cingulate Region Targeted with Deep Brain Stimulation&quot;, Cerebral Cortex 18, nr 6 (2008): 1374-1383. <a href="https://doi.org/10.1093/cercor/bhm167" target="_blank">https://doi.org/10.1093/cercor/bhm167</a>'},
            {num: 358, text: 'Choi i in., &quot;Mapping the &#x27;Depression Switch&#x27; During Intraoperative Testing of Subcallosal Cingulate Deep Brain Stimulation&quot;, JAMA Neurology 72, nr 11 (2015): 1252-1260. <a href="https://doi.org/10.1001/jamaneurol.2015.2564" target="_blank">https://doi.org/10.1001/jamaneurol.2015.2564</a>'},
            {num: 359, text: 'US FDA, FDA Grants Breakthrough Therapy Designation for Psilocybin for Treatment-Resistant Depression (Silver Spring, MD: FDA, 2018). <a href="https://www.fda.gov/drugs/development-approval-process-drugs/breakthrough-therapy" target="_blank">https://www.fda.gov/drugs/development-approval-process-drugs/breakthrough-therapy</a>'},
            {num: 360, text: 'Scangos i in., &quot;Closed-Loop Neuromodulation in an Individual with Treatment-Resistant Depression&quot;, Nature Medicine 27, nr 10 (2021): 1696-1700. <a href="https://doi.org/10.1038/s41591-021-01480-w" target="_blank">https://doi.org/10.1038/s41591-021-01480-w</a>'},
            {num: 361, text: 'Cole, E.J., Phillips, A.L., Bentzley, B.S., Stimpson, K.H., Nejad, R., Barmak, F., Veber, C., Hawkins, J., Keller, J., DeLuca, N., Choi, E.Y., Williams, N.R. (2022). Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. American Journal of Psychiatry, 179(2), 132-141. DOI: <a href="https://doi.org/10.1176/appi.ajp.2021.20101429" target="_blank">10.1176/appi.ajp.2021.20101429</a>'},
            {num: 362, text: 'Bouthour i in., &quot;Biomarkers for Closed-Loop Deep Brain Stimulation in Parkinson Disease and Beyond&quot;, Nature Reviews Neurology 15, nr 6 (2019): 343-352. <a href="https://doi.org/10.1038/s41582-019-0166-4" target="_blank">https://doi.org/10.1038/s41582-019-0166-4</a>'},
            {num: 363, text: 'Widge i in., &quot;Closing the Loop on Deep Brain Stimulation for Treatment-Resistant Depression&quot;, Frontiers in Neuroscience 12 (2018): 640. <a href="https://doi.org/10.1016/j.tins.2020.07.003" target="_blank">https://doi.org/10.1016/j.tins.2020.07.003</a>'},
            {num: 364, text: 'Compass Pathways plc, Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression, komunikat prasowy (Londyn: Compass Pathways, 23 czerwca 2025). <a href="https://compasspathways.com/our-science/psilocybin-therapy/" target="_blank">https://compasspathways.com/our-science/psilocybin-therapy/</a>'},
            {num: 365, text: 'Bewernick i in., &quot;Nucleus Accumbens Deep Brain Stimulation Decreases Ratings of Depression and Anxiety in Treatment-Resistant Depression&quot;, Biological Psychiatry 67, nr 2 (2010): 110-116. <a href="https://doi.org/10.1016/j.biopsych.2011.07.020" target="_blank">https://doi.org/10.1016/j.biopsych.2011.07.020</a>'},
            {num: 366, text: 'Riva-Posse i in., &quot;A Connectomic Approach for Subcallosal Cingulate Deep Brain Stimulation Surgery&quot;, Molecular Psychiatry 23, nr 4 (2018): 843-849. <a href="https://doi.org/10.1038/mp.2017.59" target="_blank">https://doi.org/10.1038/mp.2017.59</a>'},
            {num: 367, text: 'Choi i in., &quot;Mapping the &#x27;Depression Switch&#x27; During Intraoperative Testing of Subcallosal Cingulate Deep Brain Stimulation&quot;, JAMA Neurology 72, nr 11 (2015): 1252-1260. <a href="https://doi.org/10.1001/jamaneurol.2015.2564" target="_blank">https://doi.org/10.1001/jamaneurol.2015.2564</a>'},
            {num: 368, text: 'Holtzheimer i in., &quot;Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Unipolar and Bipolar Depression&quot;, Archives of General Psychiatry 69, nr 2 (2012): 150-158. <a href="https://doi.org/10.1016/S2215-0366(17)30371-1" target="_blank">https://doi.org/10.1016/S2215-0366(17)30371-1</a>'},
            {num: 369, text: 'Holtzheimer i in., &quot;Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Depression: A Multisite, Randomised, Sham-Controlled Trial&quot;, Lancet Psychiatry 4, nr 11 (2017): 839-849. <a href="https://doi.org/10.1016/S2215-0366(17)30371-1" target="_blank">https://doi.org/10.1016/S2215-0366(17)30371-1</a>'},
            {num: 370, text: 'Koh i in., &quot;Comprehensive Characterization of Intracranial Hemorrhage in Deep Brain Stimulation: A Systematic Review&quot;, Journal of Neurosurgery 141, nr 2 (2024): 381-392. <a href="https://doi.org/10.3171/2023.9.JNS231081" target="_blank">https://doi.org/10.3171/2023.9.JNS231081</a>'},
            {num: 371, text: 'Nonaka i in., &quot;Surgical Management of Adverse Events Associated with Deep Brain Stimulation&quot;, SAGE Open Medicine 8 (2020): 2050312120913458. <a href="https://doi.org/10.1177/2050312120913458" target="_blank">https://doi.org/10.1177/2050312120913458</a>'},
            {num: 372, text: 'Lozano i in., &quot;Deep Brain Stimulation: Current Challenges and Future Directions&quot;, Nature Reviews Neurology 15, nr 3 (2019): 148-160. <a href="https://doi.org/10.1038/s41582-019-0145-9" target="_blank">https://doi.org/10.1038/s41582-019-0145-9</a>'},
            {num: 373, text: 'Krauss i in., &quot;Technology of Deep Brain Stimulation: Current Status and Future Directions&quot;, Nature Reviews Neurology 17, nr 2 (2021): 75-87. <a href="https://doi.org/10.1038/s41582-020-00426-z" target="_blank">https://doi.org/10.1038/s41582-020-00426-z</a>'},
            {num: 374, text: 'Scangos i in., &quot;Closed-Loop Neuromodulation in an Individual with Treatment-Resistant Depression&quot;, Nature Medicine 27, nr 10 (2021): 1696-1700. <a href="https://doi.org/10.1038/s41591-021-01480-w" target="_blank">https://doi.org/10.1038/s41591-021-01480-w</a>'},
            {num: 375, text: 'Krauss i in., &quot;Technology of Deep Brain Stimulation: Current Status and Future Directions&quot;, Nature Reviews Neurology 17, nr 2 (2021): 75-87. <a href="https://doi.org/10.1038/s41582-020-00426-z" target="_blank">https://doi.org/10.1038/s41582-020-00426-z</a>'},
            {num: 376, text: 'Figee i in., &quot;Deep Brain Stimulation for Depression&quot;, Neurotherapeutics 19, nr 4 (2022): 1229-1245. <a href="https://doi.org/10.1007/s13311-022-01229-0" target="_blank">https://doi.org/10.1007/s13311-022-01229-0</a>'},
            {num: 377, text: 'Bouthour i in., &quot;Biomarkers for Closed-Loop Deep Brain Stimulation in Parkinson Disease and Beyond&quot;, Nature Reviews Neurology 15, nr 6 (2019): 343-352. <a href="https://doi.org/10.1038/s41582-019-0166-4" target="_blank">https://doi.org/10.1038/s41582-019-0166-4</a>'},
            {num: 378, text: 'Chandrabhatla i in., &quot;Landscape and Future Directions of Machine Learning Applications in Closed-Loop Brain Stimulation&quot;, npj Digital Medicine 6, nr 79 (2023): 1-17. <a href="https://doi.org/10.1016/j.brs.2020.04.008" target="_blank">https://doi.org/10.1016/j.brs.2020.04.008</a>'},
            {num: 379, text: 'Unadkat i in., &quot;Opportunities and Challenges for the Use of Deep Brain Stimulation in the Treatment of Refractory Major Depression&quot;, Discover Mental Health 4, nr 9 (2024): 1-15. <a href="https://doi.org/10.1016/j.brs.2021.01.012" target="_blank">https://doi.org/10.1016/j.brs.2021.01.012</a>'},
            {num: 380, text: 'Cernera i in., &quot;Healthcare Disparities in Deep Brain Stimulation Access and Utilization: A Systematic Review&quot;, Journal of Neurosurgery 140, nr 4 (2024): 1137-1149. <a href="https://doi.org/10.3171/2022.8.JNS221037" target="_blank">https://doi.org/10.3171/2022.8.JNS221037</a>'},
            {num: 381, text: 'Krauss i in., &quot;Technology of Deep Brain Stimulation: Current Status and Future Directions&quot;, Nature Reviews Neurology 17, nr 2 (2021): 75-87. <a href="https://doi.org/10.1038/s41582-020-00426-z" target="_blank">https://doi.org/10.1038/s41582-020-00426-z</a>'},
            {num: 382, text: 'Gadot i in., &quot;Efficacy of Deep Brain Stimulation for Treatment-Resistant Depression: Systematic Review and Meta-Analysis&quot;, Biological Psychiatry: CNNI 9, nr 9 (2024): 893-902. <a href="https://doi.org/10.1016/j.brs.2022.09.007" target="_blank">https://doi.org/10.1016/j.brs.2022.09.007</a>'},
            {num: 383, text: 'Widge i in., &quot;Closing the Loop on Deep Brain Stimulation for Treatment-Resistant Depression&quot;, Frontiers in Neuroscience 12 (2018): 640. <a href="https://doi.org/10.1016/j.tins.2020.07.003" target="_blank">https://doi.org/10.1016/j.tins.2020.07.003</a>'},
            {num: 384, text: 'Kral, T. R. A., et al. (2018). Impact of short- and long-term mindfulness meditation training on amygdala reactivity to emotional stimuli. NeuroImage, 181, 301–313. <a href="https://doi.org/10.1016/j.neuroimage.2018.07.013" target="_blank">https://doi.org/10.1016/j.neuroimage.2018.07.013</a>'},
            {num: 385, text: 'Albert Hofmann, Arthur Brack, Hans Kobel, &quot;Psilocybin, a Psychotropic Substance from the Mexican Mushroom Psilocybe Mexicana Heim&quot;, Experientia 14, nr 3 (1958): 107-109, <a href="https://doi.org/10.1007/BF02159243" target="_blank">https://doi.org/10.1007/BF02159243</a>'},
            {num: 386, text: 'Oregon Ballot Measure 109, Oregon Psilocybin Services Act, przyjęta 3 listopada 2020. <a href="https://ballotpedia.org/Oregon_Measure_109,_Psilocybin_Program_Initiative_(2020)" target="_blank">https://ballotpedia.org/Oregon_Measure_109,_Psilocybin_Program_Initiative_(2020)</a>'},
            {num: 387, text: 'Comprehensive Drug Abuse Prevention and Control Act of 1970, Pub. L. 91-513, 84 Stat. 1242 (21 U.S.C. par. 812). <a href="https://www.dea.gov/drug-information/csa" target="_blank">https://www.dea.gov/drug-information/csa</a>'},
            {num: 388, text: 'Konwencja ONZ o substancjach psychotropowych, Wiedeń, 21 lutego 1971 r. <a href="https://www.unodc.org/pdf/convention_1971_en.pdf" target="_blank">https://www.unodc.org/pdf/convention_1971_en.pdf</a>'},
            {num: 389, text: 'US FDA, FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs (Silver Spring, MD: FDA, 2023). <a href="https://www.fda.gov/media/169740/download" target="_blank">https://www.fda.gov/media/169740/download</a>'},
            {num: 390, text: 'Robin L. Carhart-Harris et al., Psilocybin with Psychological Support for Treatment-Resistant Depression: Six-Month Follow-Up, Psychopharmacology 235, nr 2 (2018): 399-408. <a href="https://doi.org/10.1056/NEJMoa2206443" target="_blank">https://doi.org/10.1056/NEJMoa2206443</a>'},
            {num: 391, text: 'Robin L. Carhart-Harris i in., &quot;Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin&quot;, Proceedings of the National Academy of Sciences 109, nr 6 (2012): 2138-2143, <a href="https://doi.org/10.1073/pnas.1119598109" target="_blank">https://doi.org/10.1073/pnas.1119598109</a>'},
            {num: 392, text: 'COMPASS Pathways, &quot;COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-resistant Depression&quot;, komunikat prasowy, 23 października 2018. <a href="https://compasspathways.com/our-science/psilocybin-therapy/" target="_blank">https://compasspathways.com/our-science/psilocybin-therapy/</a>'},
            {num: 393, text: 'Usona Institute, &quot;FDA grants Breakthrough Therapy Designation to Usona Institute&#x27;s psilocybin program for major depressive disorder&quot;, komunikat prasowy, 22 listopada 2019. <a href="https://www.usonainstitute.org" target="_blank">https://www.usonainstitute.org</a>'},
            {num: 394, text: 'Adam S. Vargas i in., &quot;Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors&quot;, Science 379, nr 6633 (2023): 700-706, <a href="https://doi.org/10.1126/science.adf0435" target="_blank">https://doi.org/10.1126/science.adf0435</a>'},
            {num: 395, text: 'Menon, &quot;20 Years of the Default Mode Network: A Review and Synthesis&quot;, Neuron 111, nr 16 (2023): 2469-2487. <a href="https://doi.org/10.1016/j.neuron.2023.01.025" target="_blank">https://doi.org/10.1016/j.neuron.2023.01.025</a>'},
            {num: 396, text: 'Matthew W. Johnson, Roland R. Griffiths, &quot;Potential Therapeutic Effects of Psilocybin&quot;, Neurotherapeutics 14, nr 3 (2017): 734-740, <a href="https://doi.org/10.1007/s13311-017-0542-y" target="_blank">https://doi.org/10.1007/s13311-017-0542-y</a>'},
            {num: 397, text: 'Johnson &amp; Johnson, SPRAVATO (esketamine) Approved in the U.S. as Monotherapy for Treatment-Resistant Depression (Titusville, NJ: Janssen, 21 stycznia 2025). <a href="https://www.janssen.com/spravato" target="_blank">https://www.janssen.com/spravato</a>'},
            {num: 398, text: 'Frederick S. Barrett i in., &quot;Emotions and brain function are altered up to one month after a single high dose of psilocybin&quot;, Scientific Reports 10 (2020): 2214, <a href="https://doi.org/10.1038/s41598-020-59282-y" target="_blank">https://doi.org/10.1038/s41598-020-59282-y</a>'},
            {num: 399, text: 'COMPASS Pathways, &quot;COMPASS Pathways Announces Positive Topline Results from Phase 3 COMP005 Trial of COMP360 Psilocybin Therapy in Treatment-Resistant Depression&quot;, komunikat prasowy, 23 czerwca 2025. <a href="https://compasspathways.com/our-science/psilocybin-therapy/" target="_blank">https://compasspathways.com/our-science/psilocybin-therapy/</a>'},
            {num: 400, text: 'Geddes, J.R., Carney, S.M., Davies, C., Furukawa, T.A., Kupfer, D.J., Frank, E., Goodwin, G.M. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet, 361(9358), 653-661. DOI: <a href="https://doi.org/10.1016/S0140-6736(03)12599-8" target="_blank">10.1016/S0140-6736(03)12599-8</a>'},
            {num: 401, text: 'John P. O&#x27;Reardon et al., Efficacy and Safety of TMS in the Acute Treatment of Major Depression, Biological Psychiatry 62, nr 11 (2007): 1208-1216, doi: <a href="https://doi.org/10.1016/j.biopsych.2007.01.018" target="_blank">10.1016/j.biopsych.2007.01.018</a>'},
            {num: 402, text: 'Kellner CH, Husain MM, Knapp RG i wsp. A novel strategy for continuation ECT in geriatric depression: phase 2 of the PRIDE study. American Journal of Psychiatry 2016; 173(11): 1110-1118. DOI: <a href="https://doi.org/10.1176/appi.ajp.2016.16010118" target="_blank">10.1176/appi.ajp.2016.16010118</a>'},
            {num: 403, text: 'World Health Organization. COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide. WHO News Release, 2 March 2022. <a href="https://www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide" target="_blank">https://www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide</a>'},
            {num: 404, text: 'Crowell i in., &quot;Long-Term Outcomes of Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Depression&quot;, American Journal of Psychiatry 176, nr 11 (2019): 949-956. <a href="https://doi.org/10.1176/appi.ajp.2019.18121427" target="_blank">https://doi.org/10.1176/appi.ajp.2019.18121427</a>'},
            {num: 405, text: 'Tompson MC, Sugar CA, Langer DA, Asarnow JR. A Randomized Clinical Trial Comparing Family-Focused Treatment and Individual Supportive Therapy for Depression in Childhood and Early Adolescence. Journal of the American Academy of Child and Adolescent Psychiatry. 2017;56(6):515-523. doi: <a href="https://doi.org/10.1016/j.jaac.2017.03.018" target="_blank">10.1016/j.jaac.2017.03.018</a>'},
            {num: 406, text: 'MDMA działa jako substrat dla transporterów monoamin i powoduje uwalnianie serotoniny, dopaminy i noradrenaliny. Zob. Schenk, S. Methylenedioxymethamphetamine (MDMA): Serotonergic and dopaminergic mechanisms related to its use and misuse. Journal of Neurochemistry, 2021; 157(6): 1714–1732. DOI: <a href="https://doi.org/10.1111/jnc.15348" target="_blank">10.1111/jnc.15348</a>'},
            {num: 407, text: 'Kirkpatrick, M. i in. Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans. Psychopharmacology, 2014; 231(6): 1091–1100. PMC4088952. Zob. także: Hysek, C.M. i in. MDMA enhances emotional empathy and prosocial behavior. Social Cognitive and Affective Neuroscience, 2014; 9(11): 1645–1652. <a href="https://doi.org/10.1016/j.psyneuen.2013.01.005" target="_blank">https://doi.org/10.1016/j.psyneuen.2013.01.005</a>'},
            {num: 408, text: 'Mitchell, J.M. i in. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 2021; 27(6): 1025–1033. DOI: <a href="https://doi.org/10.1038/s41591-021-01336-3" target="_blank">10.1038/s41591-021-01336-3</a> W badaniu uczestniczyło 90 pacjentów randomizowanych w stosunku 1:1.'},
            {num: 409, text: 'MAPS, Phase 3 Trial Program: MDMA-Assisted Therapy for PTSD. Dostęp: <a href="https://maps.org/mdma/ptsd/phase3/" target="_blank">https://maps.org/mdma/ptsd/phase3/</a> Status Breakthrough Therapy został przyznany przez FDA 16 sierpnia 2017 roku.'},
            {num: 410, text: 'FDA wydała Complete Response Letter (CRL) do Lykos Therapeutics 8 sierpnia 2024 roku, odmawiając zatwierdzenia terapii MDMA-wspomaganej dla PTSD. Zob. FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD, Psychiatric Times, wrzesień 2025. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-rejects-mdma-assisted-therapy-ptsd" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-rejects-mdma-assisted-therapy-ptsd</a>'},
            {num: 411, text: 'Mufson L, Weissman MM, Moreau D, Garfinkel R. Efficacy of interpersonal psychotherapy for depressed adolescents. Archives of General Psychiatry. 1999;56(6):573-579. doi: <a href="https://doi.org/10.1001/archpsyc.56.6.573" target="_blank">10.1001/archpsyc.56.6.573</a>'},
            {num: 412, text: 'Hofmann, A. LSD: My Problem Child. McGraw-Hill, 1980. Synteza LSD-25 miała miejsce 16 listopada 1938 roku w laboratoriach Sandoz w Bazylei. Zob. także: History of LSD, Wikipedia. <a href="https://www.hup.harvard.edu/books/9780674039612" target="_blank">https://www.hup.harvard.edu/books/9780674039612</a>'},
            {num: 413, text: 'Właściwości psychoaktywne LSD zostały odkryte przypadkowo 16 kwietnia 1943 roku. Celowe przyjęcie LSD nastąpiło 19 kwietnia 1943 roku (tzw. Bicycle Day). Zob. Hofmann, A., dz. cyt. <a href="https://www.hofmann.org/" target="_blank">https://www.hofmann.org/</a>'},
            {num: 414, text: 'LSD działa jako częściowy agonista receptora 5-HT2A. Zob. Nichols, D.E. Psychedelics. Pharmacological Reviews, 2016; 68(2): 264–355. DOI: <a href="https://doi.org/10.1124/pr.115.011478" target="_blank">10.1124/pr.115.011478</a>'},
            {num: 415, text: 'Dane dotyczące rozpowszechnienia GAD różnią się w zależności od metodologii. NIMH podaje 2,7% rocznie w USA; lifetime prevalence szacuje się na 5,7–5,9%. Zob. National Institute of Mental Health, Generalized Anxiety Disorder (dostęp: 2025). <a href="https://www.nimh.nih.gov/health/statistics/generalized-anxiety-disorder" target="_blank">https://www.nimh.nih.gov/health/statistics/generalized-anxiety-disorder</a>'},
            {num: 416, text: 'MindMed Inc. MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder. Komunikat prasowy, 14 grudnia 2023. Badanie MMED008 objęło 198 uczestników. <a href="https://mindmed.co/news/press-release/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm120-for-generalized-anxiety-disorder/" target="_blank">https://mindmed.co/news/press-release/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm120-for-generalized-anxiety-disorder/</a>'},
            {num: 417, text: 'MindMed Inc. MindMed Receives FDA Breakthrough Therapy Designation. Komunikat prasowy, 7 marca 2024. Dawka 100 μg wykazała poprawę o 7,7 punktu w skali HAM-A w porównaniu z placebo po 12 tygodniach (p&lt;0,003; Cohens d=0,81). 65% pacjentów osiągnęło odpowiedź kliniczną. <a href="https://mindmed.co/news/press-release/mindmed-receives-fda-breakthrough-therapy-designation/" target="_blank">https://mindmed.co/news/press-release/mindmed-receives-fda-breakthrough-therapy-designation/</a>'},
            {num: 418, text: 'Status Breakthrough Therapy dla MM120 w GAD został przyznany przez FDA w marcu 2024. Zob. MindMed Inc., komunikat prasowy z 7 marca 2024. <a href="https://www.fda.gov/drugs/development-approval-process-drugs/breakthrough-therapy" target="_blank">https://www.fda.gov/drugs/development-approval-process-drugs/breakthrough-therapy</a>'},
            {num: 419, text: 'LSD może promować neuroplastyczność. Zob. Ly, C. i in. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports, 2018; 23(11): 3170–3182. DOI: <a href="https://doi.org/10.1016/j.celrep.2018.05.022" target="_blank">10.1016/j.celrep.2018.05.022</a>'},
            {num: 420, text: 'Kwestię świadomej zgody i etyki w badaniach psychedelicznych omawiają m.in.: Johnson, M.W. i in. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology &amp; Therapeutics, 2019; 197: 83–102. <a href="https://doi.org/10.1016/j.neubiorev.2020.03.004" target="_blank">https://doi.org/10.1016/j.neubiorev.2020.03.004</a>'},
            {num: 421, text: 'Nutt, D. i in. The Australia story: Current status and future challenges for the clinical applications of psychedelics. British Journal of Pharmacology, 2024. DOI: <a href="https://doi.org/10.1111/bph.17398" target="_blank">10.1111/bph.17398</a>'},
            {num: 422, text: 'Therapeutic Goods Administration (TGA), Australia. Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists. Komunikat prasowy, 3 lutego 2023. Zmiany weszły w życie 1 lipca 2023 roku. <a href="https://www.tga.gov.au/scheduling-basics" target="_blank">https://www.tga.gov.au/scheduling-basics</a>'},
            {num: 423, text: 'Problem zaślepienia w badaniach psychedelicznych omawiają: Burke, M.J., Blumberger, D.M. Caution at psychiatrys psychedelic frontier. Nature Medicine, 2021; 27(10): 1687–1688. <a href="https://doi.org/10.1016/S2215-0366(19)30223-8" target="_blank">https://doi.org/10.1016/S2215-0366(19)30223-8</a>'},
            {num: 424, text: 'Singh B, Olds T, Curtis R, et al. Effectiveness of physical activity interventions for improving depression, anxiety and distress: an overview of systematic reviews. British Journal of Sports Medicine. 2023;57(18):1203-1209. doi: <a href="https://doi.org/10.1136/bjsports-2022-106195" target="_blank">10.1136/bjsports-2022-106195</a>'},
            {num: 425, text: 'Schuch FB, Vancampfort D, Richards J, Rosenbaum S, Ward PB, Stubbs B. Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. Journal of Psychiatric Research. 2016;77:42-51. doi: <a href="https://doi.org/10.1016/j.jpsychires.2016.02.023" target="_blank">10.1016/j.jpsychires.2016.02.023</a>'},
            {num: 426, text: 'Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proceedings of the National Academy of Sciences. 2011;108(7):3017-3022. doi: <a href="https://doi.org/10.1073/pnas.1015950108" target="_blank">10.1073/pnas.1015950108</a>'},
            {num: 427, text: 'Pruessner JC, Dedovic K, Pruessner M, et al. Stress regulation in the central nervous system: evidence from structural and functional neuroimaging studies in human populations. Psychoneuroendocrinology. 2010;35(1):179-191. doi: <a href="https://doi.org/10.1016/j.psyneuen.2009.02.016" target="_blank">10.1016/j.psyneuen.2009.02.016</a>'},
            {num: 428, text: 'Duffy F, Sharpe H, Schwannauer M. Review: The effectiveness of interpersonal psychotherapy for adolescents with depression - a systematic review and meta-analysis. Child and Adolescent Mental Health. 2019;24(4):307-317. doi: <a href="https://doi.org/10.1111/camh.12342" target="_blank">10.1111/camh.12342</a>'},
            {num: 429, text: 'Noetel M, Sanders T, Gallardo-Gomez D, et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2024;384:e075847. doi: <a href="https://doi.org/10.1136/bmj-2023-075847" target="_blank">10.1136/bmj-2023-075847</a>'},
            {num: 430, text: 'Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet. 2016;388(10047):881-890. doi: <a href="https://doi.org/10.1016/S0140-6736(16)30385-3" target="_blank">10.1016/S0140-6736(16)30385-3</a>'},
            {num: 431, text: 'Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. Cochrane Database of Systematic Reviews. 2013;(9):CD004366. doi: <a href="https://doi.org/10.1002/14651858.CD004366.pub6" target="_blank">10.1002/14651858.CD004366.pub6</a>'},
            {num: 432, text: 'Blumenthal JA, Babyak MA, Doraiswamy PM, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosomatic Medicine. 2007;69(7):587-596. doi: <a href="https://doi.org/10.1097/PSY.0b013e318148c19a" target="_blank">10.1097/PSY.0b013e318148c19a</a>'},
            {num: 433, text: 'Tanaka H, Monahan KD, Seals DR. Age-predicted maximal heart rate revisited. Journal of the American College of Cardiology. 2001;37(1):153-156. doi: <a href="https://doi.org/10.1016/S0735-1097(00)01054-8" target="_blank">10.1016/S0735-1097(00)01054-8</a>'},
            {num: 434, text: 'Pearce M, Garcia L, Abbas A, et al. Association Between Physical Activity and Risk of Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022;79(6):550-559. doi: <a href="https://doi.org/10.1001/jamapsychiatry.2022.0609" target="_blank">10.1001/jamapsychiatry.2022.0609</a>'},
            {num: 435, text: 'Marx W, Lane M, Hockey M, et al. Diet and depression: exploring the biological mechanisms of action. Molecular Psychiatry. 2021;26(1):134-150. doi: <a href="https://doi.org/10.1038/s41380-020-00925-x" target="_blank">10.1038/s41380-020-00925-x</a>'},
            {num: 436, text: 'Jacka FN, O&#x27;Neil A, Opie R, et al. A randomised controlled trial of dietary improvement for adults with major depression (the SMILES trial). BMC Medicine. 2017;15(1):23. doi: <a href="https://doi.org/10.1186/s12916-017-0791-y" target="_blank">10.1186/s12916-017-0791-y</a>'},
            {num: 437, text: 'Willem Kuyken i wsp., &quot;Efficacy of MBCT in Prevention of Depressive Relapse&quot;, JAMA Psychiatry 73, nr 6 (2016): 565-574. <a href="https://doi.org/10.1001/jamapsychiatry.2016.0076" target="_blank">https://doi.org/10.1001/jamapsychiatry.2016.0076</a>'},
            {num: 438, text: 'Lassale C, Batty GD, Baghdadli A, et al. Healthy dietary indices and risk of depressive outcomes: a systematic review and meta-analysis of observational studies. Molecular Psychiatry. 2019;24(7):965-986. doi: <a href="https://doi.org/10.1038/s41380-018-0237-8" target="_blank">10.1038/s41380-018-0237-8</a>'},
            {num: 439, text: 'Parletta N, Zarnowiecki D, Cho J, et al. A Mediterranean-style dietary intervention supplemented with fish oil improves diet quality and mental health in people with depression: A randomized controlled trial (HELFIMED). Nutritional Neuroscience. 2019;22(7):474-487. doi: <a href="https://doi.org/10.1080/1028415X.2017.1411320" target="_blank">10.1080/1028415X.2017.1411320</a>'},
            {num: 440, text: 'Grosso G, Pajak A, Marventano S, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One. 2014;9(5):e96905. doi: <a href="https://doi.org/10.1371/journal.pone.0096905" target="_blank">10.1371/journal.pone.0096905</a>'},
            {num: 441, text: 'Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in depression: A meta-analysis. Translational Psychiatry. 2019;9(1):190. doi: <a href="https://doi.org/10.1038/s41398-019-0515-5" target="_blank">10.1038/s41398-019-0515-5</a>'},
            {num: 442, text: 'Anglin RE, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. British Journal of Psychiatry. 2013;202:100-107. doi: <a href="https://doi.org/10.1192/bjp.bp.111.106666" target="_blank">10.1192/bjp.bp.111.106666</a>'},
            {num: 443, text: 'Boyle NB, Lawton C, Dye L. The Effects of Magnesium Supplementation on Subjective Anxiety and Stress-A Systematic Review. Nutrients. 2017;9(5):429. doi: <a href="https://doi.org/10.3390/nu9050429" target="_blank">10.3390/nu9050429</a>'},
            {num: 444, text: 'Tarleton EK, Littenberg B, MacLean CD, Kennedy AG, Daley C. Role of magnesium supplementation in the treatment of depression: A randomized clinical trial. PLoS One. 2017;12(6):e0180067. doi: <a href="https://doi.org/10.1371/journal.pone.0180067" target="_blank">10.1371/journal.pone.0180067</a>'},
            {num: 445, text: 'Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nature Reviews Neuroscience. 2012;13(10):701-712. doi: <a href="https://doi.org/10.1038/nrn3346" target="_blank">10.1038/nrn3346</a>'},
            {num: 446, text: 'Valles-Colomer M, Falony G, Darzi Y, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nature Microbiology. 2019;4(4):623-632. doi: <a href="https://doi.org/10.1038/s41564-018-0337-x" target="_blank">10.1038/s41564-018-0337-x</a>'},
            {num: 447, text: 'Kelly JR, Borre Y, O&#x27;Brien C, et al. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. Journal of Psychiatric Research. 2016;82:109-118. doi: <a href="https://doi.org/10.1016/j.jpsychires.2016.07.019" target="_blank">10.1016/j.jpsychires.2016.07.019</a>'},
            {num: 448, text: 'Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropic. Biological Psychiatry. 2013;74(10):720-726. doi: <a href="https://doi.org/10.1016/j.biopsych.2013.05.001" target="_blank">10.1016/j.biopsych.2013.05.001</a>'},
            {num: 449, text: 'Ng QX, Peters C, Ho CYX, Lim DY, Yeo WS. A meta-analysis of the use of probiotics to alleviate depressive symptoms. Journal of Affective Disorders. 2018;228:13-19. doi: <a href="https://doi.org/10.1016/j.jad.2017.11.063" target="_blank">10.1016/j.jad.2017.11.063</a>'},
            {num: 450, text: 'Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research. 2017;26(6):675-700. doi: <a href="https://doi.org/10.1111/jsr.12594" target="_blank">10.1111/jsr.12594</a>'},
            {num: 451, text: 'Nutt D, Wilson S, Paterson L. Sleep disorders as core symptoms of depression. Dialogues in Clinical Neuroscience. 2008;10(3):329-336. doi: <a href="https://doi.org/10.31887/DCNS.2008.10.3/dnutt" target="_blank">10.31887/DCNS.2008.10.3/dnutt</a>'},
            {num: 452, text: 'Tsuno N, Besset A, Ritchie K. Sleep and depression. Journal of Clinical Psychiatry. 2005;66(10):1254-1269. doi: <a href="https://doi.org/10.4088/JCP.v66n1008" target="_blank">10.4088/JCP.v66n1008</a>'},
            {num: 453, text: 'Lisanby SH, McClintock SM, Alexopoulos G i wsp. Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Venlafaxine in Geriatric Depression: Phase 1 of the PRIDE Study. American Journal of Geriatric Psychiatry 2020; 28(3): 304-316. DOI: <a href="https://doi.org/10.1016/j.jagp.2019.10.015" target="_blank">10.1016/j.jagp.2019.10.015</a>'},
            {num: 454, text: 'Benca RM, Obermeyer WH, Thisted RA, Gillin JC. Sleep and psychiatric disorders. A meta-analysis. Archives of General Psychiatry. 1992;49(8):651-668. doi: <a href="https://doi.org/10.1001/archpsyc.1992.01820080059010" target="_blank">10.1001/archpsyc.1992.01820080059010</a>'},
            {num: 455, text: 'Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377. doi: <a href="https://doi.org/10.1126/science.1241224" target="_blank">10.1126/science.1241224</a>'},
            {num: 456, text: 'Natalie Gukasyan i in., &quot;Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up&quot;, Journal of Psychopharmacology 36, nr 2 (2022): 151-158, <a href="https://doi.org/10.1177/02698811211073759" target="_blank">https://doi.org/10.1177/02698811211073759</a>'},
            {num: 457, text: 'Wirz-Justice A, Benedetti F, Terman M. Chronotherapeutics for Affective Disorders: A Clinician&#x27;s Manual for Light and Wake Therapy. 2nd ed. Basel: Karger; 2013. <a href="https://www.karger.com/Book/Home/258093" target="_blank">https://www.karger.com/Book/Home/258093</a>'},
            {num: 458, text: 'Drake C, Roehrs T, Shambroom J, Roth T. Caffeine effects on sleep taken 0, 3, or 6 hours before going to bed. Journal of Clinical Sleep Medicine. 2013;9(11):1195-1200. doi: <a href="https://doi.org/10.5664/jcsm.3170" target="_blank">10.5664/jcsm.3170</a>'},
            {num: 459, text: 'Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine. 2021;17(2):255-262. doi: <a href="https://doi.org/10.5664/jcsm.8986" target="_blank">10.5664/jcsm.8986</a>'},
            {num: 460, text: 'Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis. Annals of Internal Medicine. 2015;163(3):191-204. doi: <a href="https://doi.org/10.7326/M14-2841" target="_blank">10.7326/M14-2841</a>'},
            {num: 461, text: 'Terman M, Terman JS. Light therapy for seasonal and nonseasonal depression: efficacy, protocol, safety, and side effects. CNS Spectrums. 2005;10(8):647-663. doi: <a href="https://doi.org/10.1017/S1092852900019611" target="_blank">10.1017/S1092852900019611</a>'},
            {num: 462, text: 'Pail G, Huf W, Pjrek E, et al. Bright-light therapy in the treatment of mood disorders. Neuropsychobiology. 2011;64(3):152-162. doi: <a href="https://doi.org/10.1159/000328950" target="_blank">10.1159/000328950</a>'},
            {num: 463, text: 'Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. American Journal of Psychiatry. 2005;162(4):656-662. doi: <a href="https://doi.org/10.1176/appi.ajp.162.4.656" target="_blank">10.1176/appi.ajp.162.4.656</a>'},
            {num: 464, text: 'Perera S, Eisen R, Bhatt M, et al. Light therapy for non-seasonal depression: systematic review and meta-analysis. BJPsych Open. 2016;2(2):116-126. doi: <a href="https://doi.org/10.1192/bjpo.bp.115.001610" target="_blank">10.1192/bjpo.bp.115.001610</a>'},
            {num: 465, text: 'Lam RW, Levitt AJ, Levitan RD, et al. The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. American Journal of Psychiatry. 2006;163(5):805-812. doi: <a href="https://doi.org/10.1176/ajp.2006.163.5.805" target="_blank">10.1176/ajp.2006.163.5.805</a>'},
            {num: 466, text: 'Terman M, Terman JS. Controlled trial of naturalistic dawn simulation and negative air ionization for seasonal affective disorder. American Journal of Psychiatry. 2006;163(12):2126-2133. doi: <a href="https://doi.org/10.1176/ajp.2006.163.12.2126" target="_blank">10.1176/ajp.2006.163.12.2126</a>'},
            {num: 467, text: 'Wilson EO. Biophilia. Cambridge, MA: Harvard University Press; 1984. <a href="https://www.hup.harvard.edu/books/9780674074415" target="_blank">https://www.hup.harvard.edu/books/9780674074415</a>'},
            {num: 468, text: 'Ulrich RS. View through a window may influence recovery from surgery. Science. 1984;224(4647):420-421. doi: <a href="https://doi.org/10.1126/science.6143402" target="_blank">10.1126/science.6143402</a>'},
            {num: 469, text: 'Park BJ, Tsunetsugu Y, Kasetani T, Kagawa T, Miyazaki Y. The physiological effects of Shinrin-yoku (taking in the forest atmosphere or forest bathing): evidence from field experiments in 24 forests across Japan. Environmental Health and Preventive Medicine. 2010;15(1):18-26. doi: <a href="https://doi.org/10.1007/s12199-009-0086-9" target="_blank">10.1007/s12199-009-0086-9</a>'},
            {num: 470, text: 'Antonelli M, Barbieri G, Donelli D. Effects of forest bathing (shinrin-yoku) on levels of cortisol as a stress biomarker: a systematic review and meta-analysis. International Journal of Biometeorology. 2019;63(8):1117-1134. doi: <a href="https://doi.org/10.1007/s00484-019-01717-x" target="_blank">10.1007/s00484-019-01717-x</a>'},
            {num: 471, text: 'Li Q. Effect of forest bathing trips on human immune function. Environmental Health and Preventive Medicine. 2010;15(1):9-17. doi: <a href="https://doi.org/10.1007/s12199-008-0068-3" target="_blank">10.1007/s12199-008-0068-3</a>'},
            {num: 472, text: 'Li Q, Morimoto K, Nakadai A, et al. Forest bathing enhances human natural killer activity and expression of anti-cancer proteins. International Journal of Immunopathology and Pharmacology. 2007;20(2 Suppl 2):3-8. doi: <a href="https://doi.org/10.1177/03946320070200S202" target="_blank">10.1177/03946320070200S202</a>'},
            {num: 473, text: 'Bratman GN, Hamilton JP, Hahn KS, Daily GC, Gross JJ. Nature experience reduces rumination and subgenual prefrontal cortex activation. Proceedings of the National Academy of Sciences. 2015;112(28):8567-8572. doi: <a href="https://doi.org/10.1073/pnas.1510459112" target="_blank">10.1073/pnas.1510459112</a>'},
            {num: 474, text: 'Kaplan R, Kaplan S. The Experience of Nature: A Psychological Perspective. New York: Cambridge University Press; 1989. <a href="https://islandpress.org/books/experience-nature" target="_blank">https://islandpress.org/books/experience-nature</a>'},
            {num: 475, text: 'White MP, Alcock I, Grellier J, et al. Spending at least 120 minutes a week in nature is associated with good health and wellbeing. Scientific Reports. 2019;9(1):7730. doi: <a href="https://doi.org/10.1038/s41598-019-44097-3" target="_blank">10.1038/s41598-019-44097-3</a>'},
            {num: 476, text: 'Soga M, Gaston KJ, Yamaura Y. Gardening is beneficial for health: A meta-analysis. Preventive Medicine Reports. 2017;5:92-99. doi: <a href="https://doi.org/10.1016/j.pmedr.2016.11.007" target="_blank">10.1016/j.pmedr.2016.11.007</a>'},
            {num: 477, text: 'Coventry PA, Brown JE, Pervin J, et al. Nature-based outdoor activities for mental and physical health: Systematic review and meta-analysis. SSM - Population Health. 2021;16:100934. doi: <a href="https://doi.org/10.1016/j.ssmph.2021.100934" target="_blank">10.1016/j.ssmph.2021.100934</a>'},
            {num: 478, text: 'World Health Organization, &quot;Depressive disorder (depression)&quot;, WHO Fact Sheets, 2023, <a href="https://www.who.int/news-room/fact-sheets/detail/depression" target="_blank">https://www.who.int/news-room/fact-sheets/detail/depression</a> (dostep: 2025).'},
            {num: 479, text: 'Health Resources &amp; Services Administration, &quot;Designated Health Professional Shortage Areas Statistics&quot;, HRSA Data, 2023; Commonwealth Fund, &quot;Understanding the U.S. Behavioral Health Workforce Shortage&quot;, 2023. <a href="https://data.hrsa.gov/topics/health-workforce/shortage-areas" target="_blank">https://data.hrsa.gov/topics/health-workforce/shortage-areas</a>'},
            {num: 480, text: 'HRSA, &quot;Behavioral Health Workforce Projections, 2017-2030: Psychiatrists (Adult)&quot;, U.S. Department of Health and Human Services, 2018; Columbia University Department of Psychiatry, &quot;Addressing a Workforce Shortage&quot;, 2024. <a href="https://bhw.hrsa.gov/data-research/projecting-health-workforce-supply-demand" target="_blank">https://bhw.hrsa.gov/data-research/projecting-health-workforce-supply-demand</a>'},
            {num: 481, text: 'Otsuka Pharmaceutical Co., Ltd. i Click Therapeutics, Inc., &quot;U.S. Food and Drug Administration (FDA) Clearance of Rejoyn First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms&quot;, komunikat prasowy, 1 kwietnia 2024. <a href="https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-prescription-digital-therapeutic-adults-major-depressive-disorder" target="_blank">https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-prescription-digital-therapeutic-adults-major-depressive-disorder</a>'},
            {num: 482, text: 'Michael Bauer et al., WFSBP Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013, World Journal of Biological Psychiatry 14, nr 5 (2013): 334-385, doi: <a href="https://doi.org/10.3109/15622975.2013.804195" target="_blank">10.3109/15622975.2013.804195</a>'},
            {num: 483, text: 'Philip, N.S., Barredo, J., Aiken, E., Carpenter, L.L. (2018). Neuroimaging Mechanisms of Therapeutic Transcranial Magnetic Stimulation for Major Depressive Disorder. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 3(3), 211-222. DOI: <a href="https://doi.org/10.1016/j.bpsc.2017.10.007" target="_blank">10.1016/j.bpsc.2017.10.007</a>'},
            {num: 484, text: 'Click Therapeutics i Otsuka, &quot;MIRAI Study: A 13-week, multicenter, remote, double-blinded, randomized controlled trial&quot;, dane kliniczne, 2024; ClinicalTrials.gov: NCT04770285. <a href="https://clicktherapeutics.com/pipeline/" target="_blank">https://clicktherapeutics.com/pipeline/</a>'},
            {num: 485, text: 'Otsuka Pharmaceutical Europe Ltd., &quot;New smartphone app, Rejoyn, launched in Great Britain as a treatment for those living with depressive disorder&quot;, komunikat prasowy, 17 czerwca 2025. <a href="https://www.otsuka-europe.com/" target="_blank">https://www.otsuka-europe.com/</a>'},
            {num: 486, text: 'Otsuka Precision Health, &quot;Commercial Launch of Rejoyn&quot;, Business Wire, 13 sierpnia 2024; cena promocyjna 50 USD dla pacjentow, 200 USD dla platnikow. <a href="https://www.otsuka-us.com/" target="_blank">https://www.otsuka-us.com/</a>'},
            {num: 487, text: 'Pear Therapeutics, Inc., Chapter 11 Bankruptcy Filing, United States Bankruptcy Court for the District of Delaware, Case No. 23-10429, 7 kwietnia 2023. <a href="https://www.peartherapeutics.com/" target="_blank">https://www.peartherapeutics.com/</a>'},
            {num: 488, text: 'FDA, &quot;Summary of Safety and Effectiveness Data: FL-100&quot;. <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm" target="_blank">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm</a>'},
            {num: 489, text: 'David J. Nutt i in., &quot;Drug harms in the UK: a multicriteria decision analysis&quot;, The Lancet 376, nr 9752 (2010): 1558-1565, <a href="https://doi.org/10.1016/S0140-6736(10)61462-6" target="_blank">https://doi.org/10.1016/S0140-6736(10)61462-6</a>'},
            {num: 490, text: 'L.A. Fodor, C.D. Cotet, P. Cuijpers i in., &quot;The effectiveness of virtual reality based interventions for symptoms of anxiety and depression: A meta-analysis&quot;, Scientific Reports, 2018, t. 8, nr 1, art. 10323, DOI: <a href="https://doi.org/10.1038/s41598-018-28113-6" target="_blank">10.1038/s41598-018-28113-6</a>'},
            {num: 491, text: 'Y. Pu, X. Luo, &quot;Using virtual reality technology to treat adolescent and young adult depression disorder: a systematic review and meta-analysis&quot;, Discover Psychology, 2025, t. 5, art. 58, DOI: <a href="https://doi.org/10.1007/s44202-025-00384-x" target="_blank">10.1007/s44202-025-00384-x</a>'},
            {num: 492, text: 'Por. Freeman D. i in., &quot;Virtual reality in the assessment, understanding, and treatment of mental health disorders&quot;, Psychological Medicine, 2017, t. 47, nr 14, s. 2393-2400. <a href="https://doi.org/10.1016/j.jad.2019.11.086" target="_blank">https://doi.org/10.1016/j.jad.2019.11.086</a>'},
            {num: 493, text: 'Flow Neuroscience, &quot;FL-100 Clinical Evidence&quot; (2025). <a href="https://flowneuroscience.com/clinical-evidence/" target="_blank">https://flowneuroscience.com/clinical-evidence/</a>'},
            {num: 494, text: 'Por. T.D. Parsons, A.A. Rizzo, &quot;Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: A meta-analysis&quot;, Journal of Behavior Therapy and Experimental Psychiatry, 2008, t. 39, nr 3, s. 250-261. <a href="https://doi.org/10.1016/j.jad.2015.09.051" target="_blank">https://doi.org/10.1016/j.jad.2015.09.051</a>'},
            {num: 495, text: 'JMIR Mental Health, &quot;AI and Machine Learning Applications in Mental Health Monitoring&quot;, 2025; por. takze publikacje dotyczace cyfrowych biomarkerow zdrowia psychicznego. <a href="https://doi.org/10.2196/24668" target="_blank">https://doi.org/10.2196/24668</a>'},
            {num: 496, text: 'Por. J. Torous i in., &quot;Smartphones, sensors, and machine learning to advance real-time prediction and interventions for suicide prevention&quot;, Current Psychiatry Reports, 2018, t. 20, nr 7, art. 51. <a href="https://doi.org/10.1016/j.bpsc.2019.09.006" target="_blank">https://doi.org/10.1016/j.bpsc.2019.09.006</a>'},
            {num: 497, text: 'BJPsych Open, &quot;Telepsychiatry: A systematic review of the evidence base&quot;, 2021; por. takze American Psychiatric Association, &quot;Telepsychiatry Toolkit&quot;, 2024. <a href="https://doi.org/10.1192/bjo.2020.157" target="_blank">https://doi.org/10.1192/bjo.2020.157</a>'},
            {num: 498, text: 'Journal of Medical Internet Research, badanie Talkiatry dotyczace 1826 pacjentow leczonych telepsychiatrycznie, 2024-2025. <a href="https://www.talkiatry.com/research" target="_blank">https://www.talkiatry.com/research</a>'},
            {num: 499, text: 'Por. P. Cuijpers i in., &quot;The effects of psychotherapies for depression on response, remission, reliable change, and deterioration: A meta-analysis&quot;, Acta Psychiatrica Scandinavica, 2021. <a href="https://doi.org/10.1016/j.brat.2020.103646" target="_blank">https://doi.org/10.1016/j.brat.2020.103646</a>'},
            {num: 500, text: 'Seena Fazel et al., &quot;Health of People Experiencing Homelessness: Physical, Mental, and Substance Use Disorders - A Scoping Review,&quot; JAMA 332, nr 11 (2024): 929-940, doi: <a href="https://doi.org/10.1001/jama.2024.13656" target="_blank">10.1001/jama.2024.13656</a> Badanie wykazalo 19% rozpowszechnienia zaburzen depresyjnych wsrod osob bezdomnych.'},
            {num: 501, text: 'Seneca D. Back i in., &quot;Psilocybin-Assisted Group Therapy for Depression Among Health Care Workers Affected by the COVID-19 Pandemic: A Randomized Clinical Trial&quot;, JAMA Network Open 7, nr 12 (2024): e2449026, <a href="https://doi.org/10.1001/jamanetworkopen.2024.49026" target="_blank">https://doi.org/10.1001/jamanetworkopen.2024.49026</a>'},
            {num: 502, text: 'Santomauro DF, Mantilla Herrera AM, Shadid J, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700-1712. doi: <a href="https://doi.org/10.1016/S0140-6736(21)02143-7" target="_blank">10.1016/S0140-6736(21)02143-7</a>'},
            {num: 503, text: 'Dennis CL, Hodnett E. Psychosocial and psychological interventions for treating postpartum depression. Cochrane Database of Systematic Reviews 2007;(4):CD006116. <a href="https://doi.org/10.1002/14651858.CD001134.pub3" target="_blank">https://doi.org/10.1002/14651858.CD001134.pub3</a>'},
            {num: 504, text: 'Weisz JR, Kuppens S, Ng MY, et al. What five decades of research tells us about the effects of youth psychological therapy: A multilevel meta-analysis and implications for science and practice. American Psychologist. 2017;72(2):79-117. doi: <a href="https://doi.org/10.1037/a0040360" target="_blank">10.1037/a0040360</a>'},
            {num: 505, text: 'Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry. 1997;54(11):1031-1037. doi: <a href="https://doi.org/10.1001/archpsyc.1997.01830230069010" target="_blank">10.1001/archpsyc.1997.01830230069010</a>'},
            {num: 506, text: 'U.S. Food and Drug Administration. Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. FDA Public Health Advisory, October 15, 2004. <a href="https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications" target="_blank">https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications</a>'},
            {num: 507, text: 'Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the Treatment of Adolescent Depression: A Randomized Placebo-Controlled Multisite Trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2009;48(7):721-729. doi: <a href="https://doi.org/10.1097/CHI.0b013e3181a2b304" target="_blank">10.1097/CHI.0b013e3181a2b304</a>'},
            {num: 508, text: 'Friedman RA. Antidepressants&#x27; Black-Box Warning - 10 Years Later. New England Journal of Medicine. 2014;371(18):1666-1668. doi: <a href="https://doi.org/10.1056/NEJMp1408480" target="_blank">10.1056/NEJMp1408480</a>'},
            {num: 509, text: 'Teresi J, Abrams R, Holmes D, Ramirez M, Eimicke J. Prevalence of depression and depression recognition in nursing homes. Social Psychiatry and Psychiatric Epidemiology 2001; 36(12): 613-620. DOI: <a href="https://doi.org/10.1007/s127-001-8202-7" target="_blank">10.1007/s127-001-8202-7</a>'},
            {num: 510, text: 'Hawes MT, Szenczy AK, Klein DN, Hajcak G, Nelson BD. Increases in depression and anxiety symptoms in adolescents and young adults during the COVID-19 pandemic. Psychological Medicine. 2022;52(14):3222-3230. doi: <a href="https://doi.org/10.1017/S0033291720005358" target="_blank">10.1017/S0033291720005358</a>'},
            {num: 511, text: 'Oud M, de Winter L, Vermeulen-Smit E, et al. Effectiveness of CBT for children and adolescents with depression: A systematic review and meta-regression analysis. European Psychiatry. 2019;57:33-45. doi: <a href="https://doi.org/10.1016/j.eurpsy.2018.12.008" target="_blank">10.1016/j.eurpsy.2018.12.008</a>'},
            {num: 512, text: 'Kellner CH, Husain MM, Knapp RG i wsp. Right unilateral ultrabrief pulse ECT in geriatric depression: phase 1 of the PRIDE study. American Journal of Psychiatry 2016; 173(11): 1101-1109. DOI: <a href="https://doi.org/10.1176/appi.ajp.2016.15081101" target="_blank">10.1176/appi.ajp.2016.15081101</a>'},
            {num: 513, text: 'Venlafaxine. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. <a href="https://www.ncbi.nlm.nih.gov/books/NBK535363/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK535363/</a>'},
            {num: 514, text: 'American Geriatrics Society 2019 Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society 2019; 67(4): 674-694. DOI: <a href="https://doi.org/10.1111/jgs.15767" target="_blank">10.1111/jgs.15767</a>'},
            {num: 515, text: 'Meherali S, Punjani N, Louie-Poon S, et al. Mental Health of Children and Adolescents Amidst COVID-19 and Past Pandemics: A Rapid Systematic Review. International Journal of Environmental Research and Public Health. 2021;18(7):3432. doi: <a href="https://doi.org/10.3390/ijerph18073432" target="_blank">10.3390/ijerph18073432</a>'},
            {num: 516, text: 'Gavin NI, Gaynes BN, Lohr KN, et al. Perinatal depression: a systematic review of prevalence and incidence. Obstetrics &amp; Gynecology 2005;106(5):1071-1083. doi: <a href="https://doi.org/10.1097/01.AOG.0000183597.31630.db" target="_blank">10.1097/01.AOG.0000183597.31630.db</a>'},
            {num: 517, text: 'Woody CA, Ferrari AJ, Siskind DJ, et al. A systematic review and meta-regression of the prevalence and incidence of perinatal depression. Journal of Affective Disorders 2017;219:86-92. doi: <a href="https://doi.org/10.1016/j.jad.2017.05.003" target="_blank">10.1016/j.jad.2017.05.003</a>'},
            {num: 518, text: 'Howard LM, Molyneaux E, Dennis CL, et al. Non-psychotic mental disorders in the perinatal period. The Lancet 2014;384(9956):1775-1788. doi: <a href="https://doi.org/10.1016/S0140-6736(14)61276-9" target="_blank">10.1016/S0140-6736(14)61276-9</a>'},
            {num: 519, text: 'Howard LM, Molyneaux E, Dennis CL, et al. Non-psychotic mental disorders in the perinatal period. The Lancet 2014;384(9956):1775-1788. doi: <a href="https://doi.org/10.1016/S0140-6736(14)61276-9" target="_blank">10.1016/S0140-6736(14)61276-9</a>'},
            {num: 520, text: 'Hansen CH. Baby blues: identification and intervention. NAACOG&#x27;s Clinical Issues in Perinatal and Women&#x27;s Health Nursing 1990;1(3):369-374. PMID: 2206758. <a href="https://pubmed.ncbi.nlm.nih.gov/2206758/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/2206758/</a>'},
            {num: 521, text: 'March of Dimes. Baby blues after pregnancy. 2024. <a href="https://www.marchofdimes.org/find-support/topics/postpartum/baby-blues-after-pregnancy" target="_blank">https://www.marchofdimes.org/find-support/topics/postpartum/baby-blues-after-pregnancy</a>'},
            {num: 522, text: 'VanderKruik R, Barreix M, Chou D, et al. The global prevalence of postpartum psychosis: a systematic review. BMC Psychiatry 2017;17(1):272. doi: <a href="https://doi.org/10.1186/s12888-017-1427-7" target="_blank">10.1186/s12888-017-1427-7</a>'},
            {num: 523, text: 'Di Florio A, Meltzer-Brody S. Postpartum Psychosis. StatPearls [Internet] 2023. PMID: 31335024. <a href="https://pubmed.ncbi.nlm.nih.gov/31335024/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/31335024/</a>'},
            {num: 524, text: 'Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The impact of maternal depression during pregnancy on perinatal outcomes. Journal of Clinical Psychiatry 2013;74(4):e321-e341. <a href="https://doi.org/10.1016/j.ajog.2013.01.049" target="_blank">https://doi.org/10.1016/j.ajog.2013.01.049</a>'},
            {num: 525, text: 'Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression: Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry 1987;150:782-786. <a href="https://doi.org/10.1192/bjp.150.6.782" target="_blank">https://doi.org/10.1192/bjp.150.6.782</a>'},
            {num: 526, text: 'Sockol LE, Epperson CN, Barber JP. A meta-analysis of treatments for perinatal depression. Clinical Psychology Review 2011;31(5):839-849. <a href="https://doi.org/10.1016/j.cpr.2013.07.007" target="_blank">https://doi.org/10.1016/j.cpr.2013.07.007</a>'},
            {num: 527, text: 'UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders. The Lancet 2003;361(9360):799-808. <a href="https://doi.org/10.1016/S0140-6736(02)11438-8" target="_blank">https://doi.org/10.1016/S0140-6736(02)11438-8</a>'},
            {num: 528, text: 'Kim DR, Wang E, McGeehan B, et al. Randomized controlled trial of transcranial magnetic stimulation in pregnant women with major depressive disorder. Brain Stimulation 2019;12(1):96-102. <a href="https://doi.org/10.1016/j.brs.2020.02.008" target="_blank">https://doi.org/10.1016/j.brs.2020.02.008</a>'},
            {num: 529, text: 'Wirz-Justice A, Bader A, Frisch U, et al. A randomized, double-blind, placebo-controlled study of light therapy for antepartum depression. Journal of Clinical Psychiatry 2011;72(7):986-993. <a href="https://doi.org/10.3109/07853890.2011.579970" target="_blank">https://doi.org/10.3109/07853890.2011.579970</a>'},
            {num: 530, text: 'Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The impact of maternal depression during pregnancy on perinatal outcomes. Journal of Clinical Psychiatry 2013;74(4):e321-e341. <a href="https://doi.org/10.1016/j.ajog.2013.01.049" target="_blank">https://doi.org/10.1016/j.ajog.2013.01.049</a>'},
            {num: 531, text: 'Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. New England Journal of Medicine 2014;370(25):2397-2407. <a href="https://doi.org/10.1001/archgenpsychiatry.2011.2074" target="_blank">https://doi.org/10.1001/archgenpsychiatry.2011.2074</a>'},
            {num: 532, text: 'Gao SY, Wu QJ, Sun C, et al. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis. Human Reproduction Update 2018;24(3):379-398. doi: <a href="https://doi.org/10.1093/humupd/dmy001" target="_blank">10.1093/humupd/dmy001</a>'},
            {num: 533, text: 'Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants. Archives of General Psychiatry 2006;63(8):898-906. <a href="https://doi.org/10.1542/peds.2003-0549-L" target="_blank">https://doi.org/10.1542/peds.2003-0549-L</a>'},
            {num: 534, text: 'Nulman I, Koren G, Rovet J, et al. Neurodevelopment of children prenatally exposed to selective serotonin reuptake inhibitor antidepressants. Journal of Clinical Psychiatry 2012;73(9):1213-1219. <a href="https://doi.org/10.1176/appi.ajp.2009.09030361" target="_blank">https://doi.org/10.1176/appi.ajp.2009.09030361</a>'},
            {num: 535, text: 'Cunnington MC, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005;64(6):955-960. <a href="https://doi.org/10.1111/j.1528-1167.2007.01323.x" target="_blank">https://doi.org/10.1111/j.1528-1167.2007.01323.x</a>'},
            {num: 536, text: 'Davanzo R, Bua J, Paloni G, et al. Breastfeeding and migraine drugs. European Journal of Clinical Pharmacology 2014;70(11):1313-1324. <a href="https://doi.org/10.1007/s00431-012-1783-2" target="_blank">https://doi.org/10.1007/s00431-012-1783-2</a>'},
            {num: 537, text: 'Metz TD, Rovner P, Hoffman MC, et al. Maternal Deaths Due to Suicide and Overdose in Colorado, 2004-2012. Obstetrics &amp; Gynecology 2016;128(6):1233-1240. <a href="https://doi.org/10.1097/01.AOG.0000544687.83332.45" target="_blank">https://doi.org/10.1097/01.AOG.0000544687.83332.45</a>'},
            {num: 538, text: 'Maternal Mental Health Leadership Alliance. Policy Center for Maternal Mental Health. Maternal Suicide Report 2024. <a href="https://www.2020mom.org/mmhla/" target="_blank">https://www.2020mom.org/mmhla/</a>'},
            {num: 539, text: 'Wisner KL, Sit DK, McShea MC, et al. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry 2013;70(5):490-498. <a href="https://doi.org/10.1001/jamapsychiatry.2013.87" target="_blank">https://doi.org/10.1001/jamapsychiatry.2013.87</a>'},
            {num: 540, text: 'Paulden M, Palmer S, Hewitt C, et al. Screening for postnatal depression in primary care: cost effectiveness analysis. BMJ 2009;339:b5203. <a href="https://doi.org/10.1111/1471-0528.12310" target="_blank">https://doi.org/10.1111/1471-0528.12310</a>'},
            {num: 541, text: 'Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. The Lancet 2018;392(10152):1058-1070. <a href="https://doi.org/10.1016/S0140-6736(17)31264-3" target="_blank">https://doi.org/10.1016/S0140-6736(17)31264-3</a>'},
            {num: 542, text: 'Letourneau NL, Dennis CL, Cosic N, et al. The effect of perinatal depression treatment for mothers on parenting and child development. Depression and Anxiety 2017;34(10):928-966. <a href="https://doi.org/10.1080/14767058.2011.650221" target="_blank">https://doi.org/10.1080/14767058.2011.650221</a>'},
            {num: 543, text: 'Paulson JF, Bazemore SD. Prenatal and postpartum depression in fathers and its association with maternal depression. JAMA 2010;303(19):1961-1969. <a href="https://doi.org/10.1542/peds.2011-2558" target="_blank">https://doi.org/10.1542/peds.2011-2558</a>'},
            {num: 544, text: 'Field T, Diego M, Hernandez-Reif M, et al. Yoga and massage therapy reduce prenatal depression and prematurity. Journal of Bodywork and Movement Therapies 2012;16(2):204-209. <a href="https://doi.org/10.1177/1534735403259820" target="_blank">https://doi.org/10.1177/1534735403259820</a>'},
            {num: 545, text: 'Wayne J. Katon, &quot;Epidemiology and treatment of depression in patients with chronic medical illness&quot;, Dialogues in Clinical Neuroscience 13, nr 1 (2011): 7–23, <a href="https://doi.org/10.31887/DCNS.2011.13.1/wkaton" target="_blank">https://doi.org/10.31887/DCNS.2011.13.1/wkaton</a>'},
            {num: 546, text: 'Yali Luo et al., &quot;Medical conditions and the risk of subsequent major depressive disorder: a nationwide, register-based, retrospective cohort study&quot;, The Lancet Public Health 10, nr 5 (2025): e303–e312, <a href="https://doi.org/10.1016/S2468-2667(25)00073-8" target="_blank">https://doi.org/10.1016/S2468-2667(25)00073-8</a>'},
            {num: 547, text: 'Wayne J. Katon, &quot;Epidemiology and treatment of depression in patients with chronic medical illness&quot;, Dialogues in Clinical Neuroscience 13, nr 1 (2011): 7–23, <a href="https://doi.org/10.31887/DCNS.2011.13.1/wkaton" target="_blank">https://doi.org/10.31887/DCNS.2011.13.1/wkaton</a>'},
            {num: 548, text: 'Susan Gold et al., &quot;Comorbid depression in medical diseases&quot;, Nature Reviews Disease Primers 6 (2020): 69, <a href="https://doi.org/10.1038/s41572-020-0200-2" target="_blank">https://doi.org/10.1038/s41572-020-0200-2</a>'},
            {num: 549, text: 'Ellen R. Bradley et al., &quot;Psilocybin therapy for mood dysfunction in Parkinson&#x27;s disease: an open-label pilot trial&quot;, Neuropsychopharmacology 50, nr 8 (2025): 1200–1209, <a href="https://doi.org/10.1038/s41386-025-02097-0" target="_blank">https://doi.org/10.1038/s41386-025-02097-0</a>'},
            {num: 550, text: 'World Health Organization. Mental health of older adults. Fact sheet, October 2025. <a href="https://www.who.int/news-room/fact-sheets/detail/mental-health-of-older-adults" target="_blank">https://www.who.int/news-room/fact-sheets/detail/mental-health-of-older-adults</a>'},
            {num: 551, text: 'Parkinson&#x27;s Foundation, &quot;Statistics&quot;, dostęp: 2025, <a href="https://www.parkinson.org/understanding-parkinsons/statistics" target="_blank">https://www.parkinson.org/understanding-parkinsons/statistics</a>'},
            {num: 552, text: 'Zejin Ou et al., &quot;Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson&#x27;s Disease in 204 Countries/Territories From 1990 to 2019&quot;, Frontiers in Public Health 9 (2021): 776847, <a href="https://doi.org/10.3389/fpubh.2021.776847" target="_blank">https://doi.org/10.3389/fpubh.2021.776847</a>'},
            {num: 553, text: 'Shanshan Cong et al., &quot;Prevalence and clinical aspects of depression in Parkinson&#x27;s disease: A systematic review and meta‑analysis of 129 studies&quot;, Neuroscience &amp; Biobehavioral Reviews 141 (2022): 104749, <a href="https://doi.org/10.1016/j.neubiorev.2022.104749" target="_blank">https://doi.org/10.1016/j.neubiorev.2022.104749</a>'},
            {num: 554, text: 'Kurt A. Jellinger, &quot;The pathobiological basis of depression in Parkinson disease: challenges and outlooks&quot;, Journal of Neural Transmission 129, nr 12 (2022): 1397–1418, <a href="https://doi.org/10.1007/s00702-022-02559-5" target="_blank">https://doi.org/10.1007/s00702-022-02559-5</a>'},
            {num: 555, text: 'Laura Marsh, &quot;Depression and Parkinson&#x27;s Disease: Current Knowledge&quot;, Current Psychiatry Reports 15, nr 9 (2013): 409, <a href="https://doi.org/10.1007/s11920-013-0409-5" target="_blank">https://doi.org/10.1007/s11920-013-0409-5</a>'},
            {num: 556, text: 'Patorno E, Huybrechts KF, Bateman BT, et al. Lithium use in pregnancy and the risk of cardiac malformations. New England Journal of Medicine 2017;376(23):2245-2254. <a href="https://doi.org/10.1056/NEJMoa1612222" target="_blank">https://doi.org/10.1056/NEJMoa1612222</a>'},
            {num: 557, text: 'Laura Marsh, &quot;Depression and Parkinson&#x27;s Disease: Current Knowledge&quot;, Current Psychiatry Reports 15, nr 9 (2013): 409, <a href="https://doi.org/10.1007/s11920-013-0409-5" target="_blank">https://doi.org/10.1007/s11920-013-0409-5</a>'},
            {num: 558, text: 'Movement Disorder Society Task Force, &quot;Management of Parkinson&#x27;s disease: An evidence-based review&quot;, Movement Disorders 17, Suppl 4 (2002): S1–S166. <a href="https://doi.org/10.1002/mds.27105" target="_blank">https://doi.org/10.1002/mds.27105</a>'},
            {num: 559, text: 'Johannes S.A. Reijnders et al., &quot;A systematic review of prevalence studies of depression in Parkinson&#x27;s disease&quot;, Movement Disorders 23, nr 2 (2008): 183–189, <a href="https://doi.org/10.1002/mds.21803" target="_blank">https://doi.org/10.1002/mds.21803</a>'},
            {num: 560, text: 'Paolo Barone et al., &quot;Pramipexole for the treatment of depressive symptoms in patients with Parkinson&#x27;s disease: a randomised, double-blind, placebo-controlled trial&quot;, The Lancet Neurology 9, nr 6 (2010): 573–580, <a href="https://doi.org/10.1016/S1474-4422(10)70106-X" target="_blank">https://doi.org/10.1016/S1474-4422(10)70106-X</a>'},
            {num: 561, text: 'Guo-Hua Fan et al., &quot;Efficacy of non-pharmacological interventions for depression in individuals with Parkinson&#x27;s disease: A systematic review and network meta-analysis&quot;, Frontiers in Aging Neuroscience 14 (2022): 1050715, <a href="https://doi.org/10.3389/fnagi.2022.1050715" target="_blank">https://doi.org/10.3389/fnagi.2022.1050715</a>'},
            {num: 562, text: 'Ellen R. Bradley et al., &quot;Psilocybin therapy for mood dysfunction in Parkinson&#x27;s disease: an open-label pilot trial&quot;, Neuropsychopharmacology 50, nr 8 (2025): 1200–1209, <a href="https://doi.org/10.1038/s41386-025-02097-0" target="_blank">https://doi.org/10.1038/s41386-025-02097-0</a>'},
            {num: 563, text: 'Alexander M.H. Krebber et al., &quot;Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments&quot;, Psycho-Oncology 23, nr 2 (2014): 121–130, <a href="https://doi.org/10.1002/pon.3409" target="_blank">https://doi.org/10.1002/pon.3409</a>'},
            {num: 564, text: 'Mary Jane Massie, &quot;Prevalence of Depression in Patients With Cancer&quot;, JNCI Monographs 2004, nr 32 (2004): 57–71, <a href="https://doi.org/10.1093/jncimonographs/lgh014" target="_blank">https://doi.org/10.1093/jncimonographs/lgh014</a>'},
            {num: 565, text: 'Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Archives of Women&#x27;s Mental Health 2005;8(2):77-87. <a href="https://doi.org/10.1111/j.1600-0447.2005.00557.x" target="_blank">https://doi.org/10.1111/j.1600-0447.2005.00557.x</a>'},
            {num: 566, text: 'Susan Gold et al., &quot;Comorbid depression in medical diseases&quot;, Nature Reviews Disease Primers 6 (2020): 69, <a href="https://doi.org/10.1038/s41572-020-0200-2" target="_blank">https://doi.org/10.1038/s41572-020-0200-2</a>'},
            {num: 567, text: 'Susan Gold et al., &quot;Comorbid depression in medical diseases&quot;, Nature Reviews Disease Primers 6 (2020): 69, <a href="https://doi.org/10.1038/s41572-020-0200-2" target="_blank">https://doi.org/10.1038/s41572-020-0200-2</a>'},
            {num: 568, text: 'Mary Jane Massie, &quot;Prevalence of Depression in Patients With Cancer&quot;, JNCI Monographs 2004, nr 32 (2004): 57–71, <a href="https://doi.org/10.1093/jncimonographs/lgh014" target="_blank">https://doi.org/10.1093/jncimonographs/lgh014</a>'},
            {num: 569, text: 'Faisal Amiri i Sara Behnezhad, &quot;Global Prevalence of Suicide in Patients With Cancer: A Systematic Review and Meta-Analysis&quot;, Suicide and Life-Threatening Behavior 53, nr 5 (2023): 755–769, <a href="https://doi.org/10.1111/sltb.12991" target="_blank">https://doi.org/10.1111/sltb.12991</a>'},
            {num: 570, text: 'Ian Gilron et al., &quot;Neuropathic pain: principles of diagnosis and treatment&quot;, Mayo Clinic Proceedings 90, nr 4 (2015): 532–545, <a href="https://doi.org/10.1016/j.mayocp.2015.01.018" target="_blank">https://doi.org/10.1016/j.mayocp.2015.01.018</a>'},
            {num: 571, text: 'Cymbalta (duloksetyna) – Charakterystyka Produktu Leczniczego, Eli Lilly and Company, 2023. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/cymbalta" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/cymbalta</a>'},
            {num: 572, text: 'Ian Gilron et al., &quot;Neuropathic pain: principles of diagnosis and treatment&quot;, Mayo Clinic Proceedings 90, nr 4 (2015): 532–545, <a href="https://doi.org/10.1016/j.mayocp.2015.01.018" target="_blank">https://doi.org/10.1016/j.mayocp.2015.01.018</a>'},
            {num: 573, text: 'European League Against Rheumatism (EULAR), &quot;Recommendations for the management of fibromyalgia&quot;, Annals of the Rheumatic Diseases 76 (2017): 318–328. <a href="https://doi.org/10.1136/annrheumdis-2016-210715" target="_blank">https://doi.org/10.1136/annrheumdis-2016-210715</a>'},
            {num: 574, text: 'Lianying Feng et al., &quot;Prevalence of depression in myocardial infarction: A PRISMA-compliant meta-analysis&quot;, Medicine 98, nr 8 (2019): e14596, <a href="https://doi.org/10.1097/MD.0000000000014596" target="_blank">https://doi.org/10.1097/MD.0000000000014596</a>'},
            {num: 575, text: 'Ceri Evans et al., &quot;Pathophysiological mechanisms of post-myocardial infarction depression: a narrative review&quot;, Frontiers in Psychiatry 14 (2023): 1225794, <a href="https://doi.org/10.3389/fpsyt.2023.1225794" target="_blank">https://doi.org/10.3389/fpsyt.2023.1225794</a>'},
            {num: 576, text: 'Adriaan Honig et al., &quot;Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis&quot;, Psychosomatic Medicine 66, nr 6 (2004): 814–822, <a href="https://doi.org/10.1097/01.psy.0000146294.82810.9c" target="_blank">https://doi.org/10.1097/01.psy.0000146294.82810.9c</a>'},
            {num: 577, text: 'Anna-Lena Gundersen et al., &quot;Post–Myocardial Infarction Psychological Distress: A Scientific Statement From the American Heart Association&quot;, Circulation 151 (2025): e1–e20. <a href="https://doi.org/10.1001/jamacardio.2023.1125" target="_blank">https://doi.org/10.1001/jamacardio.2023.1125</a>'},
            {num: 578, text: 'Alexander H. Glassman et al., &quot;Sertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina&quot;, JAMA 288, nr 6 (2002): 701–709, <a href="https://doi.org/10.1001/jama.288.6.701" target="_blank">https://doi.org/10.1001/jama.288.6.701</a>'},
            {num: 579, text: 'Christopher M. O&#x27;Connor et al., &quot;Safety and Efficacy of Sertraline for Depression in Patients With Heart Failure: Results of the SADHART-CHF Trial&quot;, Journal of the American College of Cardiology 56, nr 9 (2010): 692–699, <a href="https://doi.org/10.1016/j.jacc.2010.03.068" target="_blank">https://doi.org/10.1016/j.jacc.2010.03.068</a>'},
            {num: 580, text: 'Pinquart M, Duberstein PR, Lyness JM. Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. American Journal of Psychiatry 2006; 163(9): 1493-1501. DOI: <a href="https://doi.org/10.1176/ajp.2006.163.9.1493" target="_blank">10.1176/ajp.2006.163.9.1493</a>'},
            {num: 581, text: 'François Carré, &quot;Les inhibiteurs sélectifs de la recapture de la sérotonine et le risque cardiovasculaire&quot;, Presse Médicale 34, nr 2 (2005): 175–178. <a href="https://doi.org/10.1016/S0140-6736(12)60453-4" target="_blank">https://doi.org/10.1016/S0140-6736(12)60453-4</a>'},
            {num: 582, text: 'Jacob W. Nordberg et al., &quot;Psychiatric and Psychological Interventions for Depression in Patients With Heart Disease: A Scoping Review&quot;, Journal of the American Heart Association 10 (2021): e018686, <a href="https://doi.org/10.1161/JAHA.120.018686" target="_blank">https://doi.org/10.1161/JAHA.120.018686</a>'},
            {num: 583, text: 'American Heart Association, &quot;Depression and Heart Disease&quot;, dostęp: 2025, <a href="https://www.heart.org/en/health-topics/consumer-healthcare/what-is-cardiovascular-disease/mental-health-and-heart-health" target="_blank">https://www.heart.org/en/health-topics/consumer-healthcare/what-is-cardiovascular-disease/mental-health-and-heart-health</a>'},
            {num: 584, text: 'Ellen R. Bradley et al., &quot;Psilocybin therapy for mood dysfunction in Parkinson&#x27;s disease: an open-label pilot trial&quot;, Neuropsychopharmacology 50, nr 8 (2025): 1200–1209, <a href="https://doi.org/10.1038/s41386-025-02097-0" target="_blank">https://doi.org/10.1038/s41386-025-02097-0</a>'},
            {num: 585, text: 'American Psychiatric Association, Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed. (Washington, DC: American Psychiatric Publishing, 2010). <a href="https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424462" target="_blank">https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424462</a>'},
            {num: 586, text: 'Raymond W. Lam et al., Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines: Section 1. Disease Burden and Principles of Care, Canadian Journal of Psychiatry 61, nr 9 (2016): 510-523, doi: <a href="https://doi.org/10.1177/0706743716659416" target="_blank">10.1177/0706743716659416</a>'},
            {num: 587, text: 'Johnson &amp; Johnson, SPRAVATO (esketamine) Approved in the U.S. as Monotherapy for Treatment-Resistant Depression (Titusville, NJ: Janssen, 21 stycznia 2025). <a href="https://www.janssen.com/spravato" target="_blank">https://www.janssen.com/spravato</a>'},
            {num: 588, text: 'David J. Heal et al., Psychedelics: Threshold of a Therapeutic Revolution, Neuropharmacology 236 (2023): 109610, doi: <a href="https://doi.org/10.1016/j.neuropharm.2023.109610" target="_blank">10.1016/j.neuropharm.2023.109610</a>'},
            {num: 589, text: 'NICE, Depression in Adults: Recognition and Management, Clinical Guideline CG90 (London: NICE, 2009, aktualizacja 2022). <a href="https://www.nice.org.uk/guidance/cg90" target="_blank">https://www.nice.org.uk/guidance/cg90</a>'},
            {num: 590, text: 'Andrea Cipriani et al., Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults with Major Depressive Disorder, The Lancet 391, nr 10128 (2018): 1357-1366, doi: <a href="https://doi.org/10.1016/S0140-6736(17)32802-7" target="_blank">10.1016/S0140-6736(17)32802-7</a>'},
            {num: 591, text: 'Pim Cuijpers et al., Cognitive Behavior Therapy vs. Control Conditions, Other Psychotherapies, Pharmacotherapies and Combined Treatment for Depression, World Psychiatry 22, nr 1 (2023): 105-115, doi: <a href="https://doi.org/10.1002/wps.21069" target="_blank">10.1002/wps.21069</a>'},
            {num: 592, text: 'Stefan G. Hofmann et al., The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses, Cognitive Therapy and Research 36, nr 5 (2012): 427-440, doi: <a href="https://doi.org/10.1007/s10608-012-9476-1" target="_blank">10.1007/s10608-012-9476-1</a>'},
            {num: 593, text: 'Pim Cuijpers et al., A Meta-Analysis of Cognitive-Behavioural Therapy for Adult Depression, Alone and in Comparison with Other Treatments, Canadian Journal of Psychiatry 58, nr 7 (2013): 376-385, doi: <a href="https://doi.org/10.1177/070674371305800702" target="_blank">10.1177/070674371305800702</a>'},
            {num: 594, text: 'Gerald L. Klerman et al., Interpersonal Psychotherapy of Depression (New York: Basic Books, 1984). <a href="https://doi.org/10.1521/ijct.2017.10.4.371" target="_blank">https://doi.org/10.1521/ijct.2017.10.4.371</a>'},
            {num: 595, text: 'Pim Cuijpers et al., Interpersonal Psychotherapy for Depression: A Meta-Analysis, American Journal of Psychiatry 168, nr 6 (2011): 581-592, doi: <a href="https://doi.org/10.1176/appi.ajp.2010.10101411" target="_blank">10.1176/appi.ajp.2010.10101411</a>'},
            {num: 596, text: 'Andrew T. Gloster et al., The Empirical Status of Acceptance and Commitment Therapy: A Review of Meta-Analyses, Journal of Contextual Behavioral Science 18 (2020): 181-192, doi: <a href="https://doi.org/10.1016/j.jcbs.2020.09.009" target="_blank">10.1016/j.jcbs.2020.09.009</a>'},
            {num: 597, text: 'Sona Dimidjian et al., Randomized Trial of Behavioral Activation, Cognitive Therapy, and Antidepressant Medication in the Acute Treatment of Adults with Major Depression, Journal of Consulting and Clinical Psychology 74, nr 4 (2006): 658-670, doi: <a href="https://doi.org/10.1037/0022-006X.74.4.658" target="_blank">10.1037/0022-006X.74.4.658</a>'},
            {num: 598, text: 'Andrea Cipriani et al., Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults with Major Depressive Disorder, The Lancet 391, nr 10128 (2018): 1357-1366, doi: <a href="https://doi.org/10.1016/S0140-6736(17)32802-7" target="_blank">10.1016/S0140-6736(17)32802-7</a>'},
            {num: 599, text: 'Agency for Healthcare Research and Quality, Depression Treatment after Unsatisfactory Response to SSRIs, Comparative Effectiveness Review (Rockville, MD: AHRQ, 2011). <a href="https://www.ahrq.gov/research/findings/ta/index.html" target="_blank">https://www.ahrq.gov/research/findings/ta/index.html</a>'},
            {num: 600, text: 'Alexander H. Glassman et al., Sertraline Treatment of Major Depression in Patients with Acute MI or Unstable Angina, JAMA 288, nr 6 (2002): 701-709, doi: <a href="https://doi.org/10.1001/jama.288.6.701" target="_blank">10.1001/jama.288.6.701</a>'},
            {num: 601, text: 'Sagar V. Parikh et al., CANMAT 2016 Clinical Guidelines: Section 2. Psychological Treatments, Canadian Journal of Psychiatry 61, nr 9 (2016): 524-539, doi: <a href="https://doi.org/10.1177/0706743716659418" target="_blank">10.1177/0706743716659418</a>'},
            {num: 602, text: 'Pim Cuijpers et al., Cognitive Behavior Therapy vs. Control Conditions, Other Psychotherapies, Pharmacotherapies and Combined Treatment for Depression, World Psychiatry 22, nr 1 (2023): 105-115, doi: <a href="https://doi.org/10.1002/wps.21069" target="_blank">10.1002/wps.21069</a>'},
            {num: 603, text: 'Kurt Kroenke, Robert L. Spitzer i Janet B.W. Williams, The PHQ-9: Validity of a Brief Depression Severity Measure, Journal of General Internal Medicine 16, nr 9 (2001): 606-613, doi: <a href="https://doi.org/10.1046/j.1525-1497.2001.016009606.x" target="_blank">10.1046/j.1525-1497.2001.016009606.x</a>'},
            {num: 604, text: 'A. John Rush et al., Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STARD Report, American Journal of Psychiatry 163, nr 11 (2006): 1905-1917, doi: <a href="https://doi.org/10.1176/ajp.2006.163.11.1905" target="_blank">10.1176/ajp.2006.163.11.1905</a>'},
            {num: 605, text: 'Michael E. Thase et al., Cognitive Therapy versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STARD Report, American Journal of Psychiatry 164, nr 5 (2007): 739-752, doi: <a href="https://doi.org/10.1176/ajp.2007.164.5.739" target="_blank">10.1176/ajp.2007.164.5.739</a>'},
            {num: 606, text: 'Richard C. Shelton, The Nature of the Discontinuation Syndrome Associated with Antidepressant Drugs, Journal of Clinical Psychiatry 67, Suppl 4 (2006): 3-7. <a href="https://doi.org/10.1007/s11920-017-0769-4" target="_blank">https://doi.org/10.1007/s11920-017-0769-4</a>'},
            {num: 607, text: 'Roger S. McIntyre et al., The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials, International Journal of Neuropsychopharmacology 19, nr 10 (2016): pyw055, doi: <a href="https://doi.org/10.1093/ijnp/pyw055" target="_blank">10.1093/ijnp/pyw055</a>'},
            {num: 608, text: 'Roger S. McIntyre, Steven Lophaven i Christina K. Olsen, A Randomized, Double-Blind, Placebo-Controlled Study of Vortioxetine on Cognitive Function in Depressed Adults, International Journal of Neuropsychopharmacology 17, nr 10 (2014): 1557-1567, doi: <a href="https://doi.org/10.1017/S1461145714000546" target="_blank">10.1017/S1461145714000546</a>'},
            {num: 609, text: 'Christoph U. Correll et al., Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antidepressant Monotherapy in Depression, JAMA Psychiatry 81, nr 6 (2024): 563-574, doi: <a href="https://doi.org/10.1001/jamapsychiatry.2023.5596" target="_blank">10.1001/jamapsychiatry.2023.5596</a>'},
            {num: 610, text: 'Philip G. Janicak et al., Aripiprazole Augmentation of SSRIs in Depression, Journal of Clinical Psychiatry 71, nr 8 (2010): 1034-1044, doi: <a href="https://doi.org/10.4088/JCP.09r05594blu" target="_blank">10.4088/JCP.09r05594blu</a>'},
            {num: 611, text: 'BrainsWay Ltd., BrainsWay Receives FDA Clearance of Deep TMS as Adjunct Therapy for Major Depressive Disorder in Adolescents Aged 15 to 21, komunikat prasowy (Burlington, MA: BrainsWay, 13 listopada 2025). <a href="https://ir.brainsway.com/" target="_blank">https://ir.brainsway.com/</a>'},
            {num: 612, text: 'UK ECT Review Group, Efficacy and Safety of ECT in Depressive Disorders: A Systematic Review and Meta-Analysis, The Lancet 361, nr 9360 (2003): 799-808, doi: <a href="https://doi.org/10.1016/S0140-6736(03)12705-5" target="_blank">10.1016/S0140-6736(03)12705-5</a>'},
            {num: 613, text: 'US FDA, FDA Approves New Nasal Spray Medication for Treatment-Resistant Depression (Silver Spring, MD: FDA, 5 marca 2019). <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression" target="_blank">https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression</a>'},
            {num: 614, text: 'Petrides G, Fink M, Husain MM i wsp. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. Journal of ECT 2001; 17(4): 244-253. DOI: <a href="https://doi.org/10.1097/00124509-200112000-00003" target="_blank">10.1097/00124509-200112000-00003</a>'},
            {num: 615, text: 'Anthony L. Back et al., Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial, JAMA Network Open 7, nr 12 (2024): e2449026, doi: <a href="https://doi.org/10.1001/jamanetworkopen.2024.49026" target="_blank">10.1001/jamanetworkopen.2024.49026</a>'},
            {num: 616, text: 'Helen S. Mayberg et al., Deep Brain Stimulation for Treatment-Resistant Depression, Neuron 45, nr 5 (2005): 651-660, doi: <a href="https://doi.org/10.1016/j.neuron.2005.02.014" target="_blank">10.1016/j.neuron.2005.02.014</a>'},
            {num: 617, text: 'Thomas E. Schlaepfer et al., Deep Brain Stimulation to Reward Circuitry Alleviates Anhedonia, Neuropsychopharmacology 33, nr 2 (2008): 368-377. <a href="https://doi.org/10.1038/npp.2007.23" target="_blank">https://doi.org/10.1038/npp.2007.23</a>'},
            {num: 618, text: 'Yuki Morishita et al., DBS for Treatment-Resistant Depression: Systematic Review, Neurotherapeutics 11, nr 3 (2014): 475-484, doi: <a href="https://doi.org/10.1007/s13311-014-0282-1" target="_blank">10.1007/s13311-014-0282-1</a>'},
            {num: 619, text: 'Cuijpers, P., Geraedts, A.S., van Oppen, P., Andersson, G., Markowitz, J.C., van Straten, A. (2011). Interpersonal psychotherapy for depression: a meta-analysis. American Journal of Psychiatry, 168(6), 581-592. DOI: <a href="https://doi.org/10.1176/appi.ajp.2010.10101411" target="_blank">10.1176/appi.ajp.2010.10101411</a>'},
            {num: 620, text: 'David J. Heal et al., Psychedelics: Threshold of a Therapeutic Revolution, Neuropharmacology 236 (2023): 109610, doi: <a href="https://doi.org/10.1016/j.neuropharm.2023.109610" target="_blank">10.1016/j.neuropharm.2023.109610</a>'},
            {num: 621, text: 'Raymond W. Lam et al., Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines: Section 1. Disease Burden and Principles of Care, Canadian Journal of Psychiatry 61, nr 9 (2016): 510-523, doi: <a href="https://doi.org/10.1177/0706743716659416" target="_blank">10.1177/0706743716659416</a>'},
            {num: 622, text: 'Kurt Kroenke, Robert L. Spitzer i Janet B.W. Williams, The PHQ-9: Validity of a Brief Depression Severity Measure, Journal of General Internal Medicine 16, nr 9 (2001): 606-613, doi: <a href="https://doi.org/10.1046/j.1525-1497.2001.016009606.x" target="_blank">10.1046/j.1525-1497.2001.016009606.x</a>'},
            {num: 623, text: 'NICE, Depression in Adults: Recognition and Management, Clinical Guideline CG90 (London: NICE, 2009, aktualizacja 2022). <a href="https://www.nice.org.uk/guidance/cg90" target="_blank">https://www.nice.org.uk/guidance/cg90</a>'},
            {num: 624, text: 'Trivedi MH et al., Evaluation of Outcomes with Citalopram for Depression Using Measurement-Based Care in STARD, American Journal of Psychiatry 163, nr 1 (2006): 28-40. <a href="https://doi.org/10.1176/appi.ajp.163.1.28" target="_blank">https://doi.org/10.1176/appi.ajp.163.1.28</a>'},
            {num: 625, text: 'Michael E. Thase et al., Cognitive Therapy versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STARD Report, American Journal of Psychiatry 164, nr 5 (2007): 739-752, doi: <a href="https://doi.org/10.1176/ajp.2007.164.5.739" target="_blank">10.1176/ajp.2007.164.5.739</a>'},
            {num: 626, text: 'Ellen R. Bradley et al., &quot;Psilocybin therapy for mood dysfunction in Parkinson&#x27;s disease: an open-label pilot trial&quot;, Neuropsychopharmacology 50, nr 8 (2025): 1200–1209, <a href="https://doi.org/10.1038/s41386-025-02097-0" target="_blank">https://doi.org/10.1038/s41386-025-02097-0</a>'},
            {num: 627, text: 'Peter B. Rosenquist et al., Definitions of Treatment-Resistant Depression, w Managing Treatment-Resistant Depression, red. John F. Greden et al. (Cambridge: Cambridge University Press, 2011), 3-22. <a href="https://doi.org/10.1017/9781316423349" target="_blank">https://doi.org/10.1017/9781316423349</a>'},
            {num: 628, text: 'Rohan V. Milev et al., CANMAT 2016 Clinical Guidelines: Section 4. Neurostimulation Treatments, Canadian Journal of Psychiatry 61, nr 9 (2016): 561-575. <a href="https://doi.org/10.1177/0706743716660033" target="_blank">https://doi.org/10.1177/0706743716660033</a>'},
            {num: 629, text: 'George Petrides et al., ECT Remission Rates in Psychotic vs Nonpsychotic Depressed Patients: A Report from CORE, Journal of ECT 17, nr 4 (2001): 244-253. <a href="https://doi.org/10.1176/appi.ajp.158.1.22" target="_blank">https://doi.org/10.1176/appi.ajp.158.1.22</a>'},
            {num: 630, text: 'Robin L. Carhart-Harris et al., Psilocybin with Psychological Support for Treatment-Resistant Depression: Six-Month Follow-Up, Psychopharmacology 235, nr 2 (2018): 399-408. <a href="https://doi.org/10.1056/NEJMoa2206443" target="_blank">https://doi.org/10.1056/NEJMoa2206443</a>'},
            {num: 631, text: 'Andrea L. Crowell et al., Long-Term Outcomes of Subcallosal Cingulate DBS for Treatment-Resistant Depression, American Journal of Psychiatry 176, nr 11 (2019): 949-956. <a href="https://doi.org/10.1176/appi.ajp.2019.18121427" target="_blank">https://doi.org/10.1176/appi.ajp.2019.18121427</a>'},
            {num: 632, text: 'Raymond W. Lam et al., Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines: Section 1. Disease Burden and Principles of Care, Canadian Journal of Psychiatry 61, nr 9 (2016): 510-523, doi: <a href="https://doi.org/10.1177/0706743716659416" target="_blank">10.1177/0706743716659416</a>'},
            {num: 633, text: 'American Psychiatric Association, Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed. (Washington, DC: American Psychiatric Publishing, 2010). <a href="https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424462" target="_blank">https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424462</a>'},
            {num: 634, text: 'Keller, M.B., McCullough, J.P., Klein, D.N., Arnow, B., Dunner, D.L., Gelenberg, A.J., Markowitz, J.C., Nemeroff, C.B., Russell, J.M., Thase, M.E., Trivedi, M.H., Zajecka, J. (2000). A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. New England Journal of Medicine, 342(20), 1462-1470. DOI: <a href="https://doi.org/10.1056/NEJM200005183422001" target="_blank">10.1056/NEJM200005183422001</a>'},
            {num: 635, text: 'March J, Silva S, Petrycki S, et al. Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. JAMA. 2004;292(7):807-820. doi: <a href="https://doi.org/10.1001/jama.292.7.807" target="_blank">10.1001/jama.292.7.807</a>'},
            {num: 636, text: 'Berlim, M.T., van den Eynde, F. (2014). Repetitive transcranial magnetic stimulation over the dorsolateral prefrontal cortex for treating major depression: what have we learned? Expert Review of Neurotherapeutics, 14(5), 555-577. DOI: <a href="https://doi.org/10.1586/14737175.2014.906660" target="_blank">10.1586/14737175.2014.906660</a>'},
            {num: 637, text: 'Brunoni AR, Moffa AH, Sampaio-Junior B, et al. Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. New England Journal of Medicine 2017;376(26):2523-2533. doi: <a href="https://doi.org/10.1056/NEJMoa1612999" target="_blank">10.1056/NEJMoa1612999</a>'},
            {num: 638, text: 'Pim Cuijpers i wsp., &quot;Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients&quot;, World Psychiatry 22, nr 1 (2023): 105-115. <a href="https://doi.org/10.1016/j.cpr.2020.101846" target="_blank">https://doi.org/10.1016/j.cpr.2020.101846</a>'},
            {num: 639, text: 'Zindel V. Segal, J. Mark G. Williams i John D. Teasdale, Mindfulness-Based Cognitive Therapy for Depression (New York: Guilford Press, 2002). <a href="https://doi.org/10.1038/nrdp.2018.46" target="_blank">https://doi.org/10.1038/nrdp.2018.46</a>'},
            {num: 640, text: 'David D. Burns, Feeling Good: The New Mood Therapy (New York: William Morrow, 1980). <a href="https://doi.org/10.1521/ijct.2017.10.4.371" target="_blank">https://doi.org/10.1521/ijct.2017.10.4.371</a>'},
            {num: 641, text: 'Rinske A. Gotink i wsp., &quot;8-week MBSR induces brain changes&quot;, Brain and Cognition 108 (2016): 32-41. <a href="https://doi.org/10.1016/j.bandc.2016.04.001" target="_blank">https://doi.org/10.1016/j.bandc.2016.04.001</a>'},
            {num: 642, text: 'Eleanor J. Cole et al., Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression, American Journal of Psychiatry 177, nr 8 (2020): 716-726, doi: <a href="https://doi.org/10.1176/appi.ajp.2019.19070720" target="_blank">10.1176/appi.ajp.2019.19070720</a>'},
            {num: 643, text: 'JoAnne E. Epping-Jordan i wsp., &quot;Self-Help Plus (SH+): a new WHO stress management package&quot;, World Psychiatry 15, nr 3 (2016): 295-296. <a href="https://doi.org/10.1037/0022-006X.85.4.407" target="_blank">https://doi.org/10.1037/0022-006X.85.4.407</a>'},
            {num: 644, text: 'Wietse A. Tol i wsp., &quot;Guided self-help to reduce psychological distress in South Sudanese refugees&quot;, The Lancet Global Health 8, nr 2 (2020): e254-e263. <a href="https://doi.org/10.1017/S0033291720001580" target="_blank">https://doi.org/10.1017/S0033291720001580</a>'},
            {num: 645, text: 'Manpreet Sohal i wsp., &quot;Efficacy of journaling in the management of mental illness&quot;, Family Medicine and Community Health 10, nr 1 (2022): e001154. <a href="https://doi.org/10.3390/ejihpe11040114" target="_blank">https://doi.org/10.3390/ejihpe11040114</a>'},
            {num: 646, text: 'Mayberg i in., &quot;Deep Brain Stimulation for Treatment-Resistant Depression&quot;, Neuron 45, nr 5 (2005): 651-660. <a href="https://doi.org/10.1016/j.neuron.2005.02.014" target="_blank">https://doi.org/10.1016/j.neuron.2005.02.014</a>'},
            {num: 647, text: 'Lucas V. M. Aparicio i wsp., &quot;At-home tDCS treatment for MDD: a fully remote phase 2 RCT&quot;, Nature Medicine 31, nr 1 (2025): 87-95. <a href="https://doi.org/10.1016/j.brs.2023.10.013" target="_blank">https://doi.org/10.1016/j.brs.2023.10.013</a>'},
            {num: 648, text: 'Burcusa, S. L., &amp; Iacono, W. G. (2007). Risk for recurrence in depression. Clinical Psychology Review, 27(8), 959–985. <a href="https://doi.org/10.1016/j.cpr.2007.02.005;" target="_blank">https://doi.org/10.1016/j.cpr.2007.02.005;</a> Hardeveld, F., et al. (2010). Recurrence of major depressive disorder. Journal of Affective Disorders, 125(1-3), 88-94.'},
            {num: 649, text: 'British Journal of General Practice (2020). Predicting and preventing relapse of depression in primary care. BJGP, 70(691), 54-55. <a href="https://doi.org/10.3399/bjgp20X707561;" target="_blank">https://doi.org/10.3399/bjgp20X707561;</a> American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.). Washington, DC: Author.'},
            {num: 650, text: 'Buckman, J. E. J., et al. (2018). Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and meta-synthesis. Clinical Psychology Review, 64, 13–38. <a href="https://doi.org/10.1016/j.cpr.2018.07.005" target="_blank">https://doi.org/10.1016/j.cpr.2018.07.005</a>'},
            {num: 651, text: 'Santarsieri, D., &amp; Schwartz, T. L. (2015). Antidepressant efficacy and side-effect burden: A quick guide for clinicians. Drugs in Context, 4, 212290. <a href="https://doi.org/10.7573/dic.212290" target="_blank">https://doi.org/10.7573/dic.212290</a>'},
            {num: 652, text: 'National Institute for Health and Care Excellence (NICE). (2022). Depression in adults: Treatment and management (NICE Guideline NG222). <a href="https://www.nice.org.uk/guidance/ng222" target="_blank">https://www.nice.org.uk/guidance/ng222</a>'},
            {num: 653, text: 'Baldessarini, R. J., et al. (2015). Duration of initial antidepressant treatment and subsequent relapse of major depression. Journal of Clinical Psychopharmacology, 35(1), 75-76. <a href="https://doi.org/10.1002/wps.20174" target="_blank">https://doi.org/10.1002/wps.20174</a>'},
            {num: 654, text: 'Malhi, G. S., et al. (2021). The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian &amp; New Zealand Journal of Psychiatry, 55(1), 7-117. <a href="https://doi.org/10.1177/0004867420959567" target="_blank">https://doi.org/10.1177/0004867420959567</a>'},
            {num: 655, text: 'Nelson, J. C., et al. (2014). A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. Journal of Affective Disorders, 168, 269–275. <a href="https://doi.org/10.1016/j.jad.2014.05.053" target="_blank">https://doi.org/10.1016/j.jad.2014.05.053</a>'},
            {num: 656, text: 'Segal, Z. V., Williams, J. M. G., &amp; Teasdale, J. D. (2002). Mindfulness-based cognitive therapy for depression: A new approach to preventing relapse. New York: Guilford Press. <a href="https://doi.org/10.1038/nrdp.2018.46" target="_blank">https://doi.org/10.1038/nrdp.2018.46</a>'},
            {num: 657, text: 'Piet, J., &amp; Hougaard, E. (2011). The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: A systematic review and meta-analysis. Clinical Psychology Review, 31(6), 1032–1040. <a href="https://doi.org/10.1016/j.cpr.2011.05.002" target="_blank">https://doi.org/10.1016/j.cpr.2011.05.002</a>'},
            {num: 658, text: 'Kuyken, W., et al. (2016). Efficacy of mindfulness-based cognitive therapy in prevention of depressive relapse: An individual patient data meta-analysis from randomized trials. JAMA Psychiatry, 73(6), 565–574. <a href="https://doi.org/10.1001/jamapsychiatry.2016.0076" target="_blank">https://doi.org/10.1001/jamapsychiatry.2016.0076</a>'},
            {num: 659, text: 'Gotink, R. A., et al. (2016). 8-week Mindfulness Based Stress Reduction induces brain changes similar to traditional long-term meditation practice – a systematic review. Brain and Cognition, 108, 32–41. <a href="https://doi.org/10.1016/j.bandc.2016.07.001" target="_blank">https://doi.org/10.1016/j.bandc.2016.07.001</a>'},
            {num: 660, text: 'Tammi R. A. Kral i wsp., &quot;Impact of mindfulness meditation training on amygdala reactivity&quot;, NeuroImage 181 (2018): 301-313. <a href="https://doi.org/10.1016/j.neuroimage.2018.06.064" target="_blank">https://doi.org/10.1016/j.neuroimage.2018.06.064</a>'},
            {num: 661, text: 'Nierenberg, A. A., et al. (2010). Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STARD report. Psychological Medicine, 40(1), 41–50. <a href="https://doi.org/10.1017/S0033291709006011" target="_blank">https://doi.org/10.1017/S0033291709006011</a>'},
            {num: 662, text: 'Qato DM, Wilder J, Schumm LP i wsp. Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011. JAMA Internal Medicine 2016; 176(4): 473-482. DOI: <a href="https://doi.org/10.1001/jamainternmed.2015.8581" target="_blank">10.1001/jamainternmed.2015.8581</a>'},
            {num: 663, text: 'Burcusa, S.L., Iacono, W.G. (2007). Risk for recurrence in depression. Clinical Psychology Review, 27(8), 959-985. DOI: <a href="https://doi.org/10.1016/j.cpr.2007.02.005" target="_blank">10.1016/j.cpr.2007.02.005</a>'},
            {num: 664, text: 'Stanley, B., &amp; Brown, G. K. (2012). Safety planning intervention: A brief intervention to mitigate suicide risk. Cognitive and Behavioral Practice, 19(2), 256–264. <a href="https://doi.org/10.1016/j.cbpra.2011.01.001" target="_blank">https://doi.org/10.1016/j.cbpra.2011.01.001</a>'},
            {num: 665, text: 'Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD. Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain, Behavior, and Immunity 2020; 87: 901–909. DOI: <a href="https://doi.org/10.1016/j.bbi.2020.02.010" target="_blank">10.1016/j.bbi.2020.02.010</a>'},
            {num: 666, text: 'Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. Journal of Affective Disorders 2012; 139(3): 230–239. DOI: <a href="https://doi.org/10.1016/j.jad.2011.08.003" target="_blank">10.1016/j.jad.2011.08.003</a>'},
            {num: 667, text: 'Mac Giollabhui N, Ng TH, Ellman LM, Alloy LB. The longitudinal associations of inflammatory biomarkers and depression revisited: systematic review, meta-analysis, and meta-regression. Molecular Psychiatry 2021; 26(7): 3302–3314. DOI: <a href="https://doi.org/10.1038/s41380-020-00867-4" target="_blank">10.1038/s41380-020-00867-4</a>'},
            {num: 668, text: 'Jha MK, Minhajuddin A, Gadad BS, Greer T, Grannemann B, Soyombo A, Mayes TL, Rush AJ, Trivedi MH. Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology 2017; 78: 105–113. DOI: <a href="https://doi.org/10.1016/j.psyneuen.2017.01.023" target="_blank">10.1016/j.psyneuen.2017.01.023</a>'},
            {num: 669, text: 'Williams LM, Goldstein-Piekarski AN, Chowdhry N, et al. Mapping neural circuit biotypes to symptoms and behavioral dimensions of depression and anxiety. Biological Psychiatry 2022; 91(6): 561–571. DOI: <a href="https://doi.org/10.1016/j.biopsych.2021.06.024" target="_blank">10.1016/j.biopsych.2021.06.024</a>'},
            {num: 670, text: 'Tozzi L, Zhang X, Chesnut M, et al. Personalized brain circuit scores identify clinically distinct biotypes in depression and anxiety. Nature Medicine 2024; 30: 2076–2087. DOI: <a href="https://doi.org/10.1038/s41591-024-03057-9" target="_blank">10.1038/s41591-024-03057-9</a>'},
            {num: 671, text: 'Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biological Psychiatry 2008; 64(6): 527–532. DOI: <a href="https://doi.org/10.1016/j.biopsych.2008.05.005" target="_blank">10.1016/j.biopsych.2008.05.005</a>'},
            {num: 672, text: 'Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML. BDNF as a biomarker for successful treatment of mood disorders: a systematic &amp; quantitative meta-analysis. Journal of Affective Disorders 2015; 174: 432–440. DOI: <a href="https://doi.org/10.1016/j.jad.2014.11.044" target="_blank">10.1016/j.jad.2014.11.044</a>'},
            {num: 673, text: 'Trivedi MH, McGrath PJ, Fava M, Parsey RV, Kurian BT, Phillips ML, et al. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. Journal of Psychiatric Research 2016; 78: 11–23. DOI: <a href="https://doi.org/10.1016/j.jpsychires.2016.03.001" target="_blank">10.1016/j.jpsychires.2016.03.001</a>'},
            {num: 674, text: 'McEwen BS. Stress and hippocampal plasticity. Annual Review of Neuroscience 1999; 22: 105–122. DOI: <a href="https://doi.org/10.1146/annurev.neuro.22.1.105" target="_blank">10.1146/annurev.neuro.22.1.105</a>'},
            {num: 675, text: 'Savitz JB, Drevets WC. Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience 2009; 164(1): 99–119. DOI: <a href="https://doi.org/10.1016/j.neuroscience.2009.03.082" target="_blank">10.1016/j.neuroscience.2009.03.082</a>'},
            {num: 676, text: 'Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012; 338(6103): 68–72. DOI: <a href="https://doi.org/10.1126/science.1222939" target="_blank">10.1126/science.1222939</a>'},
            {num: 677, text: 'Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329(5994): 959–964. DOI: <a href="https://doi.org/10.1126/science.1190287" target="_blank">10.1126/science.1190287</a>'},
            {num: 678, text: 'Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012; 62(1): 35–41. DOI: <a href="https://doi.org/10.1016/j.neuropharm.2011.08.044" target="_blank">10.1016/j.neuropharm.2011.08.044</a>'},
            {num: 679, text: 'Moda-Sava RN, Murdock MH, Parekh PK, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science 2019; 364(6436): eaat8078. DOI: <a href="https://doi.org/10.1126/science.aat8078" target="_blank">10.1126/science.aat8078</a>'},
            {num: 680, text: 'Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry 2016; 3(7): 619–627. DOI: <a href="https://doi.org/10.1016/S2215-0366(16)30065-7" target="_blank">10.1016/S2215-0366(16)30065-7</a>'},
            {num: 681, text: 'Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. American Journal of Psychiatry 2020; 177(8): 716–726. DOI: <a href="https://doi.org/10.1176/appi.ajp.2019.19070720" target="_blank">10.1176/appi.ajp.2019.19070720</a>'},
            {num: 682, text: 'Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annual Review of Public Health 2013; 34: 119–138. DOI: <a href="https://doi.org/10.1146/annurev-publhealth-031912-114409" target="_blank">10.1146/annurev-publhealth-031912-114409</a>'},
            {num: 683, text: 'Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 2000; 47(4): 351–354. DOI: <a href="https://doi.org/10.1016/s0006-3223(99)00230-9" target="_blank">10.1016/s0006-3223(99)00230-9</a>'},
            {num: 684, text: 'Schwartz J, Murrough JW, Bhisetti S, et al. Ketamine&#x27;s Mechanism of Action: A Path to Rapid-Acting Antidepressants. Depression and Anxiety 2016; 33(8): 689–697. DOI: <a href="https://doi.org/10.1002/da.22501" target="_blank">10.1002/da.22501</a>'},
            {num: 685, text: 'Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. The Lancet 2018; 392(10152): 1058–1070. DOI: <a href="https://doi.org/10.1016/S0140-6736(18)31551-4" target="_blank">10.1016/S0140-6736(18)31551-4</a>'},
            {num: 686, text: 'Gunduz-Bruce H, Silber C, Kaber-Ekim I, et al. Trial of SAGE-217 in patients with major depressive disorder. New England Journal of Medicine 2019; 381(10): 903–911. DOI: <a href="https://doi.org/10.1056/NEJMoa1815981" target="_blank">10.1056/NEJMoa1815981</a>'},
            {num: 687, text: 'Drevets WC, Furey ML. Replication of scopolamine&#x27;s antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biological Psychiatry 2010; 67(5): 432–438. DOI: <a href="https://doi.org/10.1016/j.biopsych.2009.11.021" target="_blank">10.1016/j.biopsych.2009.11.021</a>'},
            {num: 688, text: 'Gould TD, Zarate CA Jr, Thompson SM. Molecular pharmacology and neurobiology of rapid-acting antidepressants. Annual Review of Pharmacology and Toxicology 2019; 59: 213–236. DOI: <a href="https://doi.org/10.1146/annurev-pharmtox-010617-052811" target="_blank">10.1146/annurev-pharmtox-010617-052811</a>'},
            {num: 689, text: 'Cummins N, Scherer S, Krajewski J, Schnieder S, Epps J, Quatieri TF. A review of depression and suicide risk assessment using speech analysis. Speech Communication 2015; 71: 10–49. DOI: <a href="https://doi.org/10.1016/j.specom.2015.03.004" target="_blank">10.1016/j.specom.2015.03.004</a>'},
            {num: 690, text: 'De Choudhury M, Gamon M, Counts S, Horvitz E. Predicting depression via social media. Proceedings of the 7th International AAAI Conference on Weblogs and Social Media 2013; 128–137. <a href="https://doi.org/10.1609/icwsm.v7i1.14432" target="_blank">https://doi.org/10.1609/icwsm.v7i1.14432</a>'},
            {num: 691, text: 'Chekroud AM, Zotti RJ, Shehzad Z, et al. Cross-trial prediction of treatment outcome in depression: a machine learning approach. The Lancet Psychiatry 2016; 3(3): 243–250. DOI: <a href="https://doi.org/10.1016/S2215-0366(15)00471-X" target="_blank">10.1016/S2215-0366(15)00471-X</a>'},
            {num: 692, text: 'Torous J, Larsen ME, Depp C, et al. Smartphones, sensors, and machine learning to advance real-time prediction and interventions for suicide prevention: a review of current progress and next steps. Current Psychiatry Reports 2018; 20(7): 51. DOI: <a href="https://doi.org/10.1007/s11920-018-0914-y" target="_blank">10.1007/s11920-018-0914-y</a>'},
            {num: 693, text: 'Fitzpatrick KK, Darcy A, Vierhile M. Delivering cognitive behavior therapy to young adults with symptoms of depression and anxiety using a fully automated conversational agent (Woebot): a randomized controlled trial. JMIR Mental Health 2017; 4(2): e19. DOI: <a href="https://doi.org/10.2196/mental.7785" target="_blank">10.2196/mental.7785</a>'},
            {num: 694, text: 'Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. American Journal of Psychiatry 2020; 177(8): 716–726. DOI: <a href="https://doi.org/10.1176/appi.ajp.2019.19070720" target="_blank">10.1176/appi.ajp.2019.19070720</a>'},
            {num: 695, text: 'Walsh CG, Ribeiro JD, Franklin JC. Predicting risk of suicide attempts over time through machine learning. Clinical Psychological Science 2017; 5(3): 457–469. DOI: <a href="https://doi.org/10.1177/2167702617691560" target="_blank">10.1177/2167702617691560</a>'},
            {num: 696, text: 'Segal et al., &quot;Outcomes of Online Mindfulness-Based Cognitive Therapy&quot;, 563–573. <a href="https://doi.org/10.1001/jamapsychiatry.2019.4693" target="_blank">https://doi.org/10.1001/jamapsychiatry.2019.4693</a>'},
            {num: 697, text: 'World Health Organization, &quot;Depressive disorder (depression),&quot; Fact sheet, 29 August 2025, <a href="https://www.who.int/news-room/fact-sheets/detail/depression;" target="_blank">https://www.who.int/news-room/fact-sheets/detail/depression;</a> Simone Evans-Lacko et al., &quot;Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: Results from the WHO World Mental Health (WMH) Surveys,&quot; Psychological Medicine 48, nr 9 (2018): 1560-1571, doi: <a href="https://doi.org/10.1017/S0033291717003026" target="_blank">10.1017/S0033291717003026</a>'},
            {num: 698, text: 'Tamze. W krajach o wysokich dochodach okolo 36,8% osob z zaburzeniami otrzymuje leczenie, podczas gdy w krajach o niskich/srednich dochodach odsetek ten wynosi 13,7-22%. <a href="https://doi.org/10.1016/S0140-6736(07)61414-7" target="_blank">https://doi.org/10.1016/S0140-6736(07)61414-7</a>'},
            {num: 699, text: 'World Health Organization Regional Office for Europe, &quot;&#x27;Giving mental health the attention it deserves&#x27; - Poland adopts WHO tool to boost efforts to address mental health needs,&quot; 10 October 2023, <a href="https://www.who.int/europe/news/item/10-10-2023-giving-mental-health-the-attention-it-deserves–--poland-adopts-who-tool-to-boost-efforts-to-address-mental-health-needs" target="_blank">https://www.who.int/europe/news/item/10-10-2023-giving-mental-health-the-attention-it-deserves–--poland-adopts-who-tool-to-boost-efforts-to-address-mental-health-needs</a> WHO podaje 9 psychiatrow na 100 000 mieszkancow; Katarzyna Dubas-Jakobczyk et al., &quot;Mental Health Workforce in Poland - A Descriptive Study,&quot; International Journal of Environmental Research and Public Health 19, nr 3 (2022): 1804, doi: <a href="https://doi.org/10.3390/ijerph19031804" target="_blank">10.3390/ijerph19031804</a>'},
            {num: 700, text: 'Anna K. Giovanetti et al., &quot;Videoconference-based psychotherapy interventions for depression: A systematic review and meta-analysis,&quot; Journal of Affective Disorders 323 (2023): 678-689, doi: <a href="https://doi.org/10.1016/j.jad.2022.11.095" target="_blank">10.1016/j.jad.2022.11.095</a>'},
            {num: 701, text: 'CareCredit, &quot;TMS Treatment Cost,&quot; <a href="https://www.carecredit.com/well-u/health-wellness/tms-treatment-cost/;" target="_blank">https://www.carecredit.com/well-u/health-wellness/tms-treatment-cost/;</a> koszty wahaja sie od 300-500 USD za sesje, pelny cykl 20-36 sesji wynosi 6000-15000 USD.'},
            {num: 702, text: 'U.S. Food and Drug Administration, &quot;FDA Authorizes First Over-the-Counter Device to Treat Depression,&quot; News Release, 8 December 2025, <a href="https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-over-counter-device-treat-depression" target="_blank">https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-over-counter-device-treat-depression</a> Urzadzenie Flow FL-100 zostalo zatwierdzone jako pierwsze dostepne bez recepty urzadzenie do leczenia depresji.'},
            {num: 703, text: 'American Psychiatric Association, &quot;What Is Mental Illness Stigma?,&quot; <a href="https://www.psychiatry.org/patients-families/stigma-and-discrimination" target="_blank">https://www.psychiatry.org/patients-families/stigma-and-discrimination</a>'},
            {num: 704, text: 'Sara Clement et al., &quot;What is the impact of mental health-related stigma on help-seeking? A systematic review of quantitative and qualitative studies,&quot; Psychological Medicine 45, nr 1 (2015): 11-27, doi: <a href="https://doi.org/10.1017/S0033291714000129" target="_blank">10.1017/S0033291714000129</a> Metaanaliza 144 badan potwierdzila, ze stygmatyzacja jest istotna bariera w poszukiwaniu pomocy.'},
            {num: 705, text: 'World Health Organization, Mental Health Atlas 2017 (Geneva: WHO, 2018), <a href="https://www.who.int/publications/i/item/9789241514019;" target="_blank">https://www.who.int/publications/i/item/9789241514019;</a> World Health Organization, Mental Health Atlas 2020 (Geneva: WHO, 2021), <a href="https://www.who.int/publications/i/item/9789240036703" target="_blank">https://www.who.int/publications/i/item/9789240036703</a>'},
            {num: 706, text: 'UNICEF and WHO, &quot;The State of the World&#x27;s Children 2023: For every child, a fair chance,&quot; UNICEF, 2023, <a href="https://www.unicef.org/reports/state-worlds-children-2023;" target="_blank">https://www.unicef.org/reports/state-worlds-children-2023;</a> Charity S. Achungo, &quot;Mental Health in Africa: Rethinking Care from Individual to Community,&quot; BMJ Blogs, 11 March 2025, <a href="https://blogs.bmj.com/bmj/2025/03/11/mental-health-in-africa-rethinking-care-from-individual-to-community/" target="_blank">https://blogs.bmj.com/bmj/2025/03/11/mental-health-in-africa-rethinking-care-from-individual-to-community/</a> W wielu krajach Afryki Subsaharyjskiej na milion mieszkancow przypada mniej niz jeden psychiatra.'},
            {num: 707, text: 'Heads Up Guys, &quot;Male Depression and Suicide Risk,&quot; <a href="https://headsupguys.org/male-depression-and-suicide-risk/;" target="_blank">https://headsupguys.org/male-depression-and-suicide-risk/;</a> Lakshmi Vijayakumar, &quot;Suicide in women,&quot; Indian Journal of Psychiatry 57, Suppl 2 (2015): S233-S238, doi: <a href="https://doi.org/10.4103/0019-5545.161484" target="_blank">10.4103/0019-5545.161484</a>'},
            {num: 708, text: 'Cuijpers P, Karyotaki E, de Wit L, Ebert DD. The effects of fifteen evidence-supported therapies for adult depression: A meta-analytic review. Psychotherapy Research 2020; 30(3): 279-293. DOI: <a href="https://doi.org/10.1080/10503307.2019.1649732" target="_blank">10.1080/10503307.2019.1649732</a>'},
            {num: 709, text: 'Michael Bauer et al., WFSBP Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013, World Journal of Biological Psychiatry 14, nr 5 (2013): 334-385, doi: <a href="https://doi.org/10.3109/15622975.2013.804195" target="_blank">10.3109/15622975.2013.804195</a>'},
            {num: 710, text: 'American Psychiatric Association. (2010). Practice guideline for the treatment of patients with major depressive disorder (3rd ed.). Washington, DC: Author. <a href="https://doi.org/10.1176/appi.books.9780890423387" target="_blank">https://doi.org/10.1176/appi.books.9780890423387</a>'},
            {num: 711, text: 'Cipriani, A., et al. (2013). Lithium in the prevention of suicide in mood disorders: Updated systematic review and meta-analysis. BMJ, 346, f3646. <a href="https://doi.org/10.1136/bmj.f3646" target="_blank">https://doi.org/10.1136/bmj.f3646</a>'},
            {num: 712, text: 'Karyotaki, E., Smit, Y., Holdt Henningsen, K., Huibers, M.J.H., Robays, J., de Beurs, D., Cuijpers, P. (2016). Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects. Journal of Affective Disorders, 194, 144-152. DOI: <a href="https://doi.org/10.1016/j.jad.2016.01.036" target="_blank">10.1016/j.jad.2016.01.036</a>'},
            {num: 713, text: 'Cole, E.J., Stimpson, K.H., Bentzley, B.S., Gulser, M., Cherian, K., Tischler, C., Nejad, R., Pankow, H., Choi, E., Aaron, H., Espil, F.M., Pannu, J., Xiao, X., Duvio, D., Solvason, H.B., Hawkins, J., Guerra, A., Jo, B., Raj, K.S., Phillips, A.L., Barmak, F., Bishop, J.H., Coetzee, J.P., DeBattista, C., Keller, J., Schatzberg, A.F., Bhati, M.T., Williams, N.R. (2020). Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. American Journal of Psychiatry, 177(8), 716-726. DOI: <a href="https://doi.org/10.1176/appi.ajp.2019.19070720" target="_blank">10.1176/appi.ajp.2019.19070720</a>'},
        ];

        // Display references
        let displayedCount = 0;
        const batchSize = 50;

        function displayReferences(filter = '') {
            const list = document.getElementById('referenceList');
            const filtered = filter 
                ? references.filter(r => r.text.toLowerCase().includes(filter.toLowerCase()))
                : references;

            if (filter) {
                list.innerHTML = '';
                displayedCount = 0;
            }

            const toDisplay = filtered.slice(displayedCount, displayedCount + batchSize);
            
            toDisplay.forEach(ref => {
                const item = document.createElement('div');
                item.className = 'reference-item';
                item.innerHTML = `<span class="ref-number">[${ref.num}]</span><span class="ref-text">${formatReference(ref.text)}</span>`;
                list.appendChild(item);
            });

            displayedCount += toDisplay.length;
            
            const loadMoreBtn = document.getElementById('loadMoreBtn');
            if (displayedCount >= filtered.length) {
                loadMoreBtn.style.display = 'none';
            } else {
                loadMoreBtn.style.display = 'block';
                loadMoreBtn.textContent = `Załaduj więcej (${filtered.length - displayedCount} pozostało)`;
            }
        }

        function formatReference(text) {
            // Links are already formatted in the data
            return text;
        }

        // Initial load
        displayReferences();

        // Load more button
        document.getElementById('loadMoreBtn').addEventListener('click', () => {
            displayReferences();
        });

        // Search functionality
        let searchTimeout;
        document.getElementById('searchInput').addEventListener('input', (e) => {
            clearTimeout(searchTimeout);
            searchTimeout = setTimeout(() => {
                displayedCount = 0;
                document.getElementById('referenceList').innerHTML = '';
                displayReferences(e.target.value);
            }, 300);
        });
    </script>
    <!-- Floating ElevenLabs Widget - visible on all tabs -->
    <div class="widget-container">
        <elevenlabs-convai agent-id="agent_0701ke5j9260e74saxyv1fx7zzjv"></elevenlabs-convai>
    </div>
</body>
</html>
